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Abstract
Raman spectroscopy is a growing technology in the fields of in-vitro drug and
nanoparticle screening. The label free capability provided by vibrational
spectroscopy, as well as the ability of the technique to probe the chemical nature
of samples, makes it a good candidate for use in these fields. Crucial to the
progress of these methods is the development and validation of robust and
accurate multivariate statistical analysis protocols. In this thesis, both established
and novel methods are examined using both real and simulated datasets. In
particular, simulated datasets are used to validate and assess the accuracy of these
methods in a spectroscopic setting. Firstly, partial least squares regression (PLSR)
is examined using a simulated model based on real experimental data. This is
applied to investigate the application of the algorithm to continuously varying
data with known spectral perturbations introduced over a range of concentrations
and responses. The results show that, while PLSR is valid for some dose ranges,
sub-lethal, low concentrations and thus subtle spectral changes in the data may
lead to difficulties in model construction. Multiple trends present in the data were
also investigated and possible model error based on spectral bleedthrough in the
regression coefficients RCs is explored. Principal component analysis (PCA) was
also investigated using simulated datasets based on known changes in the data.
Some of the limitations of PCA for data partitioning and trend analysis are
overcome by a novel variant termed, ‘seeded’ PCA. 1st and 2nd derivative data is
also explored for improvements in Raman spectral analysis using seeded PCA.
Additionally, analytical methods used for Raman cellular imaging are also
explored for nano applications, with two methods, classical least squares analysis
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(CLSA) and a novel method spectral cross correlation analysis (SCCA) showing
some improvements over current methodologies. Future work is also described
pertaining to the use of a simulated cellular imaging dataset for validating data
analysis protocols for spectral classification and in-vitro screening.
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Figure 2.1 shows (a, f, k) the brightfield image, (b, g, l) the darkfield image of the
nanoparticles, c, h, m) the SERS image of CO at 2030cm-1, (d, I, o) merged SERS
and brightfield, and (e, j, p) the SERS image generated using the protein band at
1600cm1. a – e shows OSCC cells, f – g SKOV3 cells not expressing EGFR and k
– p OSCC cells treated with anti-EGFR.
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Figure 2.2 TERS probing hemozoin crystal formation inside malaria infected red
blood cells. A – C show AFM images of infected red blood cells. D shows the
TERS spectrum for the edge of the hemozoin crystal deposit, E is the spectrum of
the tip following retraction from the cell, F SERS spectrum of β-hematin, G
resonance Raman (RR) spectrum of β-hematin.
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Figure 2.3. Identification of intracellular distributions of polystyrene
nanoparticles using Raman spectroscopy. (i) A shows the brightfield and (B) Kmeans image of the cell. (ii) shows the K-means cluster average spectra
associated with the clusters in the K-means image in the panel above, (iii) shows
the K-means cluster spectrum associated with polystyrene nanoparticles (A)
compared with a pure spectrum of polystyrene (B). The Right panels show a
Principal Component Analysis scatter plot (top), differentiating the green
(nanoparticle) and light blue clusters (cytoplasm), and the loading of Principal
Component 1 (Bottom, A), suggesting the local environment surrounding the
nanoparticles is lipid rich.
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Figure 2.4 CARS images of the TiO2 nanoparticle distribution in Onchrhynchus
mykiss gills, (a) forward CARS image showing the nanoparticles, (b) epi-CARS
image of the gill tissue and (c) merged forward and epi CARS image.

34

Figure 2.5 Epi-CARS images with contrast derived from CD2 and CH2
resonances in GCPQ nanoparticles at 2100 cm−1 (green) and 2845cm−1 (red)
respectively. (A) Liver tissue. (B) Stomach tissue samples. (C) shows Jejunum
tissue imaged with epi-CARS with contrast derived from the CD2 resonance
(green), SHG contrast derived from collagen (blue) and TPF contrast derived
from endogenous fluorophores. (D) Ileum tissue imaged with epi-CARS with
contrast derived from the CD2 and TPF (red) (E) Duodenum imaged with epiCARS with contrast derived from the CD2 and TPF (red). (F) Gall bladder
imaged with epi-CARS with contrast derived from the CD2 resonance (green),
SHG (blue) and TPF (red).

35

Figure 3.1 Schematic diagram outlining KMCA.
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Figure. 3.2. Showing a HCA dendrogram and both divisive and agglomerative
clustering.
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Figure 4.1: Spectral Constructs based on the normalised difference spectra
between control and exposed nucleus (A) 10, and cytoplasm 11 (B). Selected Raman
peaks were used to avoid over complexity in the simulated data; (A) the A form
peak of DNA at 807 cm-1 and the B form peak at 833 cm-1 and the C-H
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deformation at 1449 cm-1 (B) the amide 1 band at ~1661 cm-1, the C-C stretch
intensity at ~939 cm-1 and the tryptophan peak at 731 cm-1.
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Figure 4.2: Control dataset taken from Nawaz et al. 10; 25 control spectra taken
from the nucleus of cells not exposed to cis-platin. Spectra have been baseline
corrected and vector normalised. The inherent spectral variability in the data is
representative of real experimental conditions. These spectra were then used in
the construction of 3 simulated datasets, each containing 8 different dose/viability
points with systematically introduced variation of the spectral constructs shown
in figure 4.1.
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Figure 4.3. PLSR modelling against Lethal Concentration for Dataset 1. Top
panel shows the calibration performance and test dataset (RMSEC 0.49673, R 2
0.99948). Bottom panel shows the performance of the model for the test dataset
(RMSEP 0.52389, R2 0.99953). Data was split in a ratio of 60:40 calibration and
test respectively.
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Figure 4.4: Plot of the regression co-efficient following PLSR of Dataset 1
against Lethal Concentration. The Concentration construct (dashed line) is
shown in the top panel for comparison with the RC’s in the bottom panel. The
solid line (bottom panel) shows the regression co-efficient following regression
of Dataset 1 against Lethal Concentration. The dotted line shows a plot of the
regression co-efficient following regression of a dataset consisting of just control
spectra against Lethal Concentration, in effect showing the baseline regression
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co-efficient when no introduced spectral perturbation (not including
sample/instrumental variations) is present. The Control RC has been offset and
multiplied by a factor of 10 for clarity.

89

Figure 4.5: PLSR modelling of Dataset 2 against the Lethal MTT target. Top
panel shows the calibration performance and test dataset (RMSEC 0.10158, R2
0.91928). Bottom panel shows the performance of the model for the test dataset
(RMSEP 0.12087, R2 0.89793). Data has been split in a ratio of 60:40 calibration
and test respectively.
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Figure 4.6: Plot of the regression co-efficient following PLSR modelling against
MTT response. The Viability construct (dashed line) is shown in the top panel for
comparison with the RC’s in the bottom panel.

The solid line shows the

regression co-efficient following regression against Lethal MTT and Dataset 2
(bottom panel). The dotted line (bottom panel) shows a plot of the regression coefficient following regression of a dataset consisting of just control spectra
against Lethal MTT, in effect showing the baseline regression co-efficient when
no introduced spectral perturbation (not including sample/instrumental
variations) is present. The Control RC is offset and multiplied by a factor of 10
for clarity.
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Figure 4.7: Evolution of the peaks of Construction construct in PLSR models of
increasing range for Dataset 1.
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Figure 4.8. A plot of regression co-efficient following multiple regression against
concentration with increasing data points. I.e. C+1 represents a dataset
consisting of the control dataset and the data point at 0.05 µM. This then
increases C+n until all data points in the dataset have been evaluated.
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Figure 4.9. Plot of peak intensities vs. concentration of regression co-efficients
for the A form peak of DNA at 807 cm-1 and the B form peak at 833 cm-1 of the
Concentration Construct (Figure 4.1A). Also plotted is the contribution of the
tryptophan peak at 731cm-1, a key feature of the Viability Construct (Figure
4.1B).
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Figure S4.1: RMSECV and RMSEP for the first 10 LV’s for the regression of
Dataset 1 against Lethal Concentration 1.
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Figure S4.2: PLSR modelling of Dataset 2 with the Lethal Concentration range
as taregt. Top panel shows the calibration performance and test dataset (RMSEC
0.4981, R2 0.99947). Bottom panel shows the performance of the model for the
test dataset (RMSEP 0.53505, R2 0.99952). Data was split in a ratio of 60:40
calibration and test respectively.
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Figure S4.3: Plot of the regression co-efficient following PLSR modelling of
Dataset 2 against Lethal Concentration. The concentration spectral construct
(dashed line) is shown in the top panel for comparison with the RC’s in the bottom
panel. The dashed line (bottom panel) shows the spectrum of regression co-
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efficients following regression of Dataset 2 against Lethal Concentration 1. The
solid line shows a plot of the regression co-efficient following regression of a
dataset consisting of just control spectra against Lethal Concentration, in effect
showing the baseline regression co-efficient when no introduced spectral
perturbation (not including sample/instrumental variations) is present. The
Control RC has been multiplied by a factor of 10 and offset for clarity.

108

Figure S4.4. A plot of regression co-efficients following multiple regression of
Dataset 2 against Lethal MTT with increasing data points. I.e. C+1 represents a
dataset consisting of the control dataset and the data point at 0.05 µM. This then
increases C+n until all data points in the dataset have been included.
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Figure S4.5 Plot of RC peak intensities for regression of Dataset 2 against Lethal
MTT; C-C stretch intensity at ~939 cm-1, the amide 1 band at ~1661 cm-1 and the
tryptophan peak at 731 cm-1 of the Viability Construct (Figure 1B).
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Figure S4.6. PLSR modelling of Dataset 3 with the Sub-lethal Concentration
range as target. Top panel shows the calibration performance and test dataset
(RMSEC 0.143, R2 0.38916). Bottom panel shows the performance of the model
for the test dataset (RMSEP 0.19392, R2 -0.24063). Data was split in a ratio of
60:40 calibration and test respectively.
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Figure S4.7. Plot of the regression co-efficients following PLSR of Dataset 3
against Sub-lethal Concentration. The concentration spectral construct (dashed
line) is shown in the top panel for comparison with the RC’s in the bottom panel.
The solid line shows the regression co-efficient following regression against sublethal concentration and Dataset 3 (bottom panel). The dotted line (bottom panel)
shows a plot of the regression co-efficient following regression of a dataset
consisting of just control spectra against sub-lethal concentration, in effect
showing the baseline regression co-efficient when no introduced spectral
perturbation (not including sample/instrumental variations) is present. The
Control RC is offset and multiplied by a factor of 100 for clarity.
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Figure 5.1. Control dataset taken from Nawaz et al18. 25 control spectra taken
from the nucleus of cells not exposed to cis-platin. Spectra have been baseline
corrected and vector normalised. The inherent spectral variability in the data is
representative of real experimental conditions.
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Figure 5.2: Spectral Constructs based on the normalised difference spectra
between control and exposed nucleus (A) and cytoplasm (B) of Nawaz et al.
(2010). Selected Raman peaks were used to avoid over complexity in the
simulated data; (A) the A form peak of DNA at 807 cm-1 and the B form peak at
833 cm-1 and the C-H deformation at 1449 cm-1 (B) the amide 1 band at ~1661
cm-1, the C-C stretch intensity at ~939 cm-1 and the tryptophan peak at 731 cm-1.
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Figure 5.3. PCA on a dataset consisting of the control and max MTT, dataset 1
(A) scatter plot of PC1 vs. PC2 (B) scatter plot of PC1 vs. PC3 (C) scatter plot of
PC2 vs. PC3. PC1, 2 and 3 account for 37.98%, 24.36% and 6.58% of the
variance in the dataset, respectively.
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Figure 5.4. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for
standard PCA on dataset 1. With PC 1, 2 and 3 accounting for 37.98%, 24.36%
and 6.58% of the variance respectively.
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Figure 5.5: Calculation of the variance explained after successive rounds of PCA
with increasing spectral construct weighting according to table 2. (A) % variance
explained by the PC loading addition (B) % variance explained by the inherent
dataset variability between control spectra acquired, instrumental error, random
noise…etc .
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Figure 5.6. PCA on a dataset consisting of the control and max MTT, dataset 1
(A) scatter plot of PC1 vs. PC2 (B) scatter plot of PC1 vs. PC3 (C) scatter plot of
PC2 vs. PC3. PC1, 2 and 3 account for 99.99%, 0.000059% and 0.000038% of
the variance in the dataset, respectively.
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Figure 5.7. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for Seeded
PCA on dataset 1. With PC 1, 2 and 3 accounting for 99.99%, 0.000059% and
0.000038% of the variance respectively.
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Figure 5.8. PCA of Dataset 2 (A) scatter plot of PC1 vs. PC2 (B) scatter plot
showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances
describe by PC 1, 2 and 3 are 93.94%, 2.22% and 1.54% respectively for
standard PCA. The loadings corresponding to the scatter plots are shown in
figure 5.9.
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Figure 5.9. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for Seeded
PCA on dataset 1. With PC 1, 2 and 3 accounting for 93.94%, 2.22% and 1.54%
of the variance respectively.
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Figure 5.10. Seeded PCA of Dataset 2 (A) scatter plot of PC1 vs. PC2 (B) scatter
plot showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances
described by PC 1, 2 and 3 are respectively 99.997%, 0.0033% and 0.000079%
for seeded PCA.
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Figure 5.11. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for
Seeded PCA on dataset 1. With PC 1, 2 and 3 accounting for 99.997%, 0.0033%
and 0.000079% of the variance respectively.
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Figure 5.12. PCA of Dataset 3 (A) scatter plot of PC1 vs. PC2 (B) scatter plot
showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances
described by PC 1, 2 and 3 are respectively 87.82%, 4.51% and 3.13% for PCA.
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Figure 5.13. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for PCA
on dataset 3. With PC 1, 2 and 3 accounting for 87.82%, 4.51% and 3.13% of the
variance respectively.
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Figure 5.14. Seeded PCA on dataset 3 (A) scatter plot of PC1 vs. PC2 (B) scatter
plot showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances
described by PC 1, 2 and 3 are respectively 99.99%, 0.004% and 0.0002% for
seeded PCA.
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Figure 5.15. Loadings of PCA of Dataset 3 corresponding to (A) PC1, (B) PC2
and (C) PC3. The variances described by PC 1, 2 and 3 are respectively 99.99%,
0.004% and 0.0002% for seeded PCA.
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Figure 5.16. Seeded PCA on 1st derivative spectra from dataset 3 (A) scatter plot
of PC1 vs.PC2 (B) scatter plot showing PC1 vs PC3 (C) scatter plot showing PC2
vs. PC3. The variances described by PC 1, 2 and 3 are respectively 99.99%,
0.0079% and 0.0001% for seeded PCA.
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Figure 5.17. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for PCA
on dataset 3. With PC 1, 2 and 3 accounting for 99.99%, 0.0079% and 0.0001%
of the variance respectively.
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Figure 5.18. Seeded PCA on 2nd derivative spectra from dataset 3 (A) scatter plot
of PC1 vs. PC2 (B) scatter plot showing PC1 vs PC3 (C) scatter plot showing
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PC2 vs. PC3. The variances described by PC 1, 2 and 3 are 99.99%, 0.0087%
and 0.000014% for seeded PCA.
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Figure 5.19. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for
seeded PCA on 2nd derivative spectra from dataset 3. With PC 1, 2 and 3
accounting for 99.99%, 0.0079% and 0.0001% of the variance respectively. 148

Figure 5.20. Seeded PCA on 2nd derivative spectra from dataset 3 (A) scatter
plot of PC2 vs. log PC1 (B) loading for PC1 (C) loading for PC2. The variances
described by PC 1 and 2 are 99.99% and 0.0087% respectively for seeded PCA.
A constant of 0.05 Arb. Units has been added to PC 2, to allow for log scaling of
the data.
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Figure 6.1 (A) Component spectra of nano-polystyrene (dotted line), 3-snphosphatidyl ethanolamine (dashed line) and isolated RNA (solid line), offset for
clarity. (B) Shows an example of the first eight simulated spectra for polystyrene
in cells, offset for clarity. Each spectrum consists of a constant cellular spectrum
with a varied concentration of polystyrene added to it, with decreasing
polystyrene concentration from top to bottom. Simulated data sets generated in
this way were then analysed by CLSA and SCCA.

169

Figure 6.2 CLSA of simulated spectral data sets of nano-polystyrene, RNA and
lipid. In each graph, the score from the CLSA is plotted against the concentration
of component spectrum added to a constant cellular spectrum (points on each

xxv

graph). The solid black line represents the ideal response which gives an
indication of the quantitative nature of the technique.

171

Figure 6.3.: Clustering of spectra identified by unsupervised CLSA. (A) Spectral
models generated from the analysis protocol and used to generate the clustered
map shown in (B). The right panel (C-I) shows the distribution of each model
created in the map. Of particular note, model 1(C), model 6(D) and model 7(H)
have strong contributions of the spectra of polystyrene, RNA and lipid
respectively. The spectra in (A) are colour coded and correspond to images (B –
F), with the exception of Model 6 which corresponds to the white image in (D).
173
Figure 6.4: A closer look at the generated model spectra created by CLSA (A-G).
The overlap between pixels corresponds to a percentage contribution from each
particular model. In some instances a pixel may contain 50% of one model and
50% of another, which is highlighted somewhat by the intensity of the pixel,
although this is visually subjective.

Figure 6.5.
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Supervised CLSA of simulated spectral data sets of nano-

polystyrene, RNA and lipid. In each graph, either the pure spectrum of
polystyrene, RNA or lipid was used to calculate the CLSA score. This score was
then plotted against the concentration ratio of pure component spectrum: cellular
spectrum used to generate the simulated data set.
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Figure 6.6: Supervised CLSA using component spectra of polystyrene (A), RNA
(B) and (C) 3-sn-phosphatidyl ethanolamine. The spectrum of each pure
component is shown on the left of the graph, with the corresponding to nonthresholded data shown in the middle and arbitrarily thresholded data shown on
the right.
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Figure 6.7. SCCA carried out on simulated data sets containing added
polystyrene, RNA and lipid component spectra. In each instance, a pure
component spectrum of polystyrene, RNA and lipid was cross correlated against
each data set to investigate the performance of the technique. The solid line shows
the idealised response.
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Figure 6.8: SCCA analysis using component spectra of polystyrene (A), 3-snphosphatidyl ethanolamine (B) and RNA (C). The spectrum of each pure
component is shown on the left of the figure and the correlation maps for nonthresholded shown in the middle and thresholded on the right.
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Figure 7.1. Initial template regions showing the known spatial distribution of
pure component spectra representing the Nucleus (A), Perinuclear 1 (B),
Cytoplasm (C), Nucleolus (D), Perinuclear 2 (E) and Polystyrene nanoparticles
(F). This spectral regions correspond to the pure component spectra in table 7.1
and figure 7.2.
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Figure 7.2: Clusters representing the Nucleus (A), Perinuclear 1 (B), Cytoplasm
(C), Nucleolus (D), Perinuclear 2 (E) and Polystyrene nanoparticles (F).
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Chapter 1: Introduction: Raman Spectroscopy In
Nanomedicine and Drug Screening
1.1 Introduction
Currently, there is a drive and a need to develop new in-vitro technologies,
which can be used for a range of applications, including screening for novel
therapeutic strategies to evaluate the potential risks of nanomaterials as well as
other toxic compounds. This follows new regulatory practices in both the EU and
US (EU Directive-2010/63/EU and US Public Law 106-545, 2010, 106th
Congress)1,2, generally based on the 3 R’s of Russell and Burch3 to replace,
reduce and refine the use of animals for scientific purposes.
In-vitro technologies are currently used for a wide range of applications
such as testing the toxicological potential of certain compounds, identifying novel
drug candidates as well as the assessment of novel nanoscale compounds4–6. This
can involve high throughput evaluation of a battery of compounds and
therapeutics, simultaneously allowing for rapid evaluation of these materials.
Increasingly, these methods are being optimised to challenge the current
convention of using animal models. In practice, novel methodologies should
provide a bio-mimetic platform which can give the same end-point evaluation as
an animal model at a fraction of the cost.
Emerging in the field of analytical science is the use of optical techniques
to characterise biological processes. These include disease diagnostics e.g.
various cancers7, as well as novel approaches to the evaluation of therapeutics
and nanomaterials in-vitro, ex-vivo and in-vivo8–10. For the most part, these optical
2

methods rely on the use of fluorescent probes, which, depending on the
application, may be specifically designed dyes or fluorescent proteins which aim
to provide an optical visualisation of these processes11–13. Newly developed
nanoprobes can also be utilised for such purposes, whereby these nanomaterials
may possess inherent optical properties which allow for a visual characterisation
of their interaction, for example using microscopic techniques14–16.
However, in other cases, nanomaterials must be tagged to allow for their
visualisation e.g. with a fluorescent label17. While this is a viable technique, in
some instances the fluorescent moiety may become labile, thus creating an
ambiguity between particle and fluorescent probe18. Additionally, fluorescently
tagging these materials may alter their properties, and size and charge of the
nanomaterial are known to affect the interaction19. Asides from these issues, cost
is also a factor, as the process of fluorescently labelling can become quite
expensive and therefore there is scope for alternative strategies in the
investigation of not only nano-bio interactions, but also other biological assays.
Increasingly, Raman spectroscopy has emerged as a versatile technique
which has been used to study a number of different biological processes in a label
free manner. Applications include disease diagnostics7, cellular studies of drug
interactions20, as well as mapping nanobio interactions21–24, to list but a few. The
technique relies on the intrinsic chemical nature of a sample and therefore does
not require any additional reagents other than the sample (as well as the test
particle or chemical). Therefore, the technique circumvents the need for
additional labels and probes to investigate a sample or process.
In such applications, there is often a large number of spectra acquired and
thus interpretation soon becomes a problem. To tackle these issues, multivariate
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statistical analysis is routinely applied to the data. Depending on the application,
these methods may be used to distinguish between diseased and non-diseased7,25,
separate regions of a cell or tissue26–28, extract out features which describe a
process e.g. in toxicity9 or drug interaction studies26,8. Fundamentally, these
methods aim to classify the obtained spectra and thus provide a medium by which
the information acquired can be grouped and interpreted.
Importantly, as with any method which aims to challenge the current
paradigm, validation is a crucial concern. In most cases, Raman spectroscopic
analyses are compared to ‘gold standard’ practices, be they in diagnostics
(histopathological staining) or cellular studies (fluorescent dyes and labels). This
verification is paramount and allows for a new method to be assessed against its
established counterpart.
In this thesis, Raman spectroscopy is assessed as an in-vitro tool for the
investigation of nanoparticle-cell and drug-cell interactions. Specifically, the
multivariate methods which are applied to these problems are investigated. While
there are a number of challenges faced by the biomedical vibrational spectroscopy
community, such as sample preparation and instrument fidelity, which come
under the umbrella term of spectral reproducibility, the multivariate statistical
methodologies applied to these problems are not without their own caveats.
It is thus the aim of this thesis to investigate the application of multivariate
protocols applied in Raman spectroscopy and explore some of the potential pit
falls associated with their application. The studies utilise simulated datasets,
based on real experimental data, which contain known spectral perturbations,
such that the intricacies of these multivariate statistical methods can be explored
and the validity, sensitivity and limits of detection can be evaluated.
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This work also lays down the core foundations of a supervised data mining
approach in spectral cross correlation analysis, providing a novel approach to
tracking nanoparticles in cells using Raman spectroscopy. As validation is an
important concern, the method was compared to other data mining approaches
such as classical least squares analysis, and further comparisons were made to KMeans Cluster Analysis, employed in the original work by Dorney et al24. While
improvements in specificity were made in the identification of the intracellular
nanoparticles, it was still not possible to determine whether all spectra in the
dataset were correctly identified as containing nanoparticles or not, and thus a
more complex cellular simulation was developed to investigate this issue.
This thesis is therefore laid out as follows. The background section is split
into two chapters; chapter 2 is adapted from a review paper published in the
journal: Nanomedicine, 8(8), 1375 – 1391(2013)29, entitled; “Raman
spectroscopy in nanomedicine: current status and future perspectives”. The main
focus here is to look at where Raman spectroscopy has been applied in a
nanomedical context, focusing on some of the variants (namely SERS, TERS and
CARS) and also investigating where spontaneous Raman has been applied. Thus,
this section aims to give the reader an introduction to the nanomedical field,
specifically from a Raman perspective, but also introduce some important
concepts in the fields of nano science and nano biology.
Chapter 3 aims to describe the role of multivariate statistical methods and
their application to Raman spectroscopy in general, but also where these methods
have been used in the context of Raman cellular imaging, as well as some of their
applications in exploring nano-bio and drug interactions. Some of the benefits and
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short comings of these methods will be discussed and the concept of supervised
approaches in Raman spectral data mining will be introduced.
Chapter 4 is a reproduction of the journal publication in Analyst, 140,
2482-2492 (2015)30, and outlines the development of a simulated dataset to assess
the validity of the partial least squares regression (PLSR) algorithm used in
biomedical Raman spectroscopy. Based on the experimental results of Nawaz et
al26, a simulated dataset is generated with known spectral perturbations related to
both concentration of chemotherapeutic agent and the resultant cytotoxic
response in-vitro. Both lethal and sub-lethal dose ranges are explored with the
aim of testing the limits of the PLSR algorithm and also identifying some of the
potential pit falls of applying this method in Raman spectroscopy.
Chapter 5 details further investigations of multivariate statistical
methodologies, namely principal component analysis (PCA), applied to
biomedical Raman spectroscopy, using simulated data. Furthermore, a novel
variant of the PCA algorithm is developed, termed seeded PCA (SePCA) and is
shown to be superior to the standard algorithm for handling continuously varying
data. Further insights are also garnered on the use of 1st and 2nd derivative spectra
and the impact this mathematical transformation has on the ability of the
algorithm to separate and describe the spectral origin of differentiation of spectral
datasets.
Chapter 6 describes the development and application of a novel
supervised data mining approach, spectral cross correlation analysis (SCCA)
applied to Raman spectral data containing polystyrene nanoparticles, as well as
specifically designed simulated datasets, based on a publication in Analyst, 137,
5792-5802 (2012). The approach is compared to a supervised and unsupervised
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method in classical least squares analysis (CLSA). SCCA is also demonstrated as
a method to identify other biochemical distributions in the cell, namely lipid and
RNA distributions
Chapter 7 outlines the final discussion and conclusions drawn from this
thesis, highlighting the importance of multivariate statistical analysis in an invitro Raman spectral platform for in-vitro screening technologies, with a
particular focus on advancing data simulation in this context.
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Chapter 2: Raman spectroscopy in nanomedicine:
current status and future perspectives

The following review paper was written by the primary author Mark E. Keating,
while Hugh J. Byrne, as supervisor, was primarily responsible for editing and
refining of the text. The format is that of the journal publication, but section and
figure numbers have been adapted to the format of this thesis.

Keating ME, Byrne HJ. Raman spectroscopy in nanomedicine: current status and
future perspective. Nanomedicine (Lond). 2013 Aug;8(8):1335-51. doi:
10.2217/nnm.13.108.
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2.1 Abstract:
Raman spectroscopy is a branch of vibration spectroscopy which is capable of
probing the chemical composition of materials. Recent advances in Raman
microscopy have added significantly to the range of applications which now
extend from medical diagnostics to exploring interfaces between biological
organisms and nanomaterials. In this review, Raman is introduced in a general
context, highlighting some of the areas in which the technique has found success
in the past, as well as some of the potential benefits it offers over other analytical
modalities. The subset of Raman techniques which specifically probe the
nanoscale, namely Surface Enhanced and Tip Enhanced Raman Spectroscopy,
will be described and specific applications relevant to nanomedical applications
will be reviewed. Progress in the use of traditional label-free Raman applied to
investigation of nanoscale interactions will be described, and recent
developments in Coherent Anti-Stokes Raman Scattering will be explored,
particularly applications to biomedical and nanomedical fields.
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2.2 Introduction
Nanomedicine can be defined as the medical applications of nanotechnology1,
ranging from the use of nanomaterials in regenerative medicine, drug delivery
strategies, medical diagnostics and therapeutics and including potential negative
impacts of nanomaterials to human health, commonly encompassed under the
term Nanotoxicology. In the context of this review article, nanomedicine is
viewed from the perspective of how Raman spectroscopy (and its variants) can
be used in the assessment of the beneficial as well as the potential negative
impacts of Nanomaterials on human health. Nanomaterials have already found
uses in a wide range of applications, including anti-microbial paint coatings2,
textile finishing3, and novel applications in the electronics industry4. Notably,
biomedical applications are rapidly emerging, ranging from nanoparticle coated
stents for angioplasty5, contrast agents for diagnostic imaging6,7 and also potential
drug and gene delivery vehicles8–10. These applications are largely dependent on
the particular characteristics which nanomaterials and nanoparticles possess.
These include properties such as increased surface to mass ratio which in turn
results in an increase in surface reactivity, while novel optical properties
associated with some classes of nanoparticles are important for applications in
theranostic imaging and subsequent monitoring of drug delivery. However, whilst
these technologies show promise, it is important to be able to visualise how the
materials behave in situ, and particularly in the biological context, to be able to
characterise their interactions and toxicological effects, be they in-vitro or in-vivo.
While it has been highlighted that comprehensive characterisation of the physicochemical properties of nanoparticles is imperative, changes to these properties,
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such as aggregation state and effective surface chemistry, can play a critical role
in their modes of interaction and action11. Equally, to understand the modes of
action and optimise efficacies, monitoring and understanding changes to the
biological environment is critical, not only on a cellular level but also when
considering the systemic responses.
Considering the system as a whole, one must be able to track a particle or
material from initial exposure or administration through to the site of action and
on to assimilation, degradation or excretion. At each step in this process, one must
be able to access and visualise the efficacy by which the particles can overcome
certain barriers to successful administration. These can vary from the route of
exposure, assessing whether the particle causes toxicity, particle retention (e.g.
via the enhanced permeability and retention (EPR) effect), or removal for
circulation via uptake by the reticuloendothelial system (RES), accumulation of
the nanoparticles over time, non-specific interactions, the efficacy with which the
particle reaches its desired location etc..
Ideally, what is required is a method which can successfully characterise
these processes, firstly in fundamental in-vitro cytological and ex-vivo
histological studies and ultimately in more realistic in-vivo applications. This
method should be capable of identifying the particle or material of interest while
simultaneously being able to access the surrounding environment while
measuring the efficacy of the probe or nanocarrier and/or the physiological
response of the organism.
There exists a large range of analytical methods which can be used in the
classification and characterisation of nanomaterials. These include scanning and
transmission electron microscopy (SEM and TEM), atomic force microscopy
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(AFM), other label free optical methods such as differential interference contrast
(DIC) and dark field microscopy and fluorescent microscopy methods based on
intrinsic nanoparticle or external label fluorescence, to name but a few. However,
these methods are not without certain drawbacks which limit to some extent their
applicability and effectiveness.
Firstly, both AFM and SEM can be considered as primarily surface
sensitive techniques, while, when TEM is coupled with serial sectioning and
ultra-microtomy, it has been used for 3D reconstructions and tomography12,13.
However, these processes are time consuming, costly and laborious. In addition,
EM requires a particle to have contrasting electron density compared to its
environment to allow for a particle to be visualised, which renders it ineffective
for many “softer” polymeric nanoparticles. EM does not allow live cells to be
imaged and, as it requires extensive sample processing, it provides only a limited
scope for rapid or routine investigation of nanomaterials in-vitro. What EM and
AFM do provide is the capability of imaging beyond the optical diffraction limit.
More recently developed optical based methods, so-called super resolution
microscopy, have become available that allow for imaging beyond this limit 14–16.
However, their use has been limited in the field of nanomedical sciences as of yet.
In contrast, standard fluorescent based microscopy has been used
extensively in nanoparticle studies16–20. Confocal Laser Scanning (fluorescence)
Microscopy (CLSM) has become a standard in the toolbox of techniques for in vitro cytommetry 21. Although the technique is limited in resolution to hundreds
of nanometers, it can potentially detect fluorescence emission from, and therefore
the location of, individual nanoparticles. Penetration depths in-vivo can be
extended through two photon excitation techniques and/or NIR fluorophores22,23.
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In the visible region, a range of fluorescent assays and labels are commercially
available to probe a range of physiological processes in-vitro, such as lyso and
mitotracker used for labelling lysosomes and mitochondria24. Intrinsically
fluorescent nanoparticles such as inorganic semiconductor quantum dots have
been developed for similar applications25 and surface functionalisation of these
types of materials has contributed to understanding the dependence of uptake and
intracellular trafficking on surface chemistry26. Many similar studies have been
performed with fluorescently labelled nanoparticles27,28 which are commercially
available in a range of sizes and surface functionalities. However, not all
nanoparticles can be easily fluorescently labelled. Furthermore, it is not clear that
the transport mechanisms of smaller nanoparticles, fluorescently labelled with
anionic moieties, are the same as their unlabelled counterparts29. Critically, there
have been reports that labelled nanoparticles can release the dye into the
surrounding biological environment, and so the distribution of fluorescence
within the cell does not necessarily represent the presence or subcellular
distribution of the nanoparticles30–32. Other label free optical microscopy
techniques are also limited by the type of particle which can be visualised i.e. only
metal based particles are effective for dark field and DIC microscopy33.
Raman spectroscopy has been proposed as a method for monitoring
nanomaterials in biological systems, as it potentially provides a label free, noninvasive probe of the nanoparticle itself, the local environment and the physiology
of the organism34. Over the past decade, Raman spectroscopy has been applied to
a range of biomedical areas, including cancer diagnostics35, toxicity studies36,
atherosclerosis37 and investigation of skin38,39. Importantly, what Raman provides
is not just a method for differentiation between a diseased and non-diseased state,
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it is based on characterisation of the (bio) chemical nature of a sample, based on
the characteristic vibrations of the molecular bonds of the constituent
components. Raman is a form of vibrational spectroscopy, which in itself is a
subset of a more general umbrella term of spectroscopy. The vibrations are
characteristic of the molecular structure and, in polyatomic molecules, give rise
to a spectroscopic “fingerprint”. The spectrum of vibrational energies can thus be
employed to characterise a molecular structure, or changes to it due to the local
environment or external factors. The Raman spectrum is thus a truly label free
signature of the nanoparticle. Vibrational energies typically fall in the mid
Infrared (IR) region of the electromagnetic spectrum and are quite commonly
probed using IR absorption spectroscopy. Raman in many ways can be viewed as
a complementary technique to IR spectroscopy; whereas IR involves absorption
of radiation, Raman is an inelastic scattering technique whereby the incident
radiation couples with the vibrating polarisation of the molecule and thus
generates or annihilates a vibration. For a vibration to be active in IR
spectroscopy, a change in dipole is required, whereas to be Raman active, a
change in polarisability is required. As a rule of thumb, vibrations of asymmetric,
polar bonds tend to be strong in IR spectra, whereas Raman is particularly suitable
as a probe of symmetric, nonpolar groups. Importantly, this results in the O-H
bonds of water being strong absorbers in IR spectroscopy, whereas they are
relatively weak Raman scatterers. This allows for samples to be investigated in
an aqueous environment and thus the technique of Raman spectroscopy more
readily lends itself to live cell in-vitro40 or in-vivo41 measurement. As the
vibrational spectrum is measured as a frequency (or energy) shift from that of the
incident radiation, Raman spectroscopy can be performed across the UV, visible
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or near infrared spectral regions, and thus can benefit from the technologies
available and advances made for confocal optical microscopy.
A number of variants which are based around the physical principal of
Raman spectroscopy exist. Spontaneous Raman can take the form of Stokes
Raman scattering and anti-Stokes Raman scattering, the former resulting from the
creation of a vibration in a material, characterised by a decrease in the incident
photon energy (frequency), the latter from the annihilation of vibration,
characterised by an increase in the incident photon energy. If the incident
radiation is resonant with an electronic absorption of the analyte, the Raman
signal can be resonantly enhanced by several orders of magnitude. The use of
Resonant Raman Spectroscopy (RRS) in biomedical systems has been limited,
however, due to associated photochemical degradation phenomena and the
generation of fluorescence which can swamp the Raman signal of the overall
sample.
Other variants of these two techniques with increased sensitivities for
more molecularly specific characterisation have been developed. These include
resonant Raman spectroscopy, coherent anti Stokes Raman spectroscopy
(CARS), tip enhanced Raman spectroscopy (TERS) and surface enhanced Raman
spectroscopy (SERS). The majority of these techniques have been applied to
nanomedical applications; however, two of these methods deal inherently with
the nanoscale, namely TERS and SERS. Although Raman is fundamentally an
optical technique and is thus similar to confocal optical microscopy, limited to
spatial resolution of the order of hundreds of nanometres, nanometre resolution
can be obtained through localised enhancement processes. This localised
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enhancement led to the initial interest in the prospect of the use of Raman
spectroscopy to probe the specific environment of the nanoparticle.
This article will outline the applications of the various Raman
spectroscopy based technique in the broad area of Nanomedicine. As they are
nano-specific, the use of SERS and TERS techniques will be presented initially,
while the increasing interest in the use of truly label free spontaneous Raman and
Coherent Anti-Stokes Raman Spectroscopy (CARS) in nanomedical applications
will then be explored. In Raman spectroscopy, the sensitivity, spatial resolution
and penetration depth and required scan rates depend on technique employed,
resonance conditions and even the instrumental set-up (microscope objective,
grating, laser power). In the respective section describing each modality,
examples of the state of the art in nanomedical applications are provided. The
future perspectives attempts to address routes beyond the current state of the art.
A more detailed description of the historical origin and basic principles of the
Raman scattering process can be found in numerous excellent text books42–46 and
review articles47–49. A comparison of Raman and IR spectroscopies for
biomedical applications can be found in 50.

2.3 SERS
The phenomenon of surface enhanced Raman spectroscopy was described as
early as 197451,52, and is understood to arise from a localised increase in the
coupling between the electromagnetic field of the incident radiation and the
polarisation of the analyte in the presence of optically induced surface plasmons
on a metal surface. Increases of Raman intensities as high as 10 10 have been
reported53, although the spatial range of enhancement is only of the order of tens
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of nanometers. The enhancement process can be achieved using a number of
substrates including roughened metallic surfaces, structured metal arrays and
specially imprinted surfaces.
Notably, the SERS effect can be induced through the use of metallic
nanoparticles and nano colloid aggregates. SERS is a direct enhancement of the
Raman signal and in the case of nanoparticles this occurs in the immediately
surrounding local vicinity. The true principal that governs SERS enhancement is
not fully understood, although the effect has largely been attributed to an
electronic enhancement due to local fields generated by surface plasmon
resonances at the metal surface. Alternatively, the enhancement has been
attributed to a charge transfer process between the analyte and the surface,
although it is probable that the processes act in tandem54. The technique of SERS
in a biomedical context is reviewed in greater detail in the following papers 55–57.
Nanoparticles and aggregates which are used for SERS enhancement
typically consist of a metallic nanoparticle, most commonly gold and silver. Quite
often, these particles are subsequently modified via surface functionalisation
which can include targeting moieties designed for specific applications,
especially as nanosensors. The particle may also be labelled with a Raman
reporter moiety which allows for identification of the particle in the biological
milieu. Using these particles, it has thus been possible to apply SERS to a number
of biological scenarios, which include diagnostic studies in-vitro, ex-vivo58,59 and
in-vivo60,61 , novel bio assays62–64 as well as cellular studies.
SERS has been proposed as a method for understanding how
nanomaterials behave in a cellular environment, important in the study of the
fundamental interactions of nanoparticles in the context of toxicology, drug
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delivery or contrast agents for diagnostics. In 2009, Kneipp et al. proposed that
by using SERS it would be possible to probe the chemical nature of the subcellular
environment and the intracellular distribution of biomolecules. This work was
extended by incorporation of Raman reporters which allowed for localisation of
the SERS probe within the cell, leading to chemical probing of sub cellular
nanostructures65–68. For example, in 2010, the group showed how a SERS
nanosensor was capable of investigating pH changes in a cell throughout the
stages of the endocytic pathway of the nanoparticle probe. The study was based
on changes in the pH of the local environment in different cellular organelles
which can be monitored via changes in the pH sensitive nanoprobe over time 69.
Other cellular studies have also investigated the possible use of SERS in
the investigation of cell surface receptors associated with cancer. In one such
study, Kong et al 2012 used organometallic SERS active nanoparticles which
were targeted to live cells expressing the EGFR (epidermal growth factor
receptor). The SERS nanoparticles were shown to be capable of specific targeting
to the cell surface and offered increased sensitivity in comparison to other
imaging modalities70.

Figure 2.1 a-e, shows oral squamous cell carcinoma

(OSCC) cells expressing the epidermal growth factor receptor (EGFR), c and e
show the SERS image generated by CO at 2030cm-1 and protein at 1600cm-1
respectively. The targeting is verified in Figure 2.1 f – j in a non-EGFR expressing
cell line SKOV3 (ovarian carcinoma) and in Figure 2.1 k-p by blockage of the
EGFR using an EGFR antibody.
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Figure 2.1 shows (a, f, k) the brightfield image, (b, g, l) the darkfield image of the
nanoparticles, c, h, m) the SERS image of CO at 2030cm-1, (d, I, o) merged SERS
and brightfield, and (e, j, p) the SERS image generated using the protein band at
1600cm1. a – e shows OSCC cells, f – g SKOV3 cells not expressing EGFR and k
– p OSCC cells treated with anti-EGFR. Reproduced from 70
Another demonstrated application of SERS in is the analysis of human
serum. Lin et al., in 2011, demonstrated the power of SERS coupled with
multivariate analysis to distinguish in a non-invasive way between patients
previously diagnosed with colorectal cancer and control patients with 100%
diagnostic sensitivity and specificity71.
In-vivo SERS is also possible, and has been demonstrated as a potential
labelling method for a number of applications. SERS has been used in-vivo to
investigate how enhancement of the Raman signal can be used as a method for
tumour detection. Qian et al. showed how EGFR targeting PEGylated gold
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nanoparticles labelled with a Raman reporter where capable of >200 times greater
signal generation in the infrared compared to that of near infrared fluorescent
quantum dots, which allowed for the possible identification of small tumours at
penetration depths of ~ 1-2cm60. Other in-vivo applications of SERS have also
been explored, including an in-vivo study of inflammation in mice72,
demonstrating improvements over fluorescent based methods. SERS has also
been shown to be capable of single molecule detection in-vitro, a sensitivity
which sets it apart from spontaneous Raman spectroscopy73.
More complex Raman based investigations have also taken advantage of
the surface enhancement process. Techniques such as deep penetrating spatially
offset Raman (SORS) have been combined with nanoparticle based SERS in
SESORS7475. In brief, in the SORS technique, introduced in a paper by Matousek
et al, the Raman spectra are collected at positions spatially offset from the point
of incidence of the probe laser beam. Rather than using microscopic objectives
for delivery and collection, fibre probes are used. By moving the collection point
away from the probe launch site, contributions from the surface Raman photons
are diminished and those of Raman photons from deeper within the sample are
increased. Using multivariate statistical methods, it is possible to reconstruct
spectra from the different layers with a much greater depth of penetration than a
traditional confocal microscopy setup76. Depth sensitivities of up to several
millimeters are now achievable and examples of emerging applications include
non-invasive diagnosis of bone disease, cancer and monitoring of glucose levels77
SESORS uses this same principal, taking advantage of the surface enhancement
of the Raman signal from metallic nanoparticles embedded within the sample. In
a recent publication by Xie et al, SESORS was used to identify bisphosphonate-
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functionalized nanotags on bone through 20mm of porcine tissue78. This study
highlights the increasing potential for in-vivo applications which SORS and
SESORS may have, in the field of nanomedicine.
SERS has enjoyed increasing popularity over the past decade, particularly
since the emergence of as increasing range of nanoprobes. However, the uptake
rates and mechanisms as well as the subsequent trafficking may be specific to the
nanoparticle type, size and surface chemistry. Most SERS probes are specifically
designed for a target application and so are labels themselves for the SERS signal.
Furthermore, the molecular specificity of the surface enhancement process is not
well understood. Therefore, a truly label free method for generic monitoring and
characterising the cellular uptake and subcellular localisation of nanoparticles in
general is still required.
TERS another method for generating enhancement of the Raman signal.
Like nanoparticle based SERS, this method is also based on probing of the
inherent nanoscale environment of the sample in close proximity to a nanoprobe
and will therefore be discussed.

2.4 TERS
Tip Enhanced Raman spectroscopy, or TERS, is a method which combines
Raman spectroscopy and scanning probe microscopic techniques such as AFM.
TERS, like SERS, is a method to enhance the Raman signal and, in principle, the
mechanism of enhancement is the same. Scanning probe tips have dimensions of
the order of tens of nanometers or less, and when metal coated, surface plasmon
resonances can be optically induced, similar to the case for metallic nanoparticles.
In TERS, the topography of the nanoscale environment of samples can be probed
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by bringing the tip into close proximity with the area of the sample to be probed,
but the Raman signal from the environment being probed by the tip is selectively
enhanced by several orders of magnitude, swamping the spontaneous Raman
from the remainder of the illuminated spot. Therefore TERS is a method which
allows for very small areas or even individual molecules to be probed in a label
free manner.
TERS has been used to investigate viral cell interaction79, cytochrome-c
states in isolated mitochondria80, lipid and protein organisation in artificial cell
membranes81, as well as hemozoin crystal formation inside malaria infected red
blood cells, as shown in Figure 2.282. Figure 2.2. A –C show AFM images of
infected red blood cells, highlighting the hemozoin crystals inside the cellular
vacuole in C. Figure 2.2 D shows the TERS spectrum from the edge of the crystal
deposits showing characteristic peaks associated hemozoin and the profile is
compared to the SERS and RRS spectra of β-hematin in F and G . This study
highlights TERS as a nanoscale technique with can be used to probe very specific
areas which may have implications in disease. In this instance, TERS provides a
potential method to study the interaction of quinoline anti-malarial drugs which
are believed to preferentially bind to the edge of hemozoin crystals.
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Figure 2.2 TERS probing hemozoin crystal formation inside malaria infected red
blood cells. A – C show AFM images of infected red blood cells. D shows the
TERS spectrum for the edge of the hemozoin crystal deposit, E is the spectrum of
the tip following retraction from the cell, F SERS spectrum of β-hematin, G
resonance Raman (RR) spectrum of β-hematin. Reproduced from 82.
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TERS has also been used in the investigation of the interaction between
cells and nanoparticles. Alexander and Schultz (2012) were able to show the
interaction of individual antibody conjugated nanoparticles and cell surface bio
molecules using TERS, with a similar sensitivity to SERS 83.
However, as TERS requires the use of AFM tips to enhance the signal, the
method is restricted to being a surface classification technique and thus is of
limited use for intracellular or indeed ex-vivo or in-vivo tissue analysis. While
surface enhanced methods provide promise in a number of nanomedical areas,
there are some caveats associated with these methods. Firstly, the probe must be
capable of generating a surface enhancement of the Raman signal; this is only
applicable to certain types of gold and silver particles or coated tips, as well as
nanoaggregates of these metals. Additionally, these techniques require a
considerable expertise in synthetic chemistry and design of probes or tips for
specific target applications. Furthermore, reproducibility of the enhancement is
also a concern, in particular with TERS, were the reproducibility of the tip
characteristics is important in gathering reproducible spectra. Therefore it is
important to consider that, while surface enhanced methods have been shown to
be capable of nanoscale accuracy, these methods are heavily reliant on
specifically designed nanoparticle sensors or probes and tips which in some way
dilutes the label free aspect which spontaneous Raman spectroscopy provides.

2.5 Spontaneous Raman Spectroscopy
To differentiate it from the numerous variants of Raman spectroscopy which have
emerged over the past decades, including SERS and TERS, the originally named
phenomenon of Raman spectroscopy is now frequently called spontaneous
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Raman spectroscopy. Spontaneous Raman spectroscopy has been used
extensively over the past decades for a range of biomedical applications and is
emerging as a viable alternative to gold standard protocols in medical diagnostics.
Other uses include investigations in blood84 and serum samples85, investigations
of human skin38,39, cellular investigations86–88, in-vivo41 and ex-vivo35
characterisations as well as studies of interaction of nanoparticles36.
Importantly, these applications using Raman spectroscopy rely on the use
of data analytical methods which aid in the classification and understanding of
the data which has been acquired. This may entail the use of chemometric
methods to cluster a data set so that one can see a cell or tissue as a distribution
of similar spectra in a map. Multivariate statistical methods can be employed for
the separation of two different classes of spectra e.g. a diseased and non-diseased
state. A full description of such analytical methods is beyond the scope of this
review. However, it is important to highlight how Raman spectroscopy and
multivariate data mining approaches are commonly used together to investigate
the biochemical nature of samples.

Some good examples of where these

statistical methods have been applied to Rama hyperspectral datasets can be found
here87,89,90.
Despite the extensive development of Raman spectroscopy for biomedical
applications and the specific use of SERS using nanoprobes, not many studies
have explored the use of spontaneous Raman spectroscopy for nanomedical
applications. Of the reports that exist, some have aimed to look at probing cells
for a toxic response36,91, others have aimed to look at how nanomaterials behave
in a cellular environment 34,92 and some have looked at degradation patterns of
potential nanoparticle drug carriers93.
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The potential of Raman spectroscopy as a toxicological screening method
has been demonstrated for the case of carbon nanotubes and their effects on
human cells in-vitro. Kneif et al 2010, showed how the cellular spectral signatures
differed between control and exposed cells due to changes in specific Raman
spectral peaks of the cell nuclei. This method provided a way of investigating the
toxic response of cells to nanomaterials in a truly label free manner, compared to
more typical dye based cytotoxicity testing. In addition to detecting differences
in response due to nanoparticle exposure, it was also possible to statistically
compare the dose dependent responses of the Raman signatures with other gold
standard toxicity tests, demonstrating the potential of the technique as a
quantitative high throughput screening assay36.
In a different type of study by Dorney et al 2012, the aim was to
demonstrate the potential of Raman spectroscopy to visualise and investigate the
interaction of polystyrene nanoparticles in cells. The purpose was to use these
particles, which are often used as a standard in toxicity studies, as a model particle
for further applications using Raman spectroscopy. In brief, the Raman
spectroscopic signatures of the cells were mapped with a step size of 0.75µm over
a region which contained both nuclear, perinuclear and cytoplasmic regions of
the cell. Using a combination of K-means clustering and principal component
analysis, it was possible to identify the localisation of the particles inside cells
based on the intrinsic polystyrene signature and also to probe the chemical
characteristics of the local subcellular environment 34. A highlight of the results in
shown in Figure 2.3 for cells incubated for 24hrs with polystyrene nanoparticles.
The image in Figure 2.3 (i) shows the brightfield image (A) and the K-means
image constructed for the Raman hyper spectral dataset (B). The polystyrene
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nanoparticles are shown as green pixels in the image and the K-means average
spectra are shown in Figure 2.3 (ii) A-D. The cluster associated with the green
pixels clearly shows characteristic peaks associated with polystyrene when
compared to a pure sample spectrum, Figure 2.3 (iii) A and B. The light blue and
green clusters were then compared using Principal Component Analysis showing
that the nanoparticles are located in lipid rich regions of the cell, which, by
comparison with confocal fluorescence microscopy, was demonstrated to be the
endoplasmic reticulum.
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Figure 2.3. Identification of intracellular distributions of polystyrene
nanoparticles using Raman spectroscopy. (i) A shows the brightfield and (B) Kmeans image of the cell. (ii) shows the K-means cluster average spectra
associated with the clusters in the K-means image in the panel above, (iii) shows
the K-means cluster spectrum associated with polystyrene nanoparticles (A)
compared with a pure spectrum of polystyrene (B). The Right panels show a
Principal Component Analysis scatter plot (top), differentiating the green
(nanoparticle) and light blue clusters (cytoplasm), and the loading of Principal
Component 1 (Bottom, A), suggesting the local environment surrounding the
nanoparticles is lipid rich. Reproduced from 34.
Another recent study by Chernenko et al94 aimed to investigate how
different types of deuterated liposomal nanoparticles are distributed in cells.
More specifically, it aimed to investigate how different chemical compositions
affected how the liposomes associated with the mitochondrion. Notable in this
study is the use of deuterated liposomes to enhance the ability to differentiate
liposomes from endogenous lipids in the cell, based on the fact that the C-D
vibrational frequency is significantly down shifted from that of the C-H stretch of
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the very abundant intrinsic macromolecules of the cell. Another paper by the same
group also looked at the degradation of polymeric nanoparticles over time in cells
and concluded that poly lactic-co-glycolic acid (PLGA) and polycaprolactone
(PCL) drug delivery systems are degraded and incorporated into the late
endosomes of the Golgi system, based on spectral changes associated with the
specific degradation patterns of the nanocarriers93.
Spontaneous

Raman

spectroscopy

has

therefore

already

been

demonstrated to be a chemically specific method for investigating nanoparticle
interactions and also to probe the biochemical nature of cells. Notably, a number
of biochemical features can be accessed simultaneously without the need for
fluorescence or other labelling methods, or for costly cytotoxicological assays. It
should be noted, however, that, based on current technologies, spontaneous
Raman is a relatively weak effect, thus highlighting the attention which surface
enhanced techniques such as SERS and TERS have received. Relatively weak
signals can be compensated for by longer acquisition times, with maximum 2D
scan times of the order of 40-80 mins for a 50µm*50µm area with a step size of
500nm for cellular data95. However, these scan speeds are largely dependent on
the required signal to noise ratio and the step size used in image acquisition. For
these reasons real-time imaging has not been realised to date.
Ultimately, for in-vivo applications, penetration depth is also an important
consideration. In Raman microscopy, sensitivities are optimised by choice of
objective, providing optical spatial resolution but limited penetration depth (~150µm). As Raman spectroscopy is an optical technique, the penetration depth is
largely determined by the choice of wavelength of the source laser, and optimally
this can be chosen in the near infrared region where tissue has a transmission
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window. Absorption is largely governed by that of chromophores such as melanin
(in skin) or haemoglobin across the visible, and by the overtones of OH vibrations
in the near infra red regions. Scattering is an additional loss mechanism, but the
development of Spatially Off-Set Raman Spectroscopy 77 using fibre probe rather
than microscope objective delivery and collection optics, has exploited the fact
that the signal from the deeper layers is scattered to a greater extent, to improve
penetration depth sensitivities. CARS is another label free type of Raman
scattering which can be used to probe bio and nanomedical scenarios and in recent
years has seen a growth in applications in cells, tissues and in-vivo imaging. Using
single wavelengths, imaging of large areas can be achieved at video rates.

2.6 CARS
Coherent anti-Stokes Raman spectroscopy (CARS) is a form of Raman
spectroscopy whereby the anti-Stokes shifted Raman signal is used to probe the
molecular bonds within a sample. The coherent process takes advantage of a third
order non-linear optical phenomenon by which three beams are used to probe the
sample. A fixed pump laser beam, a tunable probe beam are set at a frequency
difference which is exactly equal to the frequency of a specific molecular
vibration, resulting in the coherent build-up of a scattered signal on the antiStokes side of the pump laser frequency96,97. The signal can be orders of
magnitude larger than a spontaneous Raman signal. Thus, CARS can be used to
rapidly generate images of a particular biochemical distribution and therefore can
be used in the generation of video rate image sequences of cells and tissues. To
generate a full spectroscopic signature, however, the pump beam has to be tuned
such that the difference frequencies scan the vibrational spectrum, a process
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which can take considerable time, under current technological constraints. The
nonlinear process is furthermore intensity dependent, requiring costly and
notoriously temperamental short pulse lasers, whereas spontaneous Raman can
be conducted with conventional steady state lasers.
In a biomedical context, the technique has been used to investigate a
number of phenomena, also in conjunction with other methods such as immunofluorescent labelling. Primarily, CARS has been used in the study of the C-H
stretch region which is most commonly associated with lipids in living organisms.
Examples include the use of CARS for the study of atherosclerotic lesions 98,
intracellular trafficking99, drug delivery100, cancer metastasis101, quantitative
imaging of lipid distributions in living Caenorhabditis elegans102 as well as
imaging of the axonal myelin both in-vivo and ex-vivo103,104 CARS has also been
used in the assessment of nanomaterials. Notably ,the technique has been used to
study particle interaction in biological organisms, receptor mediated particle
uptake105 as well as the effects of particle size and coating on zebra fish
embryos106. Moger et al107 used CARS to investigate the interaction of metal
oxide nanoparticles within the gills of rainbow trout, Onchrhynchus mykiss. They
were able to show in a label free manner the translocation of TIO2 particles across
the epithelial membrane and into the capillaries in fish gill tissue. This is shown
in figure 2.4, which illustrates the forward (a) and epi-CARS images (b) of
exposed fish gills. The merged image shows the localisation of the particles in
the gill tissues, revealing particle clumps in green.
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Figure 2.4 CARS images of the TiO2 nanoparticle distribution in Onchrhynchus
mykiss gills, (a) forward CARS image showing the nanoparticles, (b) epi-CARS
image of the gill tissue and (c) merged forward and epi CARS image. Images
reproduced from 107.
The method has also recently been used to investigate the mechanisms of
oral uptake of Quaternary Ammonium Palmitoyl Glycol chitosan (GCPQ)
nanoparticles. In this study, the particles were deuterated to shift the CH 2
stretching vibration located at 2840cm-1 to a CD2 stretching vibration of 2100cm1

. This allows for CARS to be carried out in the so called ‘silent region’ of the

cell. Additionally second harmonic generation and two photon fluorescence were
used to image the tissue containing nanoparticles. In doing this, Garrett et al.
were able to examine chitosan uptake and recirculation in the gut by being able
to target the nanoparticles with cellular precision to the gastrointestinal tract, liver
and gall bladder, providing novel insights in the role of enterocytes and bile
recirculation regarding chitosan nanoparticles100,108. Figure 2.5 shows the
identification of the deuterated nanoparticles in green (2100cm-1), which are
highlighted by the arrows. Figure 2.5A and 2.5B show liver and stomach tissue
respectively, with the C-D2 resonance being used to identify the deuterated
nanoparticles (2100cm-1) in green and the C-H2 (2845cm-1) in red. Figure 2.5C
shows a multimodal label free imaging approach combining CARS imaging
(green), second harmonic generation (SHG) and two photon fluorescence (TPF)
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in imaging nanoparticle interaction with jejunum tissue. Figure 2.5D and 2.5E
show the use of a combination of CARS and TPF to image the ileum and
duodenum respectively, while Figure 2.5F shows a combination of CARS, SHG
and TPF of the gall bladder. These approaches show not only how CARS can be
used to probe nanoparticle interactions, but also highlight how multiple imaging
approaches can be combined in multimodal approaches to give different types of
information building towards a more complete picture.

Figure 2.5 Epi-CARS images with contrast derived from CD2 and CH2
resonances in GCPQ nanoparticles at 2100 cm−1 (green) and 2845cm−1 (red)
respectively. (A) Liver tissue. (B) Stomach tissue samples. (C) shows Jejunum
tissue imaged with epi-CARS with contrast derived from the CD2 resonance
(green), SHG contrast derived from collagen (blue) and TPF contrast derived
from endogenous fluorophores. (D) Ileum tissue imaged with epi-CARS with
contrast derived from the CD2 and TPF (red) (E) Duodenum imaged with epiCARS with contrast derived from the CD2 and TPF (red). (F) Gall bladder
imaged with epi-CARS with contrast derived from the CD2 resonance (green),
SHG (blue) and TPF (red). Reproduced from100
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Surface enhancement can also be exploited in the CARS format. Surface
enhanced CARS (SECARS) has been used in conjunction with nanoparticles and
has been shown to be capable of achieving greater signal enhancement than that
of SERS or CARS alone. For biomedical applications, it has also been used for
the detection of single molecules of deoxyadenosine and deoxyguanosine
monophosphate (dAMP and dGMP)109 and has also been used in immunohistochemistry studies110.

2.7 Conclusions and Outlook
This article has attempted to provide an overview of the current state of the art of
the developing applications of Raman spectroscopic techniques in Nanomedicine.
A recent review has dealt more broadly with the applications of these techniques
in the investigation of the interaction of nanomaterials with complex biological
systems111. The development of biomedical applications of vibrational
spectroscopy, both Raman and IR, has been extremely active for the past two
decades and more and the challenges to nanomedical applications are intrinsically
linked, as indeed they are to those of the fundamental understanding of nanobio
interactions in general.
As a molecular specific tool, Raman spectroscopy can potentially aid
significantly to the understanding of nanobio interactions in-vitro. Even before
interaction with the cell, it has been argued that the biological identity of the
nanoparticle is determined by the surface coatings of the dispersion medium, the
co-called protein corona112. While SERS active nanoparticles can be employed to
probe this interaction acellularly, there is evidence that the nanoparticle medium
interaction is very specific to the surface characteristics and size, and thus the use
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of truly label free spontaneous Raman spectroscopy may lead to broader insights.
In this context, the increased sensitivity of TERS may be of significant benefit.
SERS has however demonstrated that the surface coating can evolve significantly
after endocytosis of the nanoparticle 111, and this is a critical consideration in the
bioavailability of surface functionalities, including release of active ingredients,
which have been specifically designed for nanomedical applications.
As an confocal optical microscopic technique, Raman holds all the
benefits of confocal fluorescence techniques, but has the potential advantage of
being truly label free, adding the promise of reduced cost and sample processing
requirements. SERS probes have demonstrated the potential to probe nanoparticle
uptake, trafficking as well as the local environment, but these probes need to be
specifically chemically tailored for the given application can so the technique
cannot be considered to be truly label free. Spontaneous Raman spectroscopy is,
on the other hand, an intrinsically weak phenomenon and cellular mapping is
often a prolonged processes. Nevertheless, a number of cellular studies have been
conducted which, although not specifically probing nanoparticles, may have
implications in future nanomedical applications. For example, some studies have
shown the application of Raman to drug delivery investigations113,114 while other
studies have identified sub cellular structures such as the mitochondrion as well
as lipid rich regions which may be associated with the Golgi and endoplasmic
reticulum88. Klein et al. used image registration and immuno-fluorescence to
verify the locations of cellular organelles and also as a means of extracting the
spectra which were specifically associated with the organelle 115. These studies
could be extended to look at nanoparticle trafficking studies, colocalizing the
particle to an organelle in a label free manner, without using fluorescently labelled
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nanoparticles or organelle stains. Although spontaneous Raman studies are
commonly conducted on fixed cells, live cell spectral profiling has been
demonstrated40. Image analysis is ultimately dependent on the reliability of
multivariate chemometric techniques and simulated model systems can prove
invaluable in validating their accuracy83. Increased acquisition rates can be
achieved by systems custom designed for biological applications, and CARS
potentially offers a route towards routine in-vitro screening of intracellular
nanobio interactions, although its ability to rapidly screen the full spectrum is
currently limited by the (tuneable) laser source technologies and applications are
thus restricted by the need to identify specific spectral marker bands.
In terms of disease diagnostics, ex-vivo applications of Raman
spectroscopy have received much attention. For the range of Raman modalities,
however, mapping of large areas of tissue biopsies also suffer from issues of weak
signals (spontaneous), specifically targeted probes (SERS), surface sensitivity
(TERS) or the need for specific spectral markers (CARS). As a chemically
specific probe, however, Raman techniques are particularly suitable for analysis
of biomarkers of disease in biological fluids7374 and this suitability is readily
extended to applications in nanomedicine.
Raman scattering is fundamentally an optical technique and in-vivo
applications are thus limited by the ability to access the area of interest. For
dermal analysis, custom designed systems are commercially available which
exploit the near infrared transmission window of skin, although, in a microscopic
format, the penetration depth is further limited by the delivery optics, typically to
some hundreds of microns. Advances in SORS have increased the depth
resolution, and such technologies could prove invaluable tools for analysis of
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transdermal nanodrug delivery or environmental exposure to nanoparticles. As an
optical technique, Raman spectroscopy readily lends itself to endoscopic
probes116, however, and recent advances in such in-vivo probes may significantly
impact on biomedical applications of Raman spectroscopy, including, inevitably
Nanomedicine.

2.8 Future Perspectives
The field of nanotechnology is set to grow ever rapidly as new applications and
avenues of research are explored over the coming decade. Crucially,
characterisation and visualisation methods in a medical setting must develop in
tandem, to access the applicability of such nanotechnology. Raman spectroscopy
represents a method proven in the field of disease diagnostics and biomedical
imaging and thus by extension holds the capability to progress the field of
nanomedicine.
Spontaneous Raman spectroscopy provides a versatile and truly label free
method which has seen success in a number of different medical applications,
most notably in disease diagnostics. Key enabling technological developments in
this context include endoscopic and other in-vivo probes. Relatively Low signal
strengths currently limit the technique to small areas and/or long scan times,
however, and continuing improvements in signal throughput and detector
sensitivities are important. EU Directives limiting the use of animal models will
put increasing emphasis on the development of in-vitro screening methods and
Raman is a potential candidate for high content analysis of, for example, the
efficacy and mode of action of novel chemotherapeutical agents of toxicants. The
high optical resolutions obtainable make Raman particularly suitable for acellular
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or subcellular studies of nanobio interactions. As the sensitivity of the Raman
technique is intimately linked with the multivariate statistical data analysis
methods, the quantitative specificities of these methods must be established. This
can only be done if the true result is known, and in this context the use of
specifically constructed model datasets may provide a quantifiable insight into
how far Raman spectroscopy can be pushed in both a medical and nanomedical
context.
SERS provides increased sensitivities to probe the nanoscale environment
surrounding metallic nanoparticles. Although the technique is not truly label free,
with the increased sensitivities achievable as well as the targeting potential of
such probes, SERS may provide alternative imaging strategies for disease
diagnostics in-vivo, as well as provide enhanced methods for the monitoring of
human fluids such as serum and other metabolic excretions ex-vivo. SERS invitro may also prove a useful tool in probing the nature of the so called protein
corona of nanoparticles in biological media and thus provide valuable insights
into the surface behaviour of nanomaterials in a biological setting. Other
enhancement methods such as TERS also provide novel insights into the
nanoscale environment although they are limited by being mainly a molecular or
surface specific technique.
Coupling these advances in spontaneous and surface enhanced Raman
with the development of SORS and SESORS, some of the shortcomings in signal
generation and depth penetration of Raman spectroscopy in-vivo may be
overcome. In addition to the development of endoscopic and needle based probes
which will increase access to the point of interest, realistic applicable in-vivo
Raman studies in nanomedicine may not be too far away. CARS provides a
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method which is capable of video rate scan speeds. However, as of yet the
technique is not a spectroscopic imaging technique as it only allows for the
probing of one particular wave number or vibrational marker at a time. The
technique therefore requires a clearly identifiable biomarker for imaging, which
may not be the case for all biomolecules. A CARS system that could provide a
spectrum of the finger print region of the sample with similar real time imaging
capabilities would be ideal. Specifically for CARS to progress as a spectroscopic
imaging modality, advances in laser technology such as rapidly tunable lasers will
need to develop in tandem. These advances would then open a myriad of
applications for CARS imaging along the lines of spontaneous Raman imaging.

2.9 Executive Summary
Raman Spectroscopy: Raman spectroscopy is a well-established chemical
analysis technique finding increasingly broader applications, particularly in
biochemical analysis and disease diagnostics.
Surface/Tip enhanced Raman Spectroscopy: The techniques of SERS and
TERS specifically probe the nanoscale and, although TERS is a topical/surface
technique, SERS probes have already been used extensively for in-vitro and invivo studies. SERS probes are normally chemically functionalised according to
the specific target, and so the technique is arguably not truly label free.
Spontaneous Raman Spectroscopy: As a truly label free technique,
(spontaneous) Raman spectroscopy, coupled with multivariate analytical
techniques potentially provides a probe of nanoparticles in cells/tissue, their
nature of their local environment, and physiological changes. Unenhanced, the
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signals are however relatively weak, and large scale mapping can be time
consuming.
Coherent anti-Stokes Raman Spectroscopy: CARS is a nonlinear optical
technique which is increasing in prominence for biomedical applications. Tuned
to a specific vibrational frequency, it can scan large areas (cm2) at video rates.
Currently, however, it is not a spectroscopic technique and does not avail of the
full biochemical information available, but relies on the presence of a specific
spectral marker.
Outlook: The range of modalities of Raman spectroscopy potentially hold great
promise for biomedical and nanomedical applications, although many technical
challenges remain.
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Chapter 3 Introduction to Raman spectroscopy and
multivariate analytical methodologies applied to spectral
datasets.

The following chapter contains sections from a journal article published in the
Chemical Society Reviews, entitled: Spectral pre and post processing for Infrared
and Raman spectroscopy of biological tissues and cells which Hugh J. Byrne was
primary author, Peter Kneif was second and contributing author, Mark E. Keating
was third contributing author with sections 3.2 – 3.9 used in the manuscript and
Franck Bonnier was final contributing author.

Byrne HJ, Knief P, Keating ME, Bonnier F. Spectral pre and post processing for
infrared and Raman spectroscopy of biological tissues and cells. Chem Soc Rev.
DOI: 10.1039/c5cs00440c.

54

3.1 Introduction to Raman spectroscopy
Upon interaction with a material, light can be reflected, absorbed, or scattered.
Raleigh scattering (elastic scattering) is when the scattered light is of the same
frequency as the incident light. Raman scattering (inelastic scattering) is a result
of light that is scattered by a material, whereby its frequency differs from that of
the incident light, as a result of the interaction of a photon with the vibrations of
a molecule.
In Raman scattering, the energy increase or decrease from the excitation is related
to the vibrational energy spacing in the ground electronic state of the molecule,
and therefore the Raman shift of the Stokes and anti-Stokes lines are a direct
measure of the vibrational energies in a molecule. In Stokes Raman scattering,
the molecule starts out in a lower vibrational energy state and, after the scattering
process, ends up in a higher vibrational energy state. Therefore, the interaction of
incident light with the molecule creates a vibration in a material and the scattered
photon is reduced in energy.
In anti-Stokes Raman scattering, the molecule begins in a higher vibrational
energy state and, after the scattering process, ends up in a lower vibrational energy
state. Thus, a vibrational quantum in the material is annihilated as a result of the
process and the scattered photon has an increased energy. The frequency
differences between the Raman lines and the incident lines are characteristic of
the scattering substance and are independent of the frequency of excitation.
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The Raman effect arises from the coupling of the induced polarisation of
scattering molecules, which is caused by the interaction of the electric field vector
of the electromagnetic radiation with the molecular vibration modes. Light of
frequency (ωL) produces a polarisation in a material given by equation 3.1
P(ωL) = χ(ωL) E0cos ωLT

Equation 3.1

where P is the polarisation, ωL is the frequency of incident light, E is the electric
field and χ(ωL) is the polarisability or susceptibility, normally considered a
constant of the material associated with its electronic properties. However, at a
finite temperature, a material is not at equilibrium and atoms will vibrate about
there equilibrium position, R, along the normal coordinates with frequency ω K, in
accordance with a simple harmonic oscillator approximation. The displacement
from equilibrium can be explained by equation 3.2
ΔR(t) = ΔRcos(ωkt)

Equation 3.2

The susceptibility to polarisation thus oscillates about its equilibrium value χ0 and
can be represented by equation 3.3
χk(t) = χ0 + Δ χkcos(ωkt)

Equation 3.3

The polarisation now has the form as illustrated in equation 3.4
P(ωL, ωk) = χ0(ωL)E0cosωLt +Δ χkE0cos(ωL)tcos(ωk - δk)
Equation 3.4
where δk takes into account any phase difference between the molecular vibration
and the electric field oscillation. This may be written as equation 3.5
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P(ωL, ωk) = χ0(ωL)E0cosωLt +1/2ΔχkE0(COS((ωL -ωk)t - δk) + cos((ωL +ωk)t + δk))
Equation 3.5
Thus, the polarisation has the form
P = P(ω0) + P(ω0 - ωk) + P(ω0 + ωk)
Equation 3.6
An oscillating dipole will reradiate at the oscillation frequency, and thus the
scattered light has three components. P(ω0) gives rise to Raleigh scattering. P(ω0
- ωk) corresponds to the subtraction of a vibrational quantum from the photon
energy and the creation of a vibration and gives rise to the Stokes lines of the
Raman spectrum. P(ω0 + ωk) corresponds to the addition of a vibrational quantum
to the photon by the annihilation of a vibration and results in the anti-Stokes lines
of a Raman spectrum

3.2 Introduction to Multivariate Methods Applied to Raman
Spectral Datasets.
Multivariate methods have become invaluable to a wide range of fields, including
geology, pharmaceutical science, pharmacology, astrophysics,

imaging,

chemistry and the list goes on. Importantly, these methods allow for complicated
and also in some instances very large datasets to be analysed and in effect they
reduce the dimensionality and complexity of the data allowing for meaningful
information to be extracted.
Specifically considering vibrational spectroscopic datasets, multivariate
methods allow analysis of multiple spectra simultaneous and interdependently.
This then allows for comparisons to be made between spectra and groups of
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spectra within a dataset and to identify trends these may contain e.g. spectral
markers of disease in control and non-control patients, identification of
nanoparticle containing spectra, response to external agents such as drug or
toxicants etc.
A Raman dataset usually consists of groups of spectra, which, depending
on the sample and study being carried out, can be a set of random points, averaged
spectra which can be the function of an external stimulus such as radiation, a
chemical agent, nanoparticle etc. As the main focus of this work is centred on
nanoparticle localisation and in-vitro drug screening using Raman spectral
microscopy, multivariate statistical methodologies applied in this area will be
discussed in more detail.
In Raman spectral microscopy, the dataset consists of a group of spectra
which have been acquired via point mapping or raster scanning of a sample which
may be cells or tissues, in in-vitro or in-vivo studies. As an imaging tool, much
like fluorescent confocal laser scanning microscopy (CLSM), the sample has been
scanned point by point, resulting in a dataset or in the case of spectral imaging a
spectral hypercube. Unlike the simplicity of standard fluorescent imaging,
whereby the dataset contains only one value per pixel, spectral hypercubes (as the
name suggests) contain multiple data points per pixel which correspond to the
spectrum acquired at that location. Similarly when spectra are acquired point by
point each spectrum corresponds to the location sampled, without the spatial
localisation achieved when imaging, with the benefit of the user knowing where
the sample was acquired i.e. nucleus, cytoplasm etc.
As an imaging modality, to generate an image from this dataset, one must
reduce the number of data points at each pixel to a single value. The simplest way
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to achieve this is to form an image from one particular wavenumber in the
spectrum. However, this method is somewhat flawed in that, if the peak in
question corresponds to multiple biomolecules in a sample, it would be difficult
to provide an accurate image of one particular composition. Nevertheless, in some
instances, for example if a sample has a very distinctive peak, this may be the
simplest way to generate an image. In a similar way, separation and classification
can be achieved by single wavenumbers or ratios using point by point acquisition,
although the multivariate nature of the technique is somewhat diluted if only a
single wavenumber is used. Again if there is a prevalent change across the dataset
this may be the simplest way to analyse the spectra.
As necessary, a myriad of methods have been developed to overcome this
problem in spectral analysis. Using Raman spectroscopy as an example of where
these methods are applied, clustering methods such as hierarchal clustering
analysis (HCA), k-means clustering analysis (KMCA) and fuzzy c-means
clustering (FCM) have been used to cluster spectra into groups and then based on
these groups or classes, images and scatter plots can thus be generated following
analysis. These clustering methods can be described as ‘hard clustering’ methods,
in that each spectra is assigned a unique value and if a spectra has been assigned
to one cluster it cannot be assigned to another.
Other methods have also been applied to Raman spectral analysis,
including principal component analysis (PCA) and vertex component analysis
(VCA). Both have been used for a number of applications. PCA has been used
quite extensively to separate different sets of data based on the spectral variance
present. This may be in a diagnostic setting and also in a spectral imaging sense.

59

VCA has also been used in this capacity although primarily in a Raman imaging
setting.
Factor analysis methods have also been applied to Raman spectral
datasets e.g. matrix factorisation (MF). In some instances, these methods are used
to generate model spectra which in turn can be combined with other analytical
approaches such as classical least squares analysis (CLSA) to evaluate, in a semi
-quantitative way, the weighted contribution of each model spectrum to a
particular spectrum for both images and individual groups of spectra.
This section of the introduction aims to give a brief description of some
of the data mining approaches used to analyse vibrational spectroscopic data,
focusing specifically on Raman spectroscopy, although examples from other
spectral modalities such as IR spectroscopy will also be discussed in this context.
The techniques which are explored more extensively in the thesis (e.g. KMCA,
CLSA, PLSR and PCA) are described in more detail.

3.3 K-Means Cluster Analysis
K-means clustering analysis (KMCA) is a statistical method which aims to
partition data into clusters based on similarity. K-means aims to minimise the sum
of distances between spectral vectors 𝑆𝑗𝑖 and cluster centroids mk where J spectral
vectors originally are randomly assigned to belong to a given cluster k with
centroid mk1, see equation 3.7.
∑(𝑆𝑗𝑖 − 𝑚𝑘 ) Equation 3.7
Firstly, the method chooses a number of seed locations which serve as initial
centroid locations in the dataset. Once a data point is assigned to one of the seed
locations, it changes to a centroid which serves as a mean value of that cluster.
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The assignment of data points to clusters is often based on the Euclidean distance
between data point and centroid, although other methods of calculating the
distance also exist 2. After each spectrum has been assigned to a centroid, the
distance is then recalculated between each point and centroid to see if any points
are closer to another centroid location, whereupon, if the point is closer to another
cluster centroid, then it is reassigned and both cluster centroids are changed as a
result. This process is completed for all data points until there is no movement
between clusters.
So, considering K-means from a Raman spectroscopic imaging
perspective, an initial number of seed locations is chosen. The spectra are then
assigned to one of the seed locations. Once all spectra have been assigned, the
mean spectrum or centroid is calculated and the distance between each spectrum
and centroid is calculated. The spectra are then reassigned if necessary and the
process is iterated until no spectra change groups. Figure 3.1., shows a diagram
highlighting the main steps in the K-means clustering algorithm.
In Raman spectroscopy, KMCA has seen a number of uses to separate
spectra into clusters based on spectral similarities. As a Raman imaging tool,
KMCA aims to separate each spectrum acquired in the image and assign it to a
cluster. This assignment is termed ‘hard’ in that each spectrum is only assigned
to one cluster. A good example of KMCA in Raman spectroscopy is shown in the
work by Dorney et al3. Here, KMCA was used to identify regions in the Raman
dataset which correspond to polystyrene nanoparticles, and differentiate them
from neighbouring cytoplasm, as well as the nucleus and nucleolus. KMCA has
also seen uses in other areas of Raman spectroscopy and spectral imaging such as
the characterisation of skin layers. Good examples of KMCA as an spectroscopic
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imaging reconstruction technique exist, the technique having been used in the
investigation of a wide range of samples including tissue sections4, cells5,6 and in
the analysis of human skin7–9.
While this method has been shown to be useful in partitioning spectra into
clusters, it is important to highlight that the method is not without certain caveats.
Firstly, as the initial choice of centroid location can be subjective, the
reproducibility of the method can in some instances be called into question i.e. if
the initial starting point of the analysis changes then it is possible to end up with
different results, so in practice if multiple datasets need to be compared all data
should be analysed using the same centroid locations as these will change if
analysis is carried out separately. Secondly, looking at the method to assess
spectral imaging, each spectrum is assigned to only one cluster, and the cluster is
represented by the average of all constituent spectra. As a Raman spectrum may
represent a number of different biological entities in differing quantities, KMCA
may be correct in grouping a spectrum based on lipidic distribution. However, it
may misclassify a spectrum which also contains a small amount of another
cluster’s biochemistry. There is no weighting element introduced into the
analysis, so one spectrum must belong to only one cluster even if multiple
biochemical constituents are present. Thirdly, the number of clusters chosen is
subjective and thus dependant on the user, if the incorrect number of clusters are
chosen then spectra could be miss classified based on the loading from that group.
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Figure 3.1 Schematic diagram outlining KMCA.
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3.4 Fuzzy C – Means Clustering
Fuzzy C-means clustering is a method which is similar to KMCA in that it also
assigns spectra to centroids in the datasets. However, unlike KMCA, the method
is a soft clustering method, whereby each point or spectrum in the dataset is
assigned a value from 0 to 1 for each particular cluster centre, with the value
closest to 1 being representative of the cluster centre and 0 having no assignment.
The algorithm developed by Bedzek et al10, to calculate the degree of membership
for each spectrum in the dataset results in a vector of the format 𝑁𝑥 𝑁𝑦 ∗ 𝐶 since
each spectrum has C membership values. The co-efficients which describe
membership to a particular cluster are defined by the following equation.
𝑈𝑖𝑁𝑆 = ∑𝑐

1

2/(𝑚−1)
𝑐=1(𝑑𝑖𝑁𝑆 /𝑑𝑐𝑁𝑆 )

Equation 3.8

Where 𝑈𝑖𝑁𝑆 is the membership of the sample Ns in one cluster, where 𝑑𝑖𝑁𝑆 and
𝑑𝑐𝑁𝑆 are the distances to the ith and cth cluster centres and m is the fuzziness factor
between w and ∞.Therefore, by analysing the C centroid spectrum it is possible
to extract chemical information which describes each reconstructed image. FCM
has seen some usage in Raman spectroscopy although primarily as an imaging
method 5,6.

3.5 Hierarchal Cluster Analysis
Hierarchal clustering analysis is another method which is commonly used for
clustering spectral data and generating images. There are two main forms of
HCA, agglomerative and divisive. Agglomerative HCA is the more commonly
used method. Briefly, this method starts out with each data point or spectrum in
a separate group or cluster. The method then aims to group each data point
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together in an iterative process until there is only one cluster which contains all
the data points. It is then possible to construct an image based on how these
clusters are linked together. Often, the data can be represented using a two
dimensional dendrogram which shows the linkage between each cluster. Divisive
HCA on the other hand starts off with each spectrum in one cluster and then aims
to separate each data point into one cluster. An example dendrogram is shown in
Figure 3.2 An important point in relation to HCA is that, once a group of spectra
has been assigned to a cluster or in the case of the agglomerative method merged
into a cluster, the spectrum cannot be reassigned, unlike KMCA where the spectra
can move clusters if closer to another centroid. This means that HCA results in a
very definite grouping of spectra into clusters.
HCA is like KMCA in that the method is deemed to be a hard clustering
method with each spectrum being assigned to a specific group. From an image
reconstruction perspective and classification, this means that each pixel again can
only be assigned to one specific biochemical grouping, which may not be
reflective of the actual Raman dataset. HCA has been used in as a classification
method in number of studies which include cellular studies6 as well as in the
investigation of vibrational spectroscopy in diagnostics11.
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Figure. 3.2. Showing a HCA dendrogram and both divisive and agglomerative
clustering. Adapted from12.
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3.6 Vertex Component Analysis
Vertex component analysis is another multivariate statistical method which is
used in Raman spectral analysis13. The algorithm makes an assumption that,
contained within the dataset, are pure endmember spectra which in turn can be
used to describe all the other spectra in the dataset. From this, abundance plots
can be generated via a linear combination of endmember spectra and constructed
into images which are described by the biochemical information contained in
these endmember spectra.
Assuming a linear mixing scenario each observed spectral vector is given
by:
𝑟 = 𝑥 + 𝑛 = 𝑀𝛾𝛼 + 𝑛
Equation 3.9
Where r is an L-vector (L is the number of bands), M = [m1,m2……mp] is the
mixing matrix (mi denotes the ith endmember signature and p is the number of
end-members present in the covered area), s = γα(γ is a scale factor modelling
illumination variability due to surface topography), 𝛼 = [α1, α2…… αp]T is the
abundance vector containing the fractions of each end-member (.)T stands for the
vector transposed) and n model system additive noise.13
Recently, VCA has seen a number of applications in hyperspectral
imaging using both IR and Raman spectroscopy, with applications including
Raman histopathological imaging and also cellular studies including nano-bio
interactions4,14 Importantly, while this method can be used quite readily to
reconstruct biochemical regions in the cell, like all methods it may be prone to
error. Firstly, as highlighted in a paper by Chernenko et al.14, endmember spectra
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may contain mixtures of different biochemical components and while this may be
reflective of the actual nature of the sample, may lead to inaccuracies in
interpretation. Additionally, the method makes a large assumption that the most
extreme spectra in the dataset are the most reflective of pure component spectra,
which may not be the case in complex biological spectra.

3.7 Principal Component Analysis
PCA is a method which aims to reduce the dimensionality of the data to describe
the variation present in a dataset, whereby the first principal component is a
description of the maximum variance present in the dataset, the second describes
the second most variance…etc. The principal component scores can then be
described by the loading vector which is an explanation of this variance. In a
Raman spectroscopy context the scores represent values which correspond to a
loading spectrum which contains peaks, both positive and negative which
explains the spectral variation in the dataset.
This tool can be quite useful for providing a method to separate spectra
into groups e.g. diseased and non-diseased15. It has also been used to reconstruct
images6,16, i.e. a variance plot based on the loadings plot. However, as these
loadings plots may often contain a number of spectral features corresponding to
different cellular biochemistry, interpretation can be difficult and it is quite
possible to misinterpret. Bonnier et al have shown that pairwise PCA of clusters
identified by KMCA can provide a clearer picture of the specific biochemical
differences between region17.
In this thesis Seeded Principal Component Analysis (SePCA) is
introduced as a novel multivariate analysis variant to address some of the
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limitations of the application of PCA in bio-spectroscopy in systematically
varying datasets. Using simulated data based on experimental spectra of in-vitro
exposure to varying doses of the chemotherapeutic agent, cis-platin, standard and
SePCA are compared, firstly based on their ability to differentiate the responses
to different exposure doses, and secondly to assess the accuracy of the loadings
that are used to describe the systematic variations of biochemistry underlying the
differentiation. Further insights are also garnered on the use of 1 st and 2nd
derivative spectra and the impact this mathematical transformation has on the
ability of the algorithm to separate and describe the spectral origin of
differentiation of spectral datasets. The implications of this novel variant of PCA
are discussed in the context of screening for drug efficacy in-vitro as well as
biomedical classification for disease diagnostics.

3.8 Partial Least Squares Regression
Partial least squares regression (PLSR) is an analytical technique which aims to
match a test data set to a series of targets. In brief, the method aims to create a
model dataset which relates a spectral dataset to a series of test points or targets
(i.e. concentration, dosed). The spectral data (X matrix) is thus related to the
targets (Y matrix) according to the linear equation;
𝑌 = 𝑋𝐵 + 𝐸
Equation 3.10
where B is a matrix of regression coefficients and E is a matrix of residuals 18. A
good practical example of this method in action in Raman spectral data is outlined
in two studies by Nawaz et al.16,17, in which the aim was to investigate the
capability of Raman as a technique to study drug interactions in cells and the
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physiological response. Looking specifically at cis-platin as an example
chemotherapeutic drug, these studies were able to extract information relating to
drug action in the cells via regression of the Raman dataset against
cytotoxicological data and dose. Features were extracted from the Raman spectra
which correspond to changes to protein conformation and structural alterations of
DNA19,20.
Importantly, while these studies show the potential of Raman
spectroscopy and PLSR as tools for studying drug interaction, PLSR used in this
capacity is only relevant if the processes studied are in themselves linear.
However, most pharmacological actions are non-linear processes and thus using
a linear method to model a non-linear process may be subject to error. Thus,
additional forms of validation of these methods in a spectral setting are necessary.
In this thesis, PLSR is investigated using simulated datasets based on
previously published data. In this way the application of the PLSR algorithm is
investigated and the limits and sensitivities are explored using a simulated dose
and cytotoxicological target dataset, providing a methodology for the assessment
of multivariate approaches used for Raman in-vitro screening.

3.9 SVM
Support vector machines is a classifier which aims to partition data to give a
separation between control and sample. Generally, the algorithm is used in
conjunction with PCA, whereby the coefficient values are used to build a model
which is then used to classify samples. Initially data with a known classification
is used to train the model i.e. control vs. cancer. Once the model has been trained,
samples with an unknown grouping are classified based on their affinity for each
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group. In this way, it is possible to classify samples as one group or the other
when the grouping is unknown.

3.10 Concluding Remark
While the list of methods is far from exhaustive, it highlights some of the commonly
used analytical methods in Raman spectral analysis. Some of these methods have
certain caveats associated with them and thus may be prone to error for certain
applications. In the following chapters, some of the possible issues associated with
these methods in an in-vitro Raman setting are explored, primarily using simulated
datasets which are based on real experimental data. Novel variants and methods are
also explored to tackle some of the issues which have arisen while investigating these
methods, with the central thesis focusing on the use of simulated datasets in assessing
the validity, accuracy and applicability of multivariate statistical methodologies for invitro Raman screening and beyond. ‘
In the following chapters, some of the possible issues associated with these methods
in an in-vitro Raman setting are explored, primarily using simulated datasets which are
based on real experimental data. More detailed descriptions of the underlying theories of

PLSR analysis (Chapter 4), PCA (Chapter 5) and CLS analysis (Chapter 6) are
provided. Novel variants and methods are also explored to tackle some of the issues which
have arisen while investigating these methods, with the central thesis focusing on the use
of simulated datasets in assessing the validity, accuracy and applicability of multivariate
statistical methodologies for in-vitro Raman screening and beyond.
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Chapter 4 Multivariate statistical methodologies applied in
biomedical Raman spectroscopy: Assessing the validity of partial
least squares regression using simulated model datasets.

The following chapter contains sections from a journal article submitted to Analyst,
entitled: Multivariate statistical methodologies applied in biomedical Raman
spectroscopy: Assessing the validity of partial least squares regression using simulated
model datasets which Mark E. Keating was primary author and responsible for data
analysis, writing and formatting of the paper, Haq Nawaz was second author and
contributed code and spectral data, Franck Bonnier was third author and co-supervisor
and Hugh J. Byrne was final author and supervisor.

Keating ME, Nawaz H, Bonnier F, Byrne HJ. Multivariate statistical
methodologies applied in biomedical Raman spectroscopy: assessing the validity
of partial least squares regression using simulated model datasets. Analyst. 2015
Mar;16;140(7):2482-92. doi: 10.1039/c4an02167c.
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4.1 Abstract
Raman spectroscopy is fast becoming a valuable analytical tool in a number of
biomedical scenarios, most notably disease diagnostics. Importantly, the
technique has also shown increasing promise in the assessment of drug
interactions on a cellular and subcellular level, particularly when coupled with
multivariate statistical analysis. However, an important consideration, both with
Raman spectroscopy and the associated statistical methodologies, is the accuracy
of these techniques and more specifically the sensitivities which can be achieved
and ultimately the limits of detection of the various methods. The purpose of this
study is thus the construction of a model simulated data set with the aim of testing
the accuracy and sensitivity of the partial least squares regression (PLSR)
approach to spectral analysis. The basis of the dataset is the experimental spectral
profiles of a previously reported Raman spectroscopic analysis of the interaction
of the cancer chemotherapeutic agent cis-platin in an adenocarcinomic human
alveolar basal epithelial cell- line, in-vitro, and is thus reflective of actual
experimental data. The simulated spectroscopic data is constructed by adding
known perturbations which are independently linear in drug dose, as well as
cytological response, experimentally determined by the 3-(4,5-dimethylthiazol2-yl)-2,5-diphenyltetrazolium bromide (MTT) cytotoxicity assay. It is
demonstrated that, through appropriate choice of dose range, PLSR against the
respective targets can differentiate between the spectroscopic signatures of the
direct chemical effect of the drug dose and the indirect cytological effect it
produces.
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4.2 Introduction
Over the past couple of decades, vibrational spectroscopy (in particular Raman
and infrared absorption) has emerged as a powerful tool for biomedical
applications. The numerous studies explore applications such as disease
diagnostics3–6, cellular imaging7–10, the study of drug1,2,11and nanoparticle
interactions12–14 on a cellular and sub-cellular level, to name but a few. In both
modalities, the spectrum of tissue or cells contains a wealth of information,
representing as it does the combined molecular fingerprints of the ensemble of
biomolecules contained in the sample, and only in the simplest of cases can a
valid interpretation be made by visual inspection of the spectrum. Multivariate
statistical methods are thus critical in the analysis, interpretation and
representation of the complex information contained within. However, given the
critical nature of the outcomes of the application, whether in terms of medical
diagnostics or in preliminary screening of drug efficacy and action mechanisms,
it is imperative that the combination of spectroscopic techniques and multivariate
analysis are rigorously and quantifiably validated. Such validation can also
establish realistic limits to what is often purported as a high content screening
methodology. To this aim, the use of simulated datasets based on experimental
studies can play a crucial role14,15.
A multitude of multivariate analytical methods exists, each of which aims
to simplify complex bio-spectroscopic information and provide a tool with which
to draw conclusions about the state of the sample. These include Principal
Component Analysis (PCA), Linear Discriminant Analysis (LDA), Vertex
Component Analysis (VCA), Spectral Cross Correlation Analysis (SCCA), K-

76

means Clustering Analysis (KMCA), Hierarchal Cluster Analysis (HCA) to name
but a few. Importantly, there also exists a number of variants of these methods
which differ slightly and can give, in some instances, different answers 14,16,17.
Recently, regression modelling (e.g. Partial Least Squares Regression,
PLSR) has seen a number of biomedical uses in both Raman and IR
spectroscopies. The core idea of using this method is to investigate the spectral
variability as a function of a systematic conditional change such as radiation
dose18 or viral infection19. PLSR can be employed to construct predictive models
for spectral response as a function of the target variable. Therefore, an unknown
dose or degree of infection can be determined from its spectrum, having obvious
potential clinical applications. Furthermore, feature selection techniques such as
PLSR co-efficient, Jack-Knifing (JK) and genetic algorithms, amongst others20,
can be employed to identify the most statistically relevant spectral changes, such
that the biological mechanisms underlying the spectral changes can explored and
understood. Importantly, there are many variants of the PLSR algorithm and, in
some instances; hybrid methods which use a combination of two statistical tools
in order to extract relevant chemical information have been employed. Although
these methods have been applied to a wide range of studies, the details are beyond
the scope of this paper although good examples can be found in literature 1,2,18,21–
24

The potential of Raman spectroscopic microscopy for initial screening of
chemotherapeutic efficacy and mechanism of action has been demonstrated by
Nawaz et al.1,2,23. Taking the interaction of cis-platin with the human lung
adenocarcinoma cell line, A549, in-vitro, as an example, PLSR of Raman
spectroscopic datasets was reported to identify and differentiate the direct effects
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of cis-platin on the cellular biochemistry as a function of drug concentration
(dose) and the resultant toxicological response as measured by the MTT
cytotoxicity assay. This simultaneously provides a parallel gold standard
technique to compare to the spectroscopic endpoint as well as range finding for
the initial dose response curve i.e. establishing values of Inhibitory
Concentrations (IC) etc. In an operational model of pharmacological agonism, the
former is a linear process, whereas the latter results in the more complex
sigmoidal response of cell populations to drug exposure25. PLSR against the drug
concentration returned changes in the Raman peaks associated with both
conformational and chemical changes in DNA, while changes to the lipid and
protein distributions were dominant when the data was regressed against the
cytotoxicological end point, indicating the biochemical changes associated with
the resultant cytological response to the interaction with cis-platin. The statistic
relevance of the results were confirmed using the JK approach.
The potential to differentiate the direct chemical effects from the
subsequent cytological responses opens the way to the use of the techniques to
visualise and interpret the mode of action of chemotherapeutic agents intracellular
and to quantify the efficacy to produce the desired cellular response in a single
truly label free measurement. The emergence of ever higher throughput
spectrometers would enable real-time and time resolved visualisation of the
respective processes as they evolve. Notably, however, while the studies of
Nawaz et al. show great promise towards this end, the technique is as yet unvalidated. The expected changes in the spectra with concentration and
toxicological endpoint are inferred, based on prior knowledge about the biological
action of cis-platin in the model in-vitro system. This leads to a difficulty when
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trying to confirm the validity of the method or compare two different methods to
quantitatively assess the sensitivity, accuracy and specificity of the technique.
Here, we aim to validate the application of these methodologies using
simulated datasets based on the previously published experimental results of
Nawaz et al.. In particular, we aim to test the ability of PLSR to model and thus
extract spectroscopic variations (based on the regression co-efficient) which vary
systematically as a function of different targets. Thus, the study will confirm
whether the method is capable of extracting and differentiating spectroscopic
features which differ based on linear or non-linear changes of the targets.
Additionally, the accuracy or fidelity of the method in extracting systematically
varied features will be explored as the spectral perturbations introduced decrease
in magnitude, exploring the sensitivity of the method. Thus, the overarching aim
is to establish the validity of the algorithms applied to Raman spectral datasets
containing changes pertaining to the direct and indirect effects of the anti-cancer
drug cis-platin in-vitro. For the purposes of this study, we propose the use of a
modelled simulated dataset. The dataset is constructed based on experimental
observations, but the systematic spectral variation that is introduced is known
precisely and thus an exact and complete assessment of the method can be carried
out.

4.3 Methods
4.3.1 Experimental
Experimental results were obtained as described in previous publications by
Nawaz et al1,2 which investigated Raman spectroscopy as a tool to study cis-
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platin-cellular interactions in-vitro. The experimental methods are described in
detail in the publications, but are summarised in brief as follows.
Human lung adenocarcinoma (A549) cells were routinely cultured at 37
°C, 5 % CO2 in DMEM F12 supplemented with 10% FBS, 1% pen/strep and 2mM
l-glutamine. Cells were cultured until 70-80% confluence and plated on quartz
substrates for Raman spectroscopy. A standard MTT assay, using a concentration
range of 0.05µM – 50µM, was used to assess the toxicity of cis-platin to provide
a comparison to Raman spectroscopy. This was carried out in standard 96 well
plates and experiments were all completed in triplicate. This range resulted in a
sigmoidal variation in cell culture viability over the range ~90% to ~20%, from
which the Inhibitory Concentration (IC50) of cis-platin in A549 cells in-vitro was
determined to be 1.2 ± 0.2 µM.
Cis-platin, at varying concentrations in the range 0.05 µM - 50µM, was
added to cells and Raman microscopic measurements of cells exposed to each
dose, including unexposed control, were acquired at a source wavelength of
785nm for both nuclear1and cytoplasmic regions2 . The PLSR approach was used
to model the spectroscopic data as well as to select and distinguish the relevant
features indicative of the chemical effects of cis-platin and the cellular response
to cis-platin via a regression against dose and the MTT cytotoxicity endpoint
respectively. By examination of the regression co-efficient, it was possible to
discern the major features responsible for model construction.
In this work, these experimental spectral datasets are employed to
construct semi-realistic simulated data to probe the reliability, sensitivity and
quantitative nature of these methods when applied to drug-interaction studies.
More details of the experimental set up can be found in Nawaz et al. 1,11
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4.3.2 Partial Least Squares Regression
PLSR is a multivariate statistical method which aims to establish a model that
relates the variations of the spectral data to a series of relevant targets. The
spectral data (X matrix) is thus related to the targets (Y matrix) according to the
linear equation Y = XB +E, where B is a matrix of regression coefficients and E
is a matrix of residuals. The PLSR algorithms used in this study have been
previously published elsewhere1,2,18,22 and are based on scripts written in house
using Matlab 7.2 (The Mathworks Inc.). The algorithm allows for the construction
of a regression model which can be used to predict the outcome in a number of
different situations. In this case, the examples used are concentration and MTT
response, and therefore the algorithm can be used to predict for example the
toxicological response of a particular drug dose.
Latent variables (LV’s) in PLSR modelling are a series of underlying
variables which aim to describe the behaviour of the modelled system. The exact
number of latent variables which are necessary to build an entirely accurate model
is not known a priori. However, it is one of the goals of PLSR models to
accurately predict the number necessary to build a robust and accurate model26.
Predicting the number of LVs which will build an accurate model is usually
achieved during the cross validation step, typically using the root mean squared
error of cross validation (RMSECV) as a metric for latent variable selection.
4.3.3 Spectral Constructs
Spectral constructs were generated for the purpose of imparting a known
perturbation to the dataset which could be systematically varied to evaluate the
capability of the PLSR modelling to accurately predict and extract spectral
variations correlated to a known external variable, in this case, drug dose and the
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resultant cytological changes. Using the original datasets of Nawaz et al., derived
from the nuclear and cytoplasmic regions, specific spectral changes were
identified in the mean difference spectra of a 3µM exposed cell population versus
the unexposed control (Figure 3, of reference 10, Figure 4 of reference 11). In this
way, spectral constructs were generated from the changes in the spectra of the
nuclear region, including increases in the characteristic A form of DNA peak at
807 cm-1 and the B form peak at 833 cm-1 and a change in the C-H deformation
at 1449 cm-1 (Figure 4.1A) and in the cytoplasmic region, containing the
following peak changes or shifts; a change in the amide 1 band at ~1661 cm-1, a
decrease in the C-C stretch intensity at ~939 cm-1 and an increase in the
tryptophan peak at 731 cm-1 (Figure 4.1B). The relative intensities of the peaks in
each construct were derived from the experimental difference spectra at a cisplatin exposure dose of 3µM10 and were normalised for concentration (Figure
4.1A) and a loss of viability at that concentration of 0.52

10

(Figure 4.1B).

Different weightings of these spectral constructs (termed hereafter the
Concentration and Viability construct respectively) were then added to a control
dataset as described in the following section.
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Figure 4.1: Spectral Constructs based on the normalised difference spectra
between control and exposed nucleus (A) 10, and cytoplasm 11 (B). Selected Raman
peaks were used to avoid over complexity in the simulated data; (A) the A form
peak of DNA at 807 cm-1 and the B form peak at 833 cm-1 and the C-H
deformation at 1449 cm-1 (B) the amide 1 band at ~1661 cm-1, the C-C stretch
intensity at ~939 cm-1 and the tryptophan peak at 731 cm-1.

4.3.4 Simulated data
Simulated datasets were generated in the following manner. A control
dataset containing 25 spectra acquired from the nucleus of non-cis-platin exposed
(control) cells was selected from Nawaz et al

1

(Figure 4.2). Notably, this real

experimental dataset contains instrumental noise and sample variability. To this
dataset, weighted contributions of the Concentration construct shown in Figure
4.1A, based on the experimentally observed difference spectra of the nuclear
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region, were added, over the Lethal Concentration range 0.05 µM - 50µM used
in the original study, based on a direct weighting of the spectral construct by the
range of concentrations (Table 4.1). Initially, only the concentration dependent
weighted constructs were added to the control, to produce Dataset 1.

Figure 4.2: Control dataset taken from Nawaz et al. 1; 25 control spectra taken
from the nucleus of cells not exposed to cis-platin. Spectra have been baseline
corrected and vector normalised. The inherent spectral variability in the data is
representative of real experimental conditions. These spectra were then used in
the construction of 3 simulated datasets, each containing 8 different dose/viability
points with systematically introduced variation of the spectral constructs shown
in figure 4.1.

As the MTT assay is expressed in viability compared to control (0.845
being maximum (Vmax) and 0.135 being minimum values of fit to the
experimentally observed viability over the concentration range 10), the spectral
construct of Figure 4.1B, derived from the experimentally observed differences
in the cytoplasmic region, was similarly weighted by the (V max – MTT) endpoints
in Table 4.1 and also added to Dataset 1. Each spectral construct was therefore
added following a linear trend based on concentration (Figure 4.1A) plus a linear
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trend based on MTT response (Figure 4.1B). The MTT endpoint data are,
however, nonlinearly related to the concentration, in a sigmoidal fashion typical
of cytotoxic responses, as shown in Nawaz et al1,2. The resultant dataset therefore
contains 25 spectra for each of 8 dose points (including control) which
incorporate spectral variations, systematically dependent on both the exposure
dose and the measured cytological response. For simplicity, this is referred to as
Dataset 2.
It is noted that the spectral construct of Figure 4.1B is derived from
exposure dose dependent, experimentally observed, spectral changes in the
cytoplasmic region. No direct biological significance is inferred by the weighted
addition of this spectral construct to the dataset derived from the nuclear regions.
However, the addition serves to provide an independently variable perturbation
to the dataset, which may serve to mimic a cytological effect of the direct action
of the drug in the nucleus.
To probe the sensitivity of the methodology, the experimental range for
cis-platin (Lethal Concentration, in table 4.1) has been extended (Sub lethal
Concentration in table 4.1) to represent non-lethal doses of the drug. The MTT
values have also been extrapolated according to the original fit of the Hill
equation10 to reflect these changes in concentration (Sub-lethal MTT in table 4.1).
The corresponding simulated dataset will be referred to as Dataset 3. A dataset
was also constructed which consisted solely of control spectra. This Control
dataset did not contain any systematically introduced spectral variations and was
used to establish a baseline regression endpoint for both Lethal Concentration and
Lethal MTT.

85

Table 4.1: The weightings of the spectral constructs added to the control data.
The Lethal Concentration and Lethal MTT ranges are derived from the actual
experiment data of references 1,2. Lethal MTT represents the values obtained
when the experimental MTT value is subtracted from Vmax. The Sub-lethal
Concentrations extend the concentration range and are representative of sublethal doses of cis-platin, for which sub-lethal MTT values are derived from the
extrapolated fit of the Hill equation in Reference 1.

4.4 Results
4.4.1 Concentration Simulated data
The PLSR method aims to establish a model that relates the variations of the
spectral data to a series of relevant targets. In this case, the spectral data is a series
of simulated datasets which are based on known introduced perturbations based
on cis-platin-cellular interactions as described in the previous sections.
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Figure 4.3. PLSR modelling against Lethal Concentration for Dataset 1. Top
panel shows the calibration performance and test dataset (RMSEC 0.49673, R 2
0.99948). Bottom panel shows the performance of the model for the test dataset
(RMSEP 0.52389, R2 0.99953). Data was split in a ratio of 60:40 calibration and
test respectively.

Regression of Dataset 1 against the Lethal Concentration range (table 4.1) yielded
the model shown in figure 4.3. The data were split, 60:40, to create calibration
and test sets to build the model. 60% of the data was used to calibrate the model
and 40% of the data was then used to assess the performance of the model in
predicting the expected target with unseen data. Leave-one out cross validation
with the calibration set was used to determine the optimal model complexity for
use in testing (Meade et al., 2010)27. This process was performed with
randomization of the data matrix and splitting of the data to prevent data bias
(Varmuza and Filzmoser, 2009)28. Control of over fitting was achieved using a
procedure previously described by Martens and Naes29. The procedure involves
selection of the optimal number of latent variables (LV) to retain within the PLSR
model via cross-validation with the calibration data set. The optimal number of
LV's was then selected on the basis of the number which provided the lowest root

87

mean squared error after cross validation. This is illustrated in Supplementary
Material figure S4.1A and B, which show plots of the RMSECV and RMSEP for
the first 10 LV’s for the regression of Dataset 1 against Lethal Concentration 1,
and thus the optimum number of LV’s was selected as 10. The calibration and
test set had RMSEC=0.49673, RMSEP=0.52389 and R2 values of 0.99948 and
0.99953 respectively, indicating a good linear fit of the model.
As the regression co-efficient (RC) are descriptors of the spectral features
which are used to build the model, we also aimed to assess the accuracy with
which the algorithm can faithfully extract the known spectral perturbations
introduced in the dataset. For regression of Dataset 1 against Lethal
Concentration, we expect that the spectrum of the RC will be comprised of the
Concentration construct which has been added based on the Lethal Concentration
range (Figure 4.1A).
In figure 4.4, a direct comparison between the RC of regression of Dataset
1 against the Lethal Concentration range and the concentration spectral construct
is shown. The spectrum of the RC is dominated by the peaks of the systematically
added spectral construct, at 807cm-1, 833cm-1 , which correspond to A and B form
DNA10 and the C-H deformation at 1449cm-1 (solid line figure 4.4 bottom panel).
This verifies that the simulated changes are the major contributors to the PLSR
model construction.
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Figure 4.4: Plot of the regression co-efficient following PLSR of Dataset 1
against Lethal Concentration. The Concentration construct (dashed line) is
shown in the top panel for comparison with the RC’s in the bottom panel. The
solid line (bottom panel) shows the regression co-efficient following regression
of Dataset 1 against Lethal Concentration. The dotted line shows a plot of the
regression co-efficient following regression of a dataset consisting of just control
spectra against Lethal Concentration, in effect showing the baseline regression
co-efficient when no introduced spectral perturbation (not including
sample/instrumental variations) is present. The Control RC has been offset and
multiplied by a factor of 10 for clarity.

However, it should be noted that the RC spectrum in figure 4.4 also contains other
peaks which are not present in the spectral construct and so should not show a
systematic variation with concentration. By regression of just the control data
(with no spectral perturbations) against the Y target (Lethal Concentration) it was
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possible to establish a Control RC, as shown by the dotted line (bottom panel) in
figure 4.4 (offset and multiplied by a factor of 10 for clarity). The control RC
spectrum shows a high degree of similarity with the original cellular spectra
(Figure 4.2) and thus derives from the inherent variability in the experimental
measurement. Close examination of the RC for the Dataset 1 regression reveals
that some of the peaks in the Control RC are also present.
The PLSR modelling process was repeated for Dataset 2, which included
the combined perturbations of the Concentration construct of Figure 4.1A,
linearly weighted according to Lethal Concentration of Table 4.1, and the MTT
Construct of Figure 4.1B, linearly weighted according to Lethal MTT of Table
4.1. A similar performance of model calibration and test were achieved, with
RMSEC=0.4981, RMSEP=0.53505 and R2 values of 0.99947 and 0.99952
respectively, again indicating a good linear fit of the model (Figure S4.2). The
spectrum of RC again faithfully reproduced the Concentration Construct of
Figure 4.1A, on a background which matches well the Control RC spectrum
(Figure S4.3).
4.4.2 MTT Simulated Data
Dataset 2 also contains systematic perturbations which have been weighted
according to the viability as measured using the MTT assay, and it is of critical
interest whether these spectral variations can be independently extracted using
PLSR, as suggested by Nawaz et al.10. Regression of Dataset 2 against Lethal
MTT (table 4.1) yielded the model shown in figure 4.5. As for the concentration
dependent model, the data are split according to 60% calibration and 40% test
data. The calibration and test set had RMSEC=0.10158, RMSEP=0.12087 and R2
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values of 0.91928 and 0.89793 respectively. Based on these values, it can be seen
that, while the model has fitted the data, it does not provide as good prediction as
shown for concentration (figure 4.3). This is also reflected by the lower R2 values,
considering that the accuracy of the linear fit is measured by how close the value
is to 1. A possible explanation for this is the lower magnitude and range of
weightings of spectral construct added corresponding to the MTT response (Table
4.1, Lethal MTT).

Figure 4.5: PLSR modelling of Dataset 2 against the Lethal MTT target. Top
panel shows the calibration performance and test dataset (RMSEC 0.10158, R2
0.91928). Bottom panel shows the performance of the model for the test dataset
(RMSEP 0.12087, R2 0.89793). Data has been split in a ratio of 60:40 calibration
and test respectively.

Inspection of the MTT RC in Figure 4.6 shows that the peaks of the
systematically added Viability construct (Figure 4.6, dashed line, top panel), the
amide 1 band at ~1661 cm-1, the C-C stretch intensity at ~939 cm-1 and the
tryptophan peak at 731 cm-1, are faithfully reproduced and dominate the MTT RC
(Figure 4.6, solid line, bottom panel).

91

Figure 4.6: Plot of the regression co-efficient following PLSR modelling against
MTT response. The Viability construct (dashed line) is shown in the top panel for
comparison with the RC’s in the bottom panel. The solid line shows the
regression co-efficient following regression against Lethal MTT and Dataset 2
(bottom panel). The dotted line (bottom panel) shows a plot of the regression coefficient following regression of a dataset consisting of just control spectra
against Lethal MTT, in effect showing the baseline regression co-efficient when
no introduced spectral perturbation (not including sample/instrumental
variations) is present. The Control RC is offset and multiplied by a factor of 10
for clarity.

The baseline sensitivity is evaluated by regressing the control dataset
against the Lethal MTT target, yielding the Control RC of Figure 4.6 (bottom
panel, dotted line). The resultant RC spectrum has been offset and multiplied by
a factor of 10, for clarity. As in the case for regression against Lethal
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Concentration targets, the Control RC resembles the cellular spectra of figure 4.2,
indicating that the baseline variation is limited by the variations in the original
spectral measurement.
4.4.3 Quantitative evaluation of regression co-efficient
In an attempt to evaluate the quantitative nature of the regression co-efficient, a
method was devised which looked at varying the number of data-points used to
build the PLSR model. For the analysis of the spectral variations of Dataset 1,
based on variations of the Concentration construct of figure 4.1A weighted
according to Lethal Concentration (Table 4.1), multiple regressions were
conducted (models not shown). Each model was constructed by increasing the
number of data points, C+1 being the first data set used, consisting of the control
dataset (Fig 4.2) and the 0.05 µM data-point of the Lethal Concentration range
(Table 4.1). The data set was then successively extended by 1 data-point, such
that C+2 consists of control, 0.05 µM and 0.5 µM, and so on, until all data points
in the Lethal Concentration were included.
For all models, the spectrum of the RC displayed a combination of the
Concentration construct of Figure 4.1A and the Control RC of Figure 4.4, and, as
expected, regression over the full range reproduced the RC spectrum of Figure
4.4. Notably, as shown in Figure 4.7, the peaks of the Concentration construct
increase linearly as the range of the regression is increased and reach a saturation
value above ~ C+4. Extension of the model to 1000µM results in no further
significant increase of these maximum peak intensities (data not shown). The Aform DNA peak at 807cm-1 reaches a maximum value of 18.46. Although this
does not quantitatively equate to the corresponding peak value of the Control
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construct of Figure 4.1A, the relative magnitudes of the respective peaks is
consistent with those of the original Concentration construct, and notably the
relative contribution of the Control RC is reduced with increasing range.

Figure 4.7: Evolution of the peaks of Construction construct in PLSR models of
increasing range for Dataset 1.

A similar analysis was conducted for the PLSR of Dataset 2 against the
Lethal Concentration range. Figure 4.8 shows a plot of the extracted RCs for all
successive regressions. As expected, C+7 reproduces the Lethal Concentration
RC of Figure 4.4, and extracts the expected introduced spectral construct (Figure
4.1 A). However, notably for all other regressions, C+1 to C+6, the presence of
peaks which are not explicitly dependant on Lethal Concentration are observed.
In addition to those of the Control RC, peaks of the MTT construct (Figure 4.1B)
are evident in the RCs of the regressions over the incomplete concentration range.
A similar phenomenon can be seen in the equivalent sequential modelling of the
MTT data of Dataset 2 (Figure S4.4 and S4.5).
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Figure 4.8. A plot of regression co-efficient following multiple regression against
concentration with increasing data points. I.e. C+1 represents a dataset
consisting of the control dataset and the data point at 0.05 µM. This then
increases C+n until all data points in the dataset have been evaluated.

Figure 4.9 shows a plot of selected RC peak intensities associated with
the spectral construct relating to concentration following successive rounds of
regression as described above, namely the A form peak of DNA at 807 cm-1 and
the B form peak at 833 cm-1, which are associated with the physical changes
associated with cis-platin-cellular interaction2. In fact the evolution of the peaks
is observed to be identical to that observed for Dataset 1, shown in Figure 4.7,
and although the plot of Figure 4.9 is in a linear/logarithmic format, it can be seen
that the predicted relative intensities again increase linearly initially, before
reaching a point of saturation at, or above, the dataset C+4, and further addition
of data-points makes no difference (data not shown) to the quantitative prediction
of the features.
Also shown in Figure 4.9 is the dependence of the peak of the Viability
construct at 731cm-1, (for example) which “bleeds through” in the regression of
Dataset 2 against the incomplete concentration range. This bleed through occurs
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for all peaks of the MTT Construct. The contribution of the peaks of the Viability
Construct follows a trend of the derivative of the viability curve, indicating that
it is the rate of change of the contributed spectral variations which governs the
contribution to the RC. Notably, when the full Lethal Concentration range is
included in the model, at the extremes of which the change in viability has
reduced to the minimum value, the bleed through of the MTT construct is
minimal, and the Concentration Construct of Figure 4.1A is faithfully extracted,
albeit with an underlying background as a result of the inherent spectral
variability.

Figure 4.9. Plot of peak intensities vs. concentration of regression co-efficients
for the A form peak of DNA at 807 cm-1 and the B form peak at 833 cm-1 of the
Concentration Construct (Figure 4.1A). Also plotted is the contribution of the
tryptophan peak at 731cm-1, a key feature of the Viability Construct (Figure 4.1B)

A similar PLSRA of the contributions of the Viability construct to Dataset
2 reveals similar bleed through and more complex evolution of the features
contributing to the spectrum of the RC (Supplementary Material Figures S4.4 and
S4.5). The bleed through of the features of the spectral constructs shown in
Figures 4.8 and 4.9 is a clear demonstration that it is not trivial to independently
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extract the contributions of the two constructs over the lethal concentration range,
as speculated by Nawaz et al.10. However, over concentration ranges in which the
viability does not change significantly, the bleed through is minimal, and the
concentration dependent spectral changes can be independently extracted. Thus,
it should be possible to determine the direct chemical interactions of an external
agent in the sub-lethal range.
Figure S4.6 shows the calibration and test performance of the PLSR of
Dataset 3 versus the sub-lethal concentration range of Table 4.1. The model yields
RMSEC and RMSEP values of 0.143 and 0.19392, respectively, with R2 values
of 0.38916 and -0.24063, accuracies considerably less that those of the equivalent
model in the Lethal Concentration range. Notably, the RC spectrum is a faithful
extraction of the pure Concentration construct of Figure 4.1 A, as shown in Figure
S4.7. Little or no bleed through of features associated with the Viability construct
is apparent (although still present in minimal quantities) although this is not
surprising as, with little or no change in viability, the contributions of the
Viability construct to Dataset 3 are minimal.

4.5 Discussion
Given the drive for a reduction in the use of animal models for evaluating toxicity,
screening of drugs and even cosmetics, due to regulatory developments in both
the EU and US (EU Directive-2010/63/EU and US Public Law 106-545, 2010,
106th Congress)30–32 generally based on the 3 R’s of Russell and Burch30 to
replace, reduce and refine the use of animals used for scientific purposes, there is
increased emphasis on the development of reliable and rapid in-vitro screening
methodologies. This includes more representative culture models which better
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mimic the in-vivo environment as well as more rapid, cost efficient, high content,
and ideally label free screening technologies. It is crucial, however, that these
models and technologies are well validated against established gold standards33,34.
Raman spectra, in principle, contain high content information about the
biochemical make up of the sample, and changes to it, related to pathology or an
external agent. Raman spectra contain numerous peaks which vary dependently
and independently of each other. Crucially, for real applications and particularly
in the instance of drug interactions, it is difficult to tell whether these differences
are inherently based on cell to cell variability or whether they are dependent on
the primary action of the drug (i.e. the direct chemical effects) or the secondary
effects the drug has on the cell (i.e. the response of the cell to said drug).
In this study, simulated datasets were used to evaluate the capability of
PLSR to extract known and systematic spectral variation from a control dataset,
which contained intrinsic experimental variability. The spectral variations
introduced varied linearly with the applied drug dose and also with the measured
cell population response, as measured by a standard cytotoxicity assay. Notably,
however, the two spectral variations are not completely independent, as the
viability response is sigmoidal dependent on the applied dose.
In the case where only a concentration dependent systematic variation in
the spectra is introduced, the PLSR model provides an accurate predictive
response tool, the regression co-efficient of which are based on the systematic
variation which has been introduced to the dataset, linearly dependent on the
targets. The model shows high sensitivity, and the limits of detection are
determined only by the intrinsic variability of the experimental method, as
determined by the PLSR of the Control spectral dataset. This limit can be
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improved by optimising sample preparation and measurement protocols. In
principle, such a PLSR model can predict the response of a drug dose in a cell
population, or determine an unknown drug dose from a measured spectral
response.
However, the spectral changes which result from the interaction and
action of a drug within a cell are manifold, and it is of interest to differentiate the
spectral signatures of the direct interaction from the subsequent cellular response.
Notably, this study demonstrates that, although PLSR predictive models based on
regression of the combined dataset, including all spectral responses, against the
target of concentration range produce a similarly accurate, linear predictive
model, the contributing RCs are only derived exclusively from the introduced
concentration dependent variations in ranges where all other spectral variations
are limited. For example, as shown in Figures 4.8 and 4.9, regression over the
limited range of C+4 produces a model which is based on RCs which includes
contributions derived from the direct effect of the interaction of the drug within
the cell (Concentration construct), as well as the resultant cytological response
(Viability construct). Thus, care should be taken in interpreting the spectral
features which contribute to such regressions to elucidate the underlying
mechanisms.
Nevertheless, in sub-lethal regions, the direct effects of the drug
interaction can confidently be investigated employing such a PLSR analysis of
Raman spectral data, independent of the cytological responses, and these are
easily discernible above the intrinsic variability of the control. Although this
seems a trivial conclusion, such rapid, label free analysis could prove invaluable
in screening of, for example, the mechanisms and efficacy of drug interactions,
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evaluating drug uptake and receptor binding25 or nanoparticle uptake and
trafficking in regions where cytoxicity assays are insensitive.
The use of a parallel cytotoxic assay such as MTT serves as a range
finding test to establish the IC50, but also provides vital information about the sublethal doses and maximum responses. It also provides a target for regression of
the data in the regions of toxicity. Thus, the subsequent cytological effects can be
differentiated from the direct chemical effects of the agent and extracted from the
overall spectral response in the dose range where the viability is impacted, and
the cellular response can be independently mapped spectroscopically, as a
function of dose and time. Notably, the model described here, which includes a
single spectral construct to represent the cellular response is very simplistic, as
the response is a cascade of many responses, depending on the mechanism of
interaction35. Nevertheless, the analysis presented here demonstrates that the
spectral fingerprints of the direct mechanisms of interaction and the subsequent
cellular responses can be independently extracted from the dose dependent
spectral data, and thus, ultimately with improved screening sensitivities and
speeds, Raman spectroscopy could be employed to monitor in quasi real time, in
a label free manner, the efficacy and mode of action of, for example
chemotherapeutic agents and other exogenous agents, laying the basis for
improved quantitative structure activity relationships to guide drug development
or chemical regulation strategies.

4.6 Conclusions
This study demonstrates the reliability and also limitations of PLSR as a method
for predictive modelling and analysis of spectroscopic signatures of cellular
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responses to exogenous agents such as radiation, chemotherapeutic agents or
toxins. The spectroscopic profiles at any dose/time point can derive from a
complex mixture of direct interactions within the cell and a cascade of subsequent
cellular response. The analysis demonstrates that care should be taken in choosing
the response range and also highlights the importance of parallel cytological
assays in guiding the modelling and analysis. Correct choice of range can help
differentiate between the signatures of direct interactions, which are dominant at
sub-lethal doses and those of the subsequent cellular response which evolve with
increasing dose.
The study also demonstrates the importance of simulated datasets in
exploring the potential as well as the limits of the analytical techniques. Notably,
the use of real experimental data which contains sample variability and
instrumental response factors as a basis of the simulated dataset helps to visualise
the lower limits of sensitivity.
The results indicate that Raman spectroscopic screening combined with
such regression models and feature selection techniques, in parallel with
conventional cytotoxicity assays, can be used to screen for the efficacy of drug
interactions and can contribute to understanding the mechanisms of interaction.
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4.9 Supplemental Material:
Multivariate statistical methodologies applied in biomedical Raman
spectroscopy: Assessing the validity of partial least squares regression using
simulated model datasets.
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Figure S4.1: RMSECV and RMSEP for the first 10 LV’s for the regression of
Dataset 1 against Lethal Concentration 1
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Figure S4.2: PLSR modelling of Dataset 2 with the Lethal Concentration range
as taregt. Top panel shows the calibration performance and test dataset (RMSEC
0.4981, R2 0.99947). Bottom panel shows the performance of the model for the
test dataset (RMSEP 0.53505, R2 0.99952). Data was split in a ratio of 60:40
calibration and test respectively.
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Figure S4.3: Plot of the regression co-efficient following PLSR modelling of
Dataset 2 against Lethal Concentration. The concentration spectral construct
(dashed line) is shown in the top panel for comparison with the RC’s in the bottom
panel. The dashed line (bottom panel) shows the spectrum of regression coefficients following regression of Dataset 2 against Lethal Concentration 1. The
solid line shows a plot of the regression co-efficient following regression of a
dataset consisting of just control spectra against Lethal Concentration, in effect
showing the baseline regression co-efficient when no introduced spectral
perturbation (not including sample/instrumental variations) is present. The
Control RC has been multiplied by a factor of 10 and offset for clarity.
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Figure S4.4. A plot of regression co-efficients following multiple regression of
Dataset 2 against Lethal MTT with increasing data points. I.e. C+1 represents a
dataset consisting of the control dataset and the data point at 0.05 µM. This then
increases C+n until all data points in the dataset have been included.

Figure S4.5 Plot of RC peak intensities for regression of Dataset 2 against Lethal
MTT; C-C stretch intensity at ~939 cm-1, the amide 1 band at ~1661 cm-1 and the
tryptophan peak at 731 cm-1 of the Viability Construct (Figure 1B).
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Figure S4.6. PLSR modelling of Dataset 3 with the Sub-lethal Concentration
range as target. Top panel shows the calibration performance and test dataset
(RMSEC 0.143, R2 0.38916). Bottom panel shows the performance of the model
for the test dataset (RMSEP 0.19392, R2 -0.24063). Data was split in a ratio of
60:40 calibration and test respectively.
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Figure S4.7. Plot of the regression co-efficients following PLSR of Dataset 3
against Sub-lethal Concentration. The concentration spectral construct (dashed
line) is shown in the top panel for comparison with the RC’s in the bottom panel.
The solid line shows the regression co-efficient following regression against sublethal concentration and Dataset 3 (bottom panel). The dotted line (bottom panel)
shows a plot of the regression co-efficient following regression of a dataset
consisting of just control spectra against sub-lethal concentration, in effect
showing the baseline regression co-efficient when no introduced spectral
perturbation (not including sample/instrumental variations) is present. The
Control RC is offset and multiplied by a factor of 100 for clarity.
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Chapter 5 Seeded Principal Component Analysis for
biochemical screening using vibrational spectroscopy
5.1 Abstract:
Seeded Principal Component Analysis (SePCA) is introduced as a novel
multivariate analysis variant to address some of the limitations of the application
of PCA in bio-spectroscopy in systematically varying datasets. Using simulated
data based on experimental spectra of in-vitro exposure to varying doses of the
chemotherapeutic agent, cis-platin, standard and SePCA are compared, firstly
based on their ability to differentiate the responses to different exposure doses,
and secondly to assess the accuracy of the loadings that are used to describe the
systematic variations of biochemistry underlying the differentiation. Further
insights are also garnered on the use of 1st and 2nd derivative spectra and the
impact this mathematical transformation has on the ability of the algorithm to
separate and describe the spectral origin of differentiation of spectral datasets.
The implications of this novel variant of PCA are discussed in the context of
screening for drug efficacy in-vitro as well as biomedical classification for disease
diagnostics.

5.2 Introduction
Raman spectroscopy is a branch of vibrational spectroscopy which allows for a
sample to be characterised based on its inherent chemical nature in a label free
manner. The resulting spectra can then be used to classify a host of materials from
organic to inorganic compounds. Recently, vibrational spectroscopies such as IR

112

and Raman have gained momentum in a biomedical context, with a guiding focus
of translating these technologies into the clinical environment 1.
Both histopathological and cytological studies have been routinely carried
out using both IR and Raman spectroscopic analysis and have shown significant
success in the laboratory at diagnosing disease states with high sensitivity and
specificity, based on the inherent biochemical state of the sample as opposed to
the morphology2. Further studies have investigated other disease states such as
atherosclerosis3, liver cancer and disease4–6,lung cancer7, colon cancer8, blood
borne illnesses such as malaria and others9,10, as well as investigations in
dermatology11. Additionally, bio-fluid analysis has also been developed in
conjunction with IR and Raman spectroscopy as a potential alternative to current
gold standard practices12. In-vivo and ex-vivo Raman spectroscopy has also been
demonstrated in a number of studies, including the investigation of brain13,
cervical14 and oesophageal15 pathologies16
Vibrational spectroscopy has also seen usage in other medical contexts
such as Nanomedicine17, in which Raman and its variants allow for label free
characterisation of nanomaterials in cells as well as tissues and live animal
studies. Pharmacological characterisation in-vitro has also been demonstrated
with a number of drugs classified using Raman spectroscopy as a tool to monitor
drug behaviour in a cellular environment 18–22.
Crucially, there are a number of caveats associated with this technique
and all play a role in the end goal of accurate label free sample characterisation.
These range from correct sample preparation in the laboratory, precise sampling
by the spectrometer (incorporating sample location as well as instrument
precision and reproducibility), through to the correct spectral pre-processing,
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including baseline correction, smoothing, normalisation…etc. Finally, the correct
usage and development of novel multivariate statistical methodologies for
analysis and interpretation of the biochemistry underlying the spectral signatures
is important for validity, accuracy and interpretability1,23,24.
In previous publications by Keating et al25,26, simulated datasets were used to
probe the intricacies of Partial Least Squares Regression (PLSR) and a novel
multivariate approach, termed spectral cross correlation analysis (SCCA) and its
use in biomedical Raman spectroscopy. In brief, the validity of the method to
extract and differentiate the spectral signatures of the direct action of and
subsequent metabolic response to chemotherapeutic agents and nanoparticles
(respectively) in cells in-vitro, was demonstrated. The use of simulated datasets,
based on real experimental data, enabled verification of the validity of the
techniques and estimation of the limits of sensitivity, while also identifying
potential limitations of the techniques, highlighting the importance of
understanding the intricacies of multivariate statistical methodologies applied in
vibrational spectroscopy.
In a study by Bonnier and Byrne in 2011, principal component analysis
(PCA) was investigated and its use and interpretability in spectral applications
was elucidated27. While this method is commonly applied in biomedical
spectroscopy as a means of differentiating and classifying spectral datasets, the
biochemical reasoning behind separation and its dependence on the loadings can
often be misinterpreted. This publication aimed to shed light on some of the
possible pit falls in interpreting spectral separation using both real and simulated
data.
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Following on from this work, as well as the validation of the PLSR
technique by Keating et al25 , the current study aims to further probe the PCA
algorithm using simulated data, and in particular to explore its use to analyse
systematic variations in spectral responses as a result of quasi-continuous
variations in exposure of cell populations to external stimuli. Some of the
deficiencies of the method are highlighted and investigated, looking at
continuously varying data and loading interpretability in a spectral context that of
systematic variations due to variable doses of chemotherapeutic agents in cells,
in-vitro. A novel variant protocol for carrying out PCA, termed seeded PCA
(SePCA), has been developed to overcome some of the deficiencies in the current
usage of the algorithm in spectroscopy.

5.3 Methods
5.3.1 Simulated data
The generation of the simulated data used has been described in detail
elsewhere25. A modified version of the protocol is described here to tailor the
dataset for the study of PCA. The full details of the culture and experimental
conditions can also be found elsewhere18 In brief, human lung adenocarcinoma
(A549) cells were routinely cultured at 37 °C, 5 % CO 2 in DMEM F12
supplemented with 10% FBS, 1% pen/strep and 2mM l-glutamine. Cells were
cultured until 70-80% confluency and plated on quartz substrates for Raman
spectroscopy. Twenty five control spectra were acquired in the previous study by
Nawaz et al18. Figure 5.1 shows the control spectra used. These consist of spectra
acquired from the nuclei of A549 human lung adenocarcinoma cells in-vitro, with

115

no external agent added. In parallel, a standard MTT cytotoxicity assay was
carried out to establish the dose dependence of the in-vitro viability.

Figure 5.1. Control dataset taken from Nawaz et al18. 25 control spectra taken
from the nucleus of cells not exposed to cis-platin. Spectra have been baseline
corrected and vector normalised. The inherent spectral variability in the data is
representative of real experimental conditions.

Spectral constructs, shown in figure 5.2, were generated from the mean
difference between spectra from concentration dependant changes in the nucleus
and the control, as well as spectra from the cytoplasm and the control, which
correspond to the MTT cytotoxic response as described in the publications by
Nawaz et al.

18,19

. In these publications, the exposure of cells to cis-platin was

carried out over the concentration range from 0.05µM-50µM, including the mean
inhibitory concentration, IC50 of ~ 3µM, as identified using the MTT cytotoxicity
assay. This dose range in conjunction with the MTT response was then used to
construct simulated data. In this way, spectral constructs were generated from
the changes in the spectra of the nuclear region, including increases in the
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characteristic A form of DNA peak at 807 cm-1 and the B form peak at 833 cm-1
and a change in the C-H deformation at 1449 cm-1 (Figure 5.2A) and in the
cytoplasmic region, containing the following peak changes or shifts; a change in
the amide 1 band at ~1661 cm-1, a decrease in the C-C stretch intensity at ~939
cm-1 and an increase in the tryptophan peak at 731 cm-1 (Figure 5.1B).
These were then used to introduce systematically variable, known
perturbations into the control dataset, in such a way as to generate a number of
different datasets based on the original experimental results obtained by Nawaz
et al18. to investigate both the standard PCA algorithm and the novel seeded
variant.
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Figure 5.2: Spectral Constructs based on the normalised difference spectra
between control and exposed nucleus (A) and cytoplasm (B) of Nawaz et al.
(2010). Selected Raman peaks were used to avoid over complexity in the
simulated data; (A) the A form peak of DNA at 807 cm-1 and the B form peak at
833 cm-1 and the C-H deformation at 1449 cm-1 (B) the amide 1 band at ~1661
cm-1, the C-C stretch intensity at ~939 cm-1 and the tryptophan peak at 731 cm-1.

The perturbation of construct 1 (Figure 5.2 (A)) is used to represent the
systematic spectral evolution due to the direct interaction of the chemotherapeutic
agent in the nucleus, while construct 2 (Figure 5.2 (B)) is used to represent the
systematic variations in viability of the cell population, as measured by the MTT
assay. The weightings listed in table 5.1 show the magnitude of the changes added
to the control dataset of figure 5.1. Three datasets were generated from these sets
of values, one of which consists of the control (25 spectra) plus the maximal MTT
(25 spectra) value of table 5.1 (Dataset 1),

Dataset 1: (Control), (Control + WMaxMTT)

where WMaxMTT indicates the addition of the maximally weighted MTT spectral
construct in table 5.1 i.e. 0.66*MTT spectral construct (Construct 2).
The second dataset (Dataset 2) contains the control and the maximally
weighted values for both the concentration (Construct 1) and MTT (Construct 2)
constructs. Each of the weighted constructs, WMaxConc and WMaxMTT, are added
to the control dataset separately in the first instance with the purpose of creating
a simulated system to probe the ability of standard and seeded PCA to accurately
separate the three groups, each containing 25 spectra, which make up the dataset.
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Dataset 2: (Control), (Control + WMaxMTT), (Control + WMaxConc )

A further, more complex version of the dataset was constructed using all
the weightings in table 5.1, generating a dataset with simultaneous, continuously
varying concentration and continuously varying MTT constructs, the final data
matrix having the format of: 7x25 weighted spectra plus 25 controls.

Dataset 3: (Control), (Control +WMTTn+Conc.n +WMTT.n+1+Conc.n+1……)

Dataset 3 thus simulates the spectral changes observed experimentally as
a result of exposure of A549 cells in-vitro to cis-platin of continuously varying
concentration.
Approximate partial first and second derivative spectra were calculated
using the ‘diff’ function in Matlab (Mathworks, USA)), with seeded and standard
PCA carried out on selected datasets (1-3) to highlight the improvements made
possible by this mathematical transformation.
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Table 5.1 the weightings of the spectral constructs added to the control data. The
Concentration and MTT ranges are derived from the actual experiment data of
references18,19 MTT represents the values obtained when the experimental MTT
value is subtracted from the maximum viability
5.3.2 PCA
PCA is a method which aims to reduce the dimensionality of the data to describe
the variation present in a dataset, whereby the first principal component is a
description of the maximum variance present in the dataset, the second describes
the second most variance…etc. The principal component scores can then be
described by the loading vector, which is a representation of this variance. In a
Raman spectroscopy context, the scores represent values which correspond to a
loading spectrum which contains peaks, both positive and negative, which explain
the spectral variation in the dataset 17.This tool can be quite useful for classifying
spectra into groups e.g. diseased and non-diseased14. It has also been used to
reconstruct images28,29, i.e. a variance plot based on the loadings plot. However,
as these loadings plots may often contain a number of spectral features
corresponding to different cellular biochemistry, interpretation can be difficult
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and it is quite possible to misinterpret. Bonnier et al. have shown that pairwise
PCA of clusters identified by KMCA can provide a clearer picture of the specific
biochemical differences between region30. All spectra were centred using a single
value decomposition (SVD) algorithm for analysis using the following function.
All analysis was done using the ‘pca’ function in Matlab (The Mathworks Inc.).
5.3.3. Seeded PCA
Considering that PCA is sensitive to the relative scaling of the original variables,
it is postulated that seeding the examined dataset with the known perturbation
might have the effect of increasing the accuracy and or sensitivity of the standard
PCA algorithm. In the case of interest, the spectral signature of the nuclear
binding of the chemotherapeutic agent may be known, and thus the
experimentally observed spectral changes may be data-mined for this signature.
This is done by the addition of the pure spectral constructs of Figure 5.2 to the
Datasets of control and perturbed control spectra described in Section 5.3.1.
To optimise for seeding using an optimised seeded weight (O SW), it is
necessary to understand how the variance changes as the magnitude of the
spectral construct added to the dataset is increased. To do this, an exponentially
increasing weighting was explored, as is shown in table 5.2. This involved
systematically increasing the weighting of the spectral construct added to the
dataset and examining how the explained variance changes as a result.
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Table 5.2: weightings used to multiply the spectral constructs of figure 5.2 for the
determination of the optimum magnitude for seeded PCA.

5.4 Results
5.4.1. PCA Dataset 1
Figure 5.3 shows the scatter plot and loadings for PC 1, 2 and 3 following a
standard PCA of the simplified dataset consisting of the control and simulated
spectra based on the maximal MTT value, Dataset 1, shown in table 5.1. PC 1,
PC 2 and PC3 describe the majority variance in the dataset, PC 1, 2 and 3
accounting for 37.98%, 24.36% and 6.58% of the explained variance,
respectively. No discernible separation of the control and MTT dataset is
represented by the scatter plot in figure 5.3A, and this is reflected by the loadings
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shown in figure 5.4A and B. However, marginal partition of the data is
demonstrated in figure 5.3B and C, although. no separation between control and
maximal MTT data is demonstrated. This is due to the inability of PCA to extract
out the ‘pure’ spectral features introduced in the data, which are not evident in the
loadings of any of the first 3 PCs (Figure 5.4).
This poses a problem, as it is not possible to show with standard PCA a
separation based on the introduction of a known spectral perturbation, or extract
information concerning that perturbation, as the intrinsic spectral variability is
larger than that of the systematic variability introduced. To address this, a seeded
PCA (SePCA) methodology was developed, which allows for a ‘pure’ spectral
loading, in this case the MTT spectral perturbation, to be extracted with the
maximal variance described by the desired changes.
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Figure 5.3. PCA on a dataset consisting of the control and max MTT, dataset 1
(A) scatter plot of PC1 vs. PC2 (B) scatter plot of PC1 vs. PC3 (C) scatter plot of
PC2 vs. PC3. PC1, 2 and 3 account for 37.98%, 24.36% and 6.58% of the
variance in the dataset, respectively.
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Figure 5.4. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for
standard PCA on dataset 1. With PC 1, 2 and 3 accounting for 37.98%, 24.36%
and 6.58% of the variance respectively.

125

5.4.2. Seeded optimisation
Seeding of the dataset was performed as described in Section 5.3.3. Seeded PCA.
To optimise for seeding, the variance explained by PC1 and PC2 as the seeded
weighting is increased according to table 5.2 is examined. The optimisation of
the weight for seeding is shown in figure 5.5A and B, showing the increase in
variance explained by the MTT seeded loading, and decreased variance explained
by the intrinsic spectral variance. “Whereas at 0 weighting, PC1 is dominated by
the intrinsic variance, at a seeding of 102, PC1 begins to show contributions of
MTT, while at a loading of 103, it is almost completely dominated by features of
Construct 2 and completely dominated by Construct 2 at 104 .Therefore, based on
this plot, the optimal weight to seed for this dataset is ~10 4 with 99.99% of the
variance explained by the first PC and an almost negligible 0.01% described by
the inherent dataset variability.
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Figure 5.5: Calculation of the variance explained after successive rounds of PCA
with increasing spectral construct weighting according to table 2. (A) % variance
explained by the PC loading addition (B) % variance explained by the inherent
dataset variability between control spectra acquired, instrumental error, random
noise…etc
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5.4.3. Seeded PCA dataset 1
Following seeding optimisation i.e. 104 weighted addition of the MTT spectral
construct (Construct 2), it is possible to show partition of the data based on the
known perturbations to the dataset. This is shown in Figure 5.6 A for Dataset 1,
which now consists of the control spectra (25), the control + WMax MTT spectra
(25) and WMaxMTTx104 (1). Separation between control and MTT is clearly
demonstrated. The loadings of PC1, 2 and 3 are shown in figure 5.7 A, B and C
and account for 99.99%, 0.000059% and 0.000038% of the variance respectively.
The loading of PC1 faithfully reproduces the MTT spectral construct of Figure
5.2, the known spectral perturbation added to the dataset. The inherent variability
of the dataset is now represented by PC2 and 3, and no partition of the data is
evident along these axis. This demonstrates, in a simplified simulated dataset, the
enhancement seeded PCA can achieve over the standard implementation of PCA.
In real experimental data, however, the spectral variations are likely to be more
complex, as for example in the study of Nawaz et al., in which the spectral
variations as a result of a chemotherapeutic agent represented both the direct
chemical effect of the drug as well as the subsequent cellular responses.
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Figure 5.6. PCA on a dataset consisting of the control and max MTT, dataset 1
(A) scatter plot of PC1 vs. PC2 (B) scatter plot of PC1 vs. PC3 (C) scatter plot of
PC2 vs. PC3. PC1, 2 and 3 account for 99.99%, 0.000059% and 0.000038% of
the variance in the dataset, respectively.
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Figure 5.7. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for Seeded
PCA on dataset 1. With PC 1, 2 and 3 accounting for 99.99%, 0.000059% and
0.000038% of the variance respectively.
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5.4.4. PCA Dataset 2
As shown in Figure 5.8, PCA of dataset 2 results in partial differentiation
according to PC1 and PC2, which account for 93.94%, 2.22% and 1.54% of
variance in the dataset. PC1 differentiates the spectra perturbed by WMaxConc
from those of control and perturbed by WMaxMTT. Spectral features pertaining to
Construct 1 are present in the 1st principal component as shown in figure 5.9A.
Similar to the case of dataset 1, however, the spectral features of the MTT
spectral construct introduced into the data are not shown in the first three PC’s.
Therefore, no separation between control and max MTT is shown in figure 5.8 AC. Thus, while conventional PCA can extract the spectral features associated with
the chemical interaction of the chemotherapeutic agent with the cell, it is not
sensitive to the weaker changes associated with the subsequent changes to the cell
metabolism, based on this simulated example.
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Figure 5.8. PCA of Dataset 2 (A) scatter plot of PC1 vs. PC2 (B) scatter plot
showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances
describe by PC 1, 2 and 3 are 93.94%, 2.22% and 1.54% respectively for
standard PCA. The loadings corresponding to the scatter plots are shown in
figure 5.9.
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Figure 5.9. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for Seeded
PCA on dataset 1. With PC 1, 2 and 3 accounting for 93.94%, 2.22% and 1.54%
of the variance respectively.
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5.4.5. Seeded PCA Dataset 2
In the case where a spectral profile of a minority variant is known, as in the case
of the MTT construct added to the control data, SePCA can be employed, as
demonstrated in figure 5.6. To further illustrate the concept for two independent
variations, a single spectrum of Construct 2, multiplied by a factor of 10 4 was
introduced into Dataset 2, as an additional, independent spectrum. The optimised
value of 104 was chosen as it allows for the majority of the spectral variance to
be described by the first PC (figure 5.5). Thus, Dataset 2 now consists of the
control spectra (25), the control + WMaxMTT spectra (25), the control + WMaxConc
spectra (25), and OSWxC (1), where OSW is the optimised weighting for the
addition of the spectral construct.
As shown in figure 5.10, this allows for almost complete separation of
each spectral group, control, (Control + WMaxMTT) and (Control + WMaxConc )
in Dataset 2. The majority of the variance is described by the first PC; 99.99%,
PC2 and PC3 accounting for 0.003% and 0.000079% variance respectively, at
this seeded weighting. As a consequence of seeding for the MTT spectral
changes, partition of the data is now observed between Control and (Control +
WMaxMTT), according to PC1 (Figure 5.11 A), the loading of which is dominated
by the MTT construct of Figure 5.2B, as shown in Figure 5.11A. PC2 is
dominated by the loadings of the spectral features of Construct 1, which shows
separation along PC2, which differentiates Control and (Control + WMaxMTT)
from (Control + WMaxConc). No separation is evident according to PC3, the
loading describing background noise.
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Figure 5.10. Seeded PCA of Dataset 2 (A) scatter plot of PC1 vs. PC2 (B) scatter
plot showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances
described by PC 1, 2 and 3 are respectively 99.997%, 0.0033% and 0.000079%
for seeded PCA.
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Figure 5.11. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for
Seeded PCA on dataset 1. With PC 1, 2 and 3 accounting for 99.997%, 0.0033%
and 0.000079% of the variance respectively.
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5.4.6. PCA Dataset 3
Standard PCA of dataset 3 is shown in figure 5.12. This dataset consists of
systematic changes in both MTT and concentration introduced simultaneously,
according to table 5.1. As per previous examples in dataset 1 and 2, construct 2,
the MTT experimental changes are not evident in the first three principal
component loadings, with the respective variances of 90.99% 7.87%, 0.42% for
PC 1, 2 and 3. However, the concentration spectral construct is dominant in figure
5.10 B and is primarily responsible for the separation shown along the PC 2 axis,
figure 5.9C. Separation is also shown with the first principal component although
the introduced spectral features of the constructs are not apparent in PC 1, figure
5.13A-C.
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Figure 5.12. PCA of Dataset 3 (A) scatter plot of PC1 vs. PC2 (B) scatter plot
showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances
described by PC 1, 2 and 3 are respectively 87.82%, 4.51% and 3.13% for PCA.
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Figure 5.13. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for PCA
on dataset 3. With PC 1, 2 and 3 accounting for 87.82%, 4.51% and 3.13% of the
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5.4.7. Seeded PCA dataset 3
Seeding the algorithm for Construct 2 allows for both the MTT and Concentration
(Construct 1) to be extracted in the first 2 principal components, as shown in
figure 5.15 A-C. PC 1 and 2 are responsible for 87.82% and 4.51% of the variance
in the data, respectively (figure 5.14 A). PC 3 does not result in any differentiation
of the data. Notably, the differentiation of the data for both MTT and Conc
variables is continuous, although the degree of separation of each weighting is
small, in both cases. As a way of increasing the potential for separation, 1 st and
2nd derivative transformations of the data was performed.
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Figure 5.14. Seeded PCA on dataset 3 (A) scatter plot of PC1 vs. PC2 (B) scatter
plot showing PC1 vs PC3 (C) scatter plot showing PC2 vs. PC3. The variances
described by PC 1, 2 and 3 are respectively 99.99%, 0.004% and 0.0002% for
seeded PCA.
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Figure 5.15. Loadings of PCA of Dataset 3 corresponding to (A) PC1, (B) PC2
and (C) PC3. The variances described by PC 1, 2 and 3 are respectively 99.99%,
0.004% and 0.0002% for seeded PCA.
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5.4.8. Seeded PCA on 1st derivative spectra
Further improvements are shown for SePCA on 1st derivative spectra from dataset
3 in figure 5.16 A – C, a more evident systematic partition of the data being
produced according to PC1 and PC2, but not PC3, with respective variances of
99.99%, 0.0079% and 0.0001%. The loading corresponding to the 1st derivative
of Construct 2 is dominant in PC1, which is reflective of the MTT related spectral
changes which have been introduced, while PC2 is dominated by the 1 st derivative
of Construct 1, representative of the Concentration spectra changes introduced
(figure 5.17A-C). For standard PCA derivatisation resulted in no separation for
dataset 1, and, while for dataset 2 improvements in partition of the data according
to variations in Concentration were evident, no features of the MTT construct
were extracted.
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Figure 5.16. Seeded PCA on 1st derivative spectra from dataset 3 (A) scatter plot
of PC1 vs.PC2 (B) scatter plot showing PC1 vs PC3 (C) scatter plot showing PC2
vs. PC3. The variances described by PC 1, 2 and 3 are respectively 99.99%,
0.0079% and 0.0001% for seeded PCA.
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Figure 5.17. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for PCA
on dataset 3. With PC 1, 2 and 3 accounting for 99.99%, 0.0079% and 0.0001%
of the variance respectively.
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5.4.9 Seeded PCA on 2nd derivative spectra from Dataset 3
Considering the improvements in separation achieved following first
derivatization of Dataset 3, it was subjected to second derivatization, to explore
whether this resulted in a further improvement in the separation of the spectral
data. For standard PCA this resulted in no separation for dataset 1, and, while for
dataset 2 improvements in partition of the data according to variations in
Concentration were evident, no features of the MTT construct were extracted.
Figure 5.18 shows the results following seeding of second derivative of
Dataset 3 with the MTT spectral construct, in the same manner as previous
analysis. An increased in partition of the data along both PC1 and PC2 is evident
and both loadings show pure second derivative loadings, from construct 1 and 2
respectively, figure 5.19 A and B. This enhancement shows the benefits of using
second derivative spectra and extracting the correct trend from the spectral data.
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Figure 5.18. Seeded PCA on 2nd derivative spectra from dataset 3 (A) scatter plot
of PC1 vs. PC2 (B) scatter plot showing PC1 vs PC3 (C) scatter plot showing
PC2 vs. PC3. The variances described by PC 1, 2 and 3 are 99.99%, 0.0087%
and 0.000014% for seeded PCA.
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Figure 5.19. Loadings corresponding to (A) PC1, (B) PC2 and (C) PC3 for
seeded PCA on 2nd derivative spectra from dataset 3. With PC 1, 2 and 3
accounting for 99.99%, 0.0079% and 0.0001% of the variance respectively.
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5.5 Discussion
Validation of multivariate statistical protocols used in vibrational spectroscopy is
essential to ensure that the spectral analysis is reliable and accurate for
standardised and routine usage. In the development of novel in-vitro screening
tools for both nano and pharmacological screening, it is imperative that sample
preparation protocols, instrumental reliability and multivariate routines are as
reliable and accurate as possible, to ensure a smooth transition from lab bench to
clinical and company settings.
Focusing on the multivariate statistical analysis, previously published
work by Bonnier and Byrne, 201227, aimed to elucidate the use and
interpretability of PCA in vibrational spectral applications, using both real and
simulated data. Similarly, validation and development of the RMie-EMSC
algorithm was done using simulated and real data in the work of Bassan et al
201031. These selected examples show the applicability of simulations in
validation of multivariate analysis as well as spectral prepossessing in a
biomedical vibrational spectroscopic context.
The application of PLSR to independently extract information concerning
the direct chemical interaction of chemotherapeutic agents with cells (Construct
1), and the subsequent physiological response of the cells using Raman
spectroscopy in parallel with conventional in-vitro cytotoxicity assays (Construct
2) was validated using a similar set of simulated spectral datasets by Keating et
al, 201525. The current work explores the applicability of PCA to the same
simulated spectral dataset, and its ability to extract the systematic and
continuously variable spectral perturbations introduced. Limitations of PCA of
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the data was shown in figure 5.3 A, whereby the algorithm was unable to extract
the desired spectral features from the dataset, as the magnitude of the perturbation
was less than the intrinsic variability of the cellular data. A successful partition
of the data is shown to be possible when the algorithm is seeded with the known
spectral variation, as demonstrated in figure 5.5 A and B. In Dataset 3, which is
continuously perturbed by the addition of weighted contributions of the two
spectral constructs, seeding the dataset with the minority perturbation enables the
continuous differentiation of the data, and extraction of both independent spectral
perturbations. Further improvements in separation are shown using 1 st and 2nd
derivative spectral data for the seeded datasets such that, in the case of the SePCA
of Dataset 3, the PCA scatter plot shown in figure 5.20A reproduces somewhat
the experimental dose dependent toxicity study of Nawaz et al, 2010. This has
implications for in-vitro spectral screening platforms as it shows that the correct
trend in simulation can be extracted for the data once the correct features are
described to the algorithm i.e. a seeded approach. This is a positive step towards
a multivariate dose response curve.
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Figure 5.20. Seeded PCA on 2nd derivative spectra from dataset 3 (A) scatter
plot of PC2 vs. log PC1 (B) loading for PC1 (C) loading for PC2. The variances
described by PC 1 and 2 are 99.99% and 0.0087% respectively for seeded PCA.
A constant of 0.05 Arb. Units has been added to PC 2, to allow for log scaling of
the data.
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The improvements shown have possible ramifications for both diagnostics
and in-vitro screening. Notably, however, in comparison to the PLSR approach
of Keating et al, 2015, the method is supervised, in the context that it requires
some prior knowledge of the spectral changes in the data set. In terms of Construct
1, this could be facilitated by a library of spectral signatures of, for example, DNA
major and minor groove binders and intercalators, allowing a rapid screening of
mechanisms of action of novel chemotherapeutic agents. In a similar fashion,
spectral signatures could be established to represent Adverse Outcome Pathways
(AOPs), an approach to representation of toxicology recently endorsed by the
OECD32. In this approach, while the chemical binding of the agent to the receptors
represents the Molecular Initiator Event (MIE), cascade of events leading to, for
example apoptosis or necrosis constitute the AOP, which could be represented by
distinct spectral signatures.
For diagnostic applications such as classification e.g. using support vector
machines (SVM) or linear discriminant analysis (LDA), in which PCA
coefficients are input to the algorithms, seeding in combination with 1 st and 2nd
derivative spectra may provide improvements in dividing the data for training and
thus, improvements in the diagnostic classification accuracy if the correct variable
features can be identified across the patient data.
The nature of the continuously varying spectral changes is also relevant
for the interpretation of experimental changes. In this instance (Dataset 3), the
changes are continuous and linearly increasing across the entire dataset. However,
in experimental data, the changes may not be present in a continuous or linear
fashion, or across the entire sampled range. If, as in many instances, the loadings
contain an ensemble of spectral features, multiple trends may be responsible for
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the pattern of separation in the data. By seeding with the correct peaks the pattern
of partitioning in the data can be more accurately identified and adjusted based
on the correct spectral changes in the data.

5.6 Conclusions
This study demonstrates an analytical methodology, seeded PCA, which increases
the potential of the PCA algorithm to separate spectrally distinct data, particularly
in the case where continuous but minor variations are present over a dataset range.
The use of 1st and 2nd derivatisation of the dataset is demonstrated to further
enhance the differentiation potential of the algorithm. This has important
ramifications for improving separation of spectra, with a particular emphasis on
biomedical spectroscopy, be that in spectral diagnostics i.e. classification
protocols and/or in-vitro screening of drugs and nano-materials. The study also
demonstrates the benefits of analysis of simulated datasets in the development
and validation of novel multivariate analysis algorithms.
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Chapter 6: Spectral Cross Correlation as a Supervised
Approach for the Analysis of Complex Raman Datasets:
The Case of Nanoparticles in Biological Cells

The following is a journal publication in which generation of simulated datasets,
data pre-processing, writing of the paper, data analysis and development of cross
correlation as a data mining tool in Raman spectroscopy were carried out by Mark
E. Keating. Hugh J. Byrne, as supervisor, was primarily responsible for editing
and refining of the text as well as guidance with the development of the analytical
technique. Sample preparation and data acquisition were carried out as described
elsewhere in a paper by Dorney et al1. Franck Bonnier was involved with data
acquisition and guidance with cross correlation. The format is that of the journal
publication, but section and figure numbers have been adapted to the format of
this thesis.
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6.1 Abstract
Spectral Cross-correlation is introduced as a methodology to identify the presence
and subcellular distribution of nanoparticles in cells. Raman microscopy is
employed to spectroscopically image biological cells previously exposed to
polystyrene nanoparticles, as a model for the study of nano-bio interactions. The
limitations of previously deployed strategies of K-means clustering analysis and
principal component analysis are discussed and a novel methodology of Spectral
Cross Correlation Analysis is introduced and compared with the performance of
Classical Least Squares Analysis, in both unsupervised and supervised modes.
The previous study demonstrated the feasibility of using Raman spectroscopy to
map cells and identify polystyrene nanoparticles in a lipid rich environment,
which is suggestive of the membrane rich endoplasmic reticulum. However, short
comings in identification of all nanoparticle signatures in the cell using K-means
clustering are apparent, as highlighted by principal component analysis of the
identified clusters which demonstrates that K-means clustering does not identify
all regions where spectral signatures of the nanoparticles are evident. Thus, two
more sophisticated analytical approaches to the extraction of the nanoparticle
signatures from the Raman spectral data sets, namely classical least squares
analysis and cross correlation analysis, were employed and are demonstrated to
improve the identification of spectroscopic signatures characteristic of
polystyrene nanoparticles in a cellular environment. Additionally, to investigate
the local biochemical environment in which the nanoparticles are trafficked, a
pure spectrum of 3-sn-phosphatidyl ethanolamine was cross correlated against the
Raman data set, further suggesting the particles are indeed localized in a lipid rich
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environment. Furthermore, to demonstrate the robustness and versatility of the
analysis method, a spectrum of pure RNA was used to demonstrate that a
differentiation could be made between DNA of the nucleus and RNA of the
nucleolus using the supervised spectral cross-correlation technique.

6.2 Introduction
Nanotechnology is set to become the first trillion dollar industry in history, with
predicted benefits which span a wide range of fields, including applications in site
specific delivery of drugs in humans, to antimicrobial paint coatings and textile
finishing, to advances in the electronics industry2–7. However, there are caveats
associated with deploying these nanotechnologies which must be addressed
before true realistic applications can be widely accepted and adopted as the norm.
It is widely known that nanomaterials, more specifically nanoparticles, possess a
range of unique characteristics which in some ways dictate their usefulness and
applicability in fields such as medical science. Properties such as increased
surface to mass ratio result in an increased reactivity and associated novel optical
properties result in new possibilities in diagnostic and theranostic imaging and
delivery8,9, while novel semi-conductor properties are applicable to the
electronics industry10. However, these properties also potentially have negative
implications, most importantly in terms of the potential impact of nanoparticle
exposure on human health and the environment. Nanoparticles have been
demonstrated to be taken up by cells in-vitro and to elicit a toxic response while
many reports exist of adverse toxic effects in-vivo11–16.
One of the challenges facing the nanotoxicology community is the
detection and monitoring of the interaction mechanisms of nanoparticles in
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cells17,18. Currently, fluorescent microscopy is the most widely used and
accessible method to study nanoparticle uptake and trafficking 19–24. Necessarily,
however, it relies on the use of inherently fluorescent or labelled compounds for
visualization and monitoring of nanoparticles inside cells. Most nanoparticles are
not intrinsically fluorescent, however, and it has been recently demonstrated that
fluorescent labels can be labile, and that the observation and distribution of
intracellular fluorescence following nanoparticle exposure is not necessarily
representative of the presence or distribution of nanoparticles in the cell25. While
it is also possible to study the dynamics of nanoparticle trafficking using label
free optical microscopic techniques such as dark field and differential interference
contrast (DIC) microscopy, the techniques are mainly applicable to metal
particles such as gold and silver26 Transmission electron microscopy (TEM)
provides an additional method by which nanoparticles can be visualised in a
cellular environment 27–29. The high lateral resolution obtainable with TEM
renders it an ideal method for visualising sub cellular organelles and uptake and
interaction of nanoparticles. However, significant sample processing (fixing and
ultramicrotoming) is required and only particles with sufficient electronic contrast
to the cellular environment can be visualised29,30
Thus, a label-free technique is required which can ideally unambiguously
identify the presence of the nanoparticles in the cells, their sub-cellular location,
and their overall effect on the cellular metabolism. Raman spectroscopy is one
such method which may provide an alternate to traditional approaches for
studying the nanoparticle-biological interface. The technique provides not only a
label free method to visualize how the nanoparticle behaves in a biological
environment, but offers the potential to identify the local environment and
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simultaneously analyse the associated metabolic changes. To do this, one must
combine Raman spectroscopy with analytical data mining approaches to extract
the signatures associated with the nanoparticles but also to probe the environment
the particles are localized in, and to correlate the exposure and subcellular
interaction mechanisms with the metabolic changes.
Previous studies have indicated the potential of Raman as a label free
method for studying biological processes. Examples include novel approaches for
cervical cancer diagnostics31, to investigating the effects following exposure to
human papilloma virus (HPV) infection32, the effects of chemotherapeutic
anticancer agents in cells33,34, live cell analysis35,36and the toxic responses to
single walled carbon nano-tubes (SWCNT), to name but a few37.
Surface enhanced Raman scattering (SERS) is also a potential method to
study

the

intracellular

dynamics

of

nanoparticle

trafficking

and

compartmentalisation38,39. However, only certain types of nanoparticle, such as
gold and silver particles and nanoaggregates have the potential to generate SERS
spectra, thus limiting the technique to the study of only a certain type of
nanoparticles. Additionally the surface enhancement process and molecular
specificity of the technique are not fully understood, which may lead to ambiguity
in the understanding of cellular trafficking.
A more recent study indicated the ability of Raman spectroscopy to detect
the presence of intracellular polystyrene nanoparticles1. Polystyrene was chosen
as a model nanoparticle for the study as it is commercially available and regularly
employed as a standard in nanotoxicology (particularly as a positive control in its
aminated form). Furthermore, the conjugated styrene ring makes it a relatively
strong Raman scatterer. However, while the identification is somewhat straight
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forward, the presence of overlapping peaks in both the polystyrene and cellular
spectra (e.g. both cellular and polystyrene spectra exhibit a strong symmetric ring
breathing peak at ~1004cm-1) presents a challenging system with which to
validate the effectivity of the experimental and data analysis techniques. K-means
clustering analysis (KMCA) analysis was used to differentiate regions of the cell
as well as to identify and localise the nanoparticles. Analysis of the local cellular
environment of the detected nanoparticles was performed via a comparison
between loadings obtained from principal component analysis (PCA) and pure
spectra of lipids and polystyrene nanoparticles. However, when the data was
analyzed using PCA, it was noted that the clusters detected using KMCA failed
to identify all regions which contained the spectral fingerprint corresponding to
polystyrene in a biological environment. Furthermore, the average spectra of the
cluster identified by KMCA, while containing features clearly characteristic of
polystyrene, also contained spectral features of the neighbouring cellular
environment. Analysis of the loading of the principal components provided a
clearer differentiation of the nanoparticle contributions from the local cellular
environment, but neither unsupervised technique provided an unambiguous
localisation of the target species39.
Other multivariate analytical approaches have also been applied in the
field of Raman microspectroscopy of cells. In addition to KMCA, other clustering
methods such as Fuzzy C means clustering (FCM) and hierarchal cluster analysis
(HCA) have been used to separate the cellular Raman data into clusters and
subsequently reshape the data into images40,41. However, as highlighted by
Headegaard et al., these approaches have their own limitations. In particular
boundaries between sub-cellular features can often result in the addition of extra
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clusters with mixed spectral signatures. This addition can be overcome by
increasing the number of clusters; however, this in turn can result in added
complexity to interpretation and inaccuracies in regional separation. Additionally,
the reproducibility of these methods can also be questioned as the starting point
for the centroid based KMCA and FCM is subjective40.
PCA and vertex component analysis (VCA) have also been used to
separate out distinct regions of the cell. With regards to PCA, separation is based
on the variances between the spectra in the data set, the majority of the variance
being described by the first three principal components40. Thus, the score values
can be used to construct a composite image of the cell in which the biochemical
contributions of each component are described by the corresponding loadings
plot. Unlike KMCA and FCM, PCA identifies quite accurately the boundaries
between each feature. However, the images generated suffer from inferior
contrast and in some instances interpretation may be difficult as biochemical
features may be spread across different loadings.
VCA is another method which has been used for similar analytical
purposes. In brief, VCA computes a linear combination of supposed pure
component spectra which are termed endmember spectra. As described in
Miljkovic et al., the endmember spectra are acquired under the assumption that
the most extreme data points in the dataset are representative of pure component
spectra41. However, it has been pointed out that the endmembers generated are
not truly representative of the pure component they describe in the data set and
can often contain a mixture of biochemical constituents i.e. DNA and proteins 42.
While this is representative of the true nature of nucleic acids in-situ, it could lead
to inaccuracies in interpretation.
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The work presented here demonstrates the potential of a Spectral Cross
Correlation Analysis (SCCA) for the analysis of Raman spectral datasets. The
method is applied to the dataset of Dorney et al.1, of polystyrene nanoparticles in
A549 lung adenocarcinoma cells, and is thus compared with previous analyses by
KMCA and PCA. The performance of SCCA is also compared to that of classical
least squares analysis (CLSA), performed both in a supervised and unsupervised
manner, which allows for a direct comparison between both approaches. SCCA
utilises the spectrum of the target chemical component and cross correlates the
spectrum with that of the complete Raman spectral dataset. The quantitative
performance is demonstrated using simulated datasets and the potential is
demonstrated by mapping the spatial profile of the polystyrene nanoparticles in
the cells as well as other biochemical components of the cell, (RNA and lipids).

6.3 Experimental
6.3.1 Sample Preparation for Raman Imaging
A549 Cells were seeded at a density of 4 x 104 cells onto calcium fluoride (CaF2)
windows (Crystran Ltd., UK) for confocal Raman imaging. The cells were
incubated for 24 hrs in Dulbecco’s Modified Eagle’s Medium (DMEM F12),
supplemented with 10% foetal calf serum (FCS) and 1% L-Glutamine at 37°C,
5% CO2. Following cell adherence, 2 mLs of medium containing 1x 10 12
nanoparticles per mL were added to the cells. The cells and nanoparticles were
incubated for 24hrs at 37°C and 5% CO2. Following nanoparticle exposure, the
cells were washed in warm PBS three times and fixed for 10mins in 10% buffered
formalin. After fixation, the cells were washed to remove any trace of fixative
and kept in NaCl solution prior to imaging.
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Component spectra used in SCCA were generated as described in Bonnier
and Byrne 201243. For polystyrene nanoparticle spectra, nanoparticle suspension
was added drop-wise to a CaF2 window and allowed to air dry prior to Raman
acquisition. RNA from baker’s yeast (saccharomyces cerevisiae) was added to
water and subsequently deposited on a CaF2 window and allowed to air dry. 3sn-phosphatidyl ethanolamine was dispersed in chloroform and deposited on
CaF2 windows.
6.3.2 Confocal Raman Spectroscopic Imaging
Confocal Raman Spectroscopic Imaging was performed using a Horiba YobinYvon LabRAM HR800 spectrometer with a 785nm, 300mmW diode laser as
source and a Peltier cooled 16-bit CCD. A 100X, N.A. 1.2, (LUMplanF1,
Olympus) water immersion objective was used for all cellular measurements. The
confocal pin hole of the system was set to 100µm, the recommended setting for
confocal operation, to allow optical sectioning of the sample. A 300 lines per mm
spectroscopic grating, providing a dispersion of ~1.5cm-1 per pixel, was used and
the system was pre-calibrated to the spectral line at 520.7cm-1 of silicon. Using
an automated programmable stage, Raman spectra of the cell were acquired with
a 0.75µm step size over a 29*39 pixel area which encompassed the nuclear,
perinuclear and cytoplasmic regions of the cell.
6.3.3 Data Pre-Processing and Preparation
In order to prepare the data for analysis, a number of steps were taken to ensure
the spectra in the map were of a high enough quality to give accurate results. For
CLSA, all data pre-processing was carried out using Labspec 5 software which
comes as standard on the Raman instrument. Firstly, a background spectrum
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which constituted the contribution of the CaF2 substrate and water in the imaging
medium was subtracted from each spectrum in the mapped data set. Following
subtraction of the background spectrum, a Savitsky-Golay smoothing filter (5th
order, 7 points), available on the software, was used to lightly smooth the data.
The data was then baseline corrected using a nodal point baseline correction using
the minimum amount of points possible to ensure minimal alteration of the
acquired data. Normalization was carried out automatically by the software
during CLSA.
Data was prepared in a similar fashion for SCCA. However, the preprocessing was carried out in Matlab (Mathworks,USA) using previously
published protocols for data processing1. As outlined above, a background
spectrum was subtracted from the Raman data set to remove the substrate and
immersion medium contributions. A Savitsky-Golay smoothing filter (5th order,
7 points) was applied to the data and a nodal point baseline correction was used
to baseline the data using a minimum amount of reference points to do so.
Preparation of component spectra for SCCA was done in the same manner for
polystyrene, RNA and lipids.

6.3.4 Classical Least Squares Analysis
CLSA was carried out using Labspec 5 software which comes as standard on the
Raman spectrometer software. The analysis method is based on a fit of a linear
combination of reference component spectra to the spectra contained in the raw
spectral map. This is described by Equation 6.1, for the case where three reference
component spectra are used. S is the sum of the linear contribution of the
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reference components (A, B, C), and x, y, z are the respective weightings or scores
necessary for the weighted sum of the reference component spectra to match the
raw data.

S = [x*A] +[y*B] + [z*C]

Equation 6.1

Using the software, there are two different ways to obtain the reference
component spectra. The first way is to obtain a pure spectral reference from a
compound or compounds which can then be fitted according to Equation 6.1. The
second method uses a factor analysis algorithm to generate the component
spectra, the weighted sum of which is compared to the Raman spectral data set.
Using the latter of the two methods, Zavaleta et al demonstrated the power of the
technique to quantify quantum dot accumulation in an in-vivo mouse model and
to separate out the different spectral contributions from complex SERS signals in
the same data set44. In a similar and different way, both approaches to CLSA are
explored to extract spectra which contain polystyrene nanoparticles and define
other biochemical regions such as the RNA and lipid rich environments. The
relative contributions of the different components are defined by the weighting
factors (x, y, z….).
6.3.5 Spectral Cross Correlation Analysis
For SCCA, reference spectra from polystyrene, phosphatidyl-ethanolamine and
RNA (Figure 6.1 A) were used to screen the Raman spectral data set. All SCCA
was carried out using Matlab (Mathworks, USA) using the “crosscorr” function
available in the signal processing toolbox. Equation 6.2 describes the cross
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correlation between two data series, where C(x) is the correlation function, S(t) is
the Raman spectrum in the data set to be tested and A(x+t) is the reference
spectrum i.e. polystyrene, lipid or RNA. The function integrates the product of
the two data series (spectra) at each point as they are shifted relative to each other
along the x axis (wave number). The magnitude of the correlation quantifies the
relative contribution of the component spectrum at that point in the cell, and an
exact correlation occurs when the spectra are exactly matched (auto-correlation).
In this way, it is possible to screen the map or spectra in the map and, based on
the cross correlation function, cluster different biochemical regions of the cell
based on the relative contributions of the reference spectrum used.

C( X ) =



 S ( ).A( X +  )

Equation 6.2

m = −

6.3.6 Simulated Data
Simulated data sets were used to test the robustness and sensitivity of both CLSA
and SCCA in their ability to detect spectral contributions due to polystyrene, RNA
and lipid in a biological environment. To generate the simulated data sets, a
cellular spectrum was used as a template to which varied amounts of component
spectrum were added. Keeping the cellular spectrum constant, a series of 38
simulated spectra of ratios 1:1 to 1:10-4, cellular: component Raman spectra for
polystyrene, RNA and lipid were generated (Figure 6.1A). An example of the
simulated data set for polystyrene is shown in Figure 6.1B, which shows the
addition of the first 8 spectral dilutions to the constant cellular spectrum. Using
these simulated datasets, it was possible to explore how each data mining
approach performs when testing experimental data and thus facilitate accurate
interpretation of the data sets.

168

Figure 6.1 (A) Component spectra of nano-polystyrene (dotted line), 3-snphosphatidyl ethanolamine (dashed line) and isolated RNA (solid line), offset for
clarity. (B) Shows an example of the first eight simulated spectra for polystyrene
in cells, offset for clarity. Each spectrum consists of a constant cellular spectrum
with a varied concentration of polystyrene added to it, with decreasing
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polystyrene concentration from top to bottom. Simulated data sets generated in
this way were then analysed by CLSA and SCCA.

6.4 Results
6.4.1 Simulated Data – Unsupervised CLSA
CLSA can be carried out in two different ways, either by generating spectral
models using a factor analysis algorithm (unsupervised), or by manually inputting
the component spectra (supervised). The data in Figure 6.2 shows the results
using the factor analysis generated models for simulated data sets generated based
on cellular/polystyrene, RNA and lipid spectra (Figure 6.2 B). In each instance,
the score recorded form CLSA for each spectrum is plotted against the component
concentration added to the data set. In all cases, the extracted CLSA scores
accurately represent the true component ratios over the concentration range,
represented by the solid line. The results depart from nonlinearity a
cellular:component ratio of ~1:0.1, after which the CLSA weightings no longer
accurately reflect the correct component weighting, although the presence of the
component can still be identified in ratios as low as 1:0.03.
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Figure 6.2 CLSA of simulated spectral data sets of nano-polystyrene, RNA and
lipid. In each graph, the score from the CLSA is plotted against the concentration
of component spectrum added to a constant cellular spectrum (points on each
graph). The solid black line represents the ideal response which gives an
indication of the quantitative nature of the technique.
6.4.2 Single Cell Data – Unsupervised CLSA
In order to further test the ability of CLSA to identify intracellular polystyrene
nanoparticles located inside a single cell Raman map, an initial factor analysis
algorithm was applied to the data set to generate 7 model spectra to be used in the
CLSA. These model spectra were then used to compute the scores from the
Raman data set (Figure 6.3 A). It is then possible to segment the cell into different
distributions based on specific spectral differences as shown in Figure 6.3 B. The
spectral profile of each model contribution can be visualized individually
showing the percentage contribution at each pixel (Figure 6.3 C-F). A more
detailed look at the model spectra generated and corresponding cellular
distribution can be seen in Figure 6.3 A-G.
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The CLSA map shows a different spatial distribution of each model in the
Raman spectral data set. Although in all cases, the model spectra show strong
contributions of the cellular environment, they are differentiated by contributions
from distinct components. Model 1 (Figure 6.4 A) shows characteristic peaks
corresponding to those seen in pure polystyrene spectra (see Figure 6.1 A).
Therefore, the pixel distribution of model 1 is deemed to show the localisation of
the polystyrene nanoparticles, indicating a perinuclear distribution in the cell,
consistent with the K-means cluster analysis of Dorney et al1. Other models show
a different distribution in the cell. Model 6 shows a distribution which visually
corresponds to the nucleolus of the cell (Figure 6.4 B), whereas model 3 surrounds
the nucleoli and is identified as the nucleus of the cell (Figure 6.4 E). This shows
the ability of CLSA to differentiate the biochemical regions of the cell containing
RNA and DNA. Other models such as model 4 (Figure 6.4 C) and model7 (Figure
6.4 F) show a distinct distribution surrounding the nucleus, which may correspond
to perinuclear organelles such as the endoplasmic reticulum or the Golgi
apparatus which are lipid rich regions of the cell.
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Figure 6.3.: Clustering of spectra identified by unsupervised CLSA. (A) Spectral
models generated from the analysis protocol and used to generate the clustered
map shown in (B). The right panel (C-I) shows the distribution of each model
created in the map. Of particular note, model 1(C), model 6(D) and model 7(H)
have strong contributions of the spectra of polystyrene, RNA and lipid
respectively. The spectra in (A) are colour coded and correspond to images (B –
F), with the exception of Model 6 which corresponds to the white image in (D).
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Figure 6.4: A closer look at the generated model spectra created by CLSA (A-G).
The overlap between pixels corresponds to a percentage contribution from each
particular model. In some instances a pixel may contain 50% of one model and
50% of another, which is highlighted somewhat by the intensity of the pixel,
although this is visually subjective.
6.4.3 Simulated Data - Supervised CLSA
Unsupervised CLSA is clearly a powerful technique to analyse the subcellular
structure and to identify the presence and distribution of nanoparticles. However,
it should be noted that the technique does not yield pure spectra of the components
(compare for example Figure 6.4 A with the pure spectrum of polystyrene in
Figure 6.1 A), and the respective models are mixtures of spectral signatures of the
components and the background cellular spectrum. A secondary approach to
CLSA which provides a more supervised approach was therefore also tested. In a
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similar way, the simulated datasets were used to assess the technique prior to
testing the real Raman cellular map.
The simulated data sets generated to test the unsupervised factor analysis
algorithm model generation approach to CLSA were used again to test the
supervised approach which uses component spectra of polystyrene, RNA and
lipid as the model spectra to generate scores for each spectrum in the data set. In
the simulated data shown in Figure 6.5., it is observed that it is possible to identify
a trend similar to that seen in Figure 6.2. for the unsupervised CLSA. For RNA
and lipid, the trend matches well the predicted response for concentrations as low
as 1:0.1, whereupon it deviates from linearity, falling to zero at a ratio of~1:0.03.
However, for polystyrene, although the trends are similar, the results are deviate
from the predicted response much earlier than the unsupervised CLSA. This
indicates that the identification of the components using a supervised CLSA
approach may not be as accurate as the model generation approach shown in
Figure 6.2. Thus, to test this prediction and for comparison, supervised CLSA
was carried out on the same cellular data set using polystyrene, RNA and lipid
spectra as the cellular components used to generate the scores for CLSA.
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Figure 6.5. Supervised CLSA of simulated spectral data sets of nano-polystyrene,
RNA and lipid. In each graph, either the pure spectrum of polystyrene, RNA or
lipid was used to calculate the CLSA score. This score was then plotted against
the concentration ratio of pure component spectrum: cellular spectrum used to
generate the simulated data set.
6.4.4 Single Cell Data - Supervised CLSA
In order to compare the different CLSA approaches, the cellular Raman data set
was screened using three pure component spectra individually, nano-polystyrene,
RNA and lipid. The aim was to use these spectra to generate the CLSA scores and
thus identify regions of the cell which correspond to each spectrum, identifying
different regions of the cell based on their biochemical composition and also
where the nanoparticles were situated.
The spectra and corresponding score maps are shown in Figure 6.6. A –
C. Figure 6.6 A shows a spectrum of polystyrene which was used to screen the
map and corresponding visual image of the distribution of nano-polystyrene in
the cell. In the image, it is observed that the polystyrene is present in every
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spectrum in the cell, albeit in differing amounts based on the pixel intensity at
each point. This is not consistent with the model generated CLSA above or with
previously published data which show the polystyrene to be localised in clusters
surrounding the nucleus1. However, the regions of high intensity most likely
correspond to the areas which contain the nanoparticles.
Similarly this method for assessing the distribution of RNA and lipids in
the cell does not quite reproduce the results observed above for CLSA using the
unsupervised factor analysis algorithm. Again, it is observed that the distribution
of lipid and RNA is throughout the Raman map of the cell, which, while more
plausible for lipids, does not make biological sense for the RNA. Therefore, again
it must be concluded that the supervised CLSA approach is prone to error,
although it is still possible to compare regions of high intensity to the output of
the unsupervised CLSA images above. An arbitrary threshold can be applied to
the dataset, as is shown for the three component spectra in the right hand panels
of Figure 6.6 A-C. Using this method, the spatial distributions of the components
matches well that of the unsupervised CLSA. However this threshold is
ambiguous and it is not possible to say from the simulated data at what value an
accurate representation of the biochemical distribution in the cell is achieved.
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Figure 6.6: Supervised CLSA using component spectra of polystyrene (A), RNA
(B) and (C) 3-sn-phosphatidyl ethanolamine. The spectrum of each pure
component is shown on the left of the graph, with the corresponding to nonthresholded data shown in the middle and arbitrarily thresholded data shown on
the right.
6.4.5 Simulated data –Spectral Cross Correlation Analysis
The observations in Figure 6 that supervised CLSA contained a high level of error
in the Raman images prompted a search for an alternate supervised approach to
screening Raman data sets which could be used to unambiguously identify
regions of the cell which correspond to the pure component spectrum of interest
chosen, be that polystyrene, RNA, lipid or any other spectral signature which may
be of interest. A novel technique was thus investigated for the analysis of Raman
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maps, which uses cross correlation as a method to investigate the presence or
absence of a component in a complex Raman data set in a supervised manner.
Thus, SCCA was used to screen the same simulated and real data sets for the
presence of polystyrene, RNA and lipid for comparison which both methods of
CLSA.
Spectral cross correlation analysis (SCCA) was initially investigated
using the same simulated data sets that were used to investigate both CLSA
approaches. Similar to the supervised CLSA approach, pure component spectra
were used to screen each data set for the presence of each in their respective
simulated data set. Figure 6.7 compares the results of the simulated SCCA for
each of the different components polystyrene, lipid and RNA. In all cases, a
correlation of the SCCA co-efficient and the true concentration ratios is observed,
but to varying degrees of accuracy.
For polystyrene, a minimum correlation coefficient value of ~ 0.3 is
reached at a concentration ratio of cellular: polystyrene spectrum of ~ 1:0.1. This
indicates that at this concentration ratio, the presence of the polystyrene spectral
fingerprint cannot be distinguished from the cellular spectrum. Thus, for the
practical implications of screening a cell for polystyrene nanoparticles,
correlation coefficient values at or below 0.3 represent the cellular peaks which
overlap with characteristic polystyrene peaks and thus values below this are
deemed not to be nanoparticles. This hypothesis was tested using a blank Raman
map which contained no polystyrene data in (data not shown) and a value of
correlation of 0.3125 was determined, which is close to the predicted value in the
simulated data sets. This indicates the need to threshold cellular data in order to
identify polystyrene nanoparticles in the cell.
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A similar performance was observed for both RNA and lipid simulated
data sets, where an initial decrease in the correlation coefficient was observed in
relation to concentration ratio of pure component: cell spectrum. Again a
minimum baseline correlation coefficient was observed for both RNA and lipid
simulated SCCA data. Notably, however, this value was different, in both cases
higher, than that observed for polystyrene, possibly due to an increased overlap
of Raman bands present in the lipid and RNA spectra with cellular Raman bands
in comparison to the polystyrene spectrum. In the case of the lipid contribution,
the correlation with the predicted response is quantitatively poor even at ratios
above 1:0.1. However, this can possibly be explained by lipid contributions
already present in the cellular spectrum and/or the relatively broad lipid bands
present in the lipid spectrum used.
The next step was to investigate the performance of SCCA in a real
Raman data set of the cell. Thus the previous map was screened in a supervised
manner to investigate if nano-polystyrene could be identified in the Raman map.
Additionally, the lipid spectrum was used to see if the local cell environment
could be investigated. Also, as used in the above supervised CLSA, RNA was
used to see if a differentiation could be made between the nucleus and nucleolus.
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Figure 6.7. SCCA carried out on simulated data sets containing added
polystyrene, RNA and lipid component spectra. In each instance, a pure
component spectrum of polystyrene, RNA and lipid was cross correlated against
each data set to investigate the performance of the technique. The solid line shows
the idealised response.
6.4.6 Single Cell Data –SCCA
SCCA was used to screen the Raman data set for the presence of polystyrene,
RNA and lipid distributions. The spectra and correlation maps are shown in
Figure 6.8. In figure 6.8 A, the spectrum of polystyrene is shown in red and the
corresponding correlation map is shown adjacent for both thresholded (right) and
non-thresholded (left) datasets. This map shows the distribution of polystyrene
nanoparticles in the Raman map. Importantly, the threshold which was predicted
from the simulated data, or more simply from a cross-correlation of the
component spectrum with the raw average cellular spectrum, was applied to the
data set and returned a map which corresponded to the previously observed
Raman image from the unsupervised CLSA (Fig 6.3 A). Notably, however, the
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spectrum is the pure spectrum of polystyrene, rather than a cellular/polystyrene
mixture. This result shows the capability for a supervised approach for the
unambiguous identification of polystyrene nanoparticles in complex Raman
spectroscopic data sets.
Furthermore, to investigate how SCCA can be used to probe the local
cellular environment, the lipid spectrum was used to screen the data set (Fig 6.8
B). Again applying a threshold to the data set it is possible to identify regions of
the cell which contain a high density of lipids using a supervised approach to
Raman analysis. Thus it is possible to investigate the local cell environment to
which the nanoparticles are trafficked after 24hrs. This is consistent with the
previous K-means cluster analysis1 which suggests that indeed the nanoparticles
are located in a highly lipid rich environment.
As an additional demonstration of the potential of SCCA, a pure RNA
spectrum was cross correlated against the data set to see if it was possible to
differentiate spectra which corresponded to the nucleolus of the cell and thus
differentiate between DNA and RNA rich regions of the cell. Figure 4.5.7.1. C
shows that it is possible to identify the nucleolus of the cell using cross correlation
analysis. It was also observed that a high correlation coefficient was present in
regions outside the nucleus. This could possibly correspond to cytoplasmic
ribosomal RNA (rRNA) or cytoplasmic messenger RNA (mRNA). Thus a novel
approach for extracting complex spectral information from Raman data sets is
demonstrated in SCCA.
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Figure 6.8: SCCA analysis using component spectra of polystyrene (A), 3-snphosphatidyl ethanolamine (B) and RNA (C). The spectrum of each pure
component is shown on the left of the figure and the correlation maps for nonthresholded shown in the middle and thresholded on the right.

6.5 Discussion
Raman spectroscopy is a powerful tool for the investigation of biological samples.
Previous studies have shown the capability of the technique to investigate sub
cellular structures and processes which provide Raman images comparable to
images observed using wide-field and confocal fluorescent microscopy1,36,45–47.
Notably, however, Raman spectroscopy is a label free method which provides a
visualization of the biochemical make up of a cell without costly and time
consuming processing with reagents, and when combined with appropriate
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analysis methods can provide a wealth of information pertaining to biological
processes in the cell. The aim of this paper was thus to investigate two analytical
approaches both in an unsupervised and supervised approach and assess their
ability to identify polystyrene nanoparticles and biochemical distributions in a
single cell Raman map.
Unsupervised CLS analysis is demonstrated to be capable of identifying
the presence of nanoparticles in regions of the cell. However, while this method
is valuable for identifying distributions in the cell, the model spectra generated in
this manner must be further analysed to extract any real biochemical information.
Therefore, while the analysis of the simulated dataset in figure 6.2. indicates that
the unsupervised model has a higher accuracy, the model spectra yielded by the
unsupervised CLS analysis do not directly compare to the pure component spectra
shown in Figure 6.1 and therefore cannot be used to unambiguously identify the
contributing components.
In contrast, employing supervised approaches to the analysis of Raman
data sets allows for the spectral array to be screened directly with the nanoparticle
or pure biochemical component spectrum of interest. Analysis in this way enables
a direct screening of the cellular distribution of a particular component while
simultaneously probing the chemical or biochemical environment of the
particular location in the cell. CLSA and SCCA are both used in a supervised
approach for analysing Raman cellular data sets (Figure 6.6 and Figure 6.6).
However, unthresholded, both show a degree of error for all three components
tested (nano-polystyrene, RNA and Lipids). To correct for this, a threshold can
be applied to both CLSA and SCCA. Importantly, this threshold should not be
applied in an arbitrary manner, as this facilitates a loss of information from the
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dataset. While thresholding for supervised CLSA is arbitrary and subjective, the
simulated datasets generated for SCCA provided a good estimation of where this
thresholding should take place and in combination with cellular data containing
no nanoparticles it was possible to accurately reveal where the nanoparticles were
located in the cell. It should be noted that the thresholding level appears to be
dependent on the spectral profile of the individual component, as it is dependent
on the degree of similarity of the spectrum of the target component with that of
the environment. Incorrect correction of spectral background may also add to the
threshold. On the other hand the simulated data for supervised CLSA did not
provide a threshold value to apply to the dataset and thus was arbitrarily
thresholded, which is far from ideal to gain any reliable information about the
dataset. Therefore, SCCA provides a more reliable supervised approach for
identification of nanoparticles and other biological components when used in
combination with a threshold generated by simulated datasets. In addition,
quantitative information can be extracted from the simulated data sets, with each
of the three approaches showing some level of quantification based on how well
the matched the predicted response, with SCCA showing the highest level of
sensitivity of the three techniques. SCCA is specifically a supervised approach,
as it is necessary to provide the pure component spectrum. However, it is
conceivable the technique could be extended to a library of reference spectra
which could in turn be screened against the data set in an unsupervised manner.

6.6 Conclusions
CLSA and SCCA are shown to be two methods capable of identifying
intracellular polystyrene nanoparticles and also to probe the local biochemical
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environment the nanoparticles are trafficked to within the cell. CLSA is a
relatively straight forward method for analysing spectroscopy data sets. However,
SCCA is demonstrated in the simulated data sets to be a more sensitive approach
for nanoparticle identification. It is envisaged that both these and other supervised
methods will provide analytical approaches which can be used not only as
identification methods for other nanoparticles inside cells and detection of
resultant biochemical changes, but also to provide alternate analytical approaches
to the study of other processes such as chemotherapeutic response of cells to
drugs. Additionally the full quantitative nature of these analytical approaches will
need to be explored if Raman spectroscopy is to become a routine application in
the study of nano-bio interactions and beyond.
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Chapter 7: Conclusions
Given the drive for a reduction in the use of animal models for evaluating toxicity,
screening of drugs and even cosmetics, due to regulatory developments in both
the EU and US (EU Directive-2010/63/EU and US Public Law 106-545, 2010,
106th Congress)1–3 generally based on the 3 R’s of Russell and Burch30 to replace,
reduce and refine the use of animals used for scientific purposes, there is increased
emphasis on the development of reliable and rapid in-vitro screening
methodologies. This includes more representative culture models which better
mimic the in-vivo environment as well as more rapid, cost efficient, high content,
and ideally label free screening technologies. It is crucial, however, that these
models and technologies are well validated against established gold standards4,5.
Raman spectra, in principle, contain high content information about the
biochemical make-up of the sample, and changes to it, related to pathology or an
external agent. Raman spectra contain numerous peaks which vary dependently
and independently of each other. Chapter 2 reviewed some of the current and
emerging applications of Raman spectroscopy in the field of Nanomedicine, for
example. Extraction and analysis of the relevant data requires the application of
multivariate statistical protocols, and validation of such protocols used in
vibrational spectroscopy, many of the commonly employed modes of which were
introduced in Chapter 3, is essential to ensure that the spectral analysis is reliable
and accurate for standardised and routine usage. In the development of novel invitro screening tools for both nano and pharmacological screening, it is therefore
imperative that sample preparation protocols, instrumental reliability and
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multivariate routines are robust and reproducible, to ensure a smooth transition
from laboratory bench to clinical and industrial settings.
Focusing on the multivariate statistical analysis, previously published
work by Bonnier and Byrne, 20126, aimed to elucidate the use and interpretability
of PCA in vibrational spectral applications, using both real and simulated data.
Similarly, validation and development of the RMie-EMSC algorithm was done
using simulated and real data in the work of Bassan et al 2010 7. These selected
examples show the applicability of simulations in validation of multivariate
analysis as well as spectral prepossessing in a biomedical vibrational
spectroscopic context.
Crucial to the application of Raman spectroscopy in these areas is the use
of data mining and data analysis, as a way to identify trends in the spectral data,
which is important as a tool to extract and distil spectral information which may
not be apparent to the eye.
For diagnostics, classification of samples is sufficient, and accuracy of
sensitivities and specificities are important for translational to the clinic. To go
beyond, and make use of analytical capabilities of Raman spectroscopy, data
mining is important in the exploration of the potential of the technique for dose
dependent in-vitro studies and mechanistic responses for both drug and nanotoxicological and screening applications. It is also imperative that spectroscopic
techniques are compared and validated against gold standard assays and
diagnostic classification protocols to ensure accurate, reliable and robust spectral
methodologies in these settings.
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A differentiation should be made between the screening of cell
populations i.e. point by point cellular acquisition and Raman as a whole cell and
sub-cellular imaging, technique. Both provide label free analysis, although the
type of knowledge gained is different; cell population screening provides
information how a drug or nanomaterial may effect the average cell viability of a
population

8–10

, while as an imaging technique, information is gained about the

subcellular spatial distribution and mode of action of drugs and nanomaterials11,12.
Crucially, for real applications and particularly in the instance of drug
interactions, it is difficult to tell whether these differences are inherently based on
cell to cell variability or whether they are dependent on the primary action of the
drug (i.e. the direct chemical effects) or the secondary effects the drug has on the
cell (i.e. the response of the cell to said drug).
In Chapter 4, simulated datasets were used to evaluate the capability of
PLSR to extract known and systematic spectral variation from a control dataset,
which contained intrinsic experimental variability. The spectral variations
introduced varied linearly with the applied drug dose and also with the cell
population response, as measured by a standard cytotoxicity assay. Notably,
however, the two spectral variations are not completely independent, as the
viability response is sigmoidal dependent on the applied dose.
In the case where only a concentration dependent systematic variation in
the spectra is introduced, the PLSR model provides an accurate predictive
response tool, the regression co-efficients of which are based on the systematic
variation which has been introduced to the dataset, linearly dependent on the
targets. The model shows high sensitivity, and the limits of detection are
determined only by the intrinsic variability of the experimental method, as
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determined by the PLSR of the Control spectral dataset. This limit can be
improved by optimising sample preparation and measurement protocols. In
principle, such a PLSR model can predict the response of a drug dose in a cell
population, or determine an unknown drug dose from a measured spectral
response.
However, the spectral changes which result from the interaction and
action of a drug within a cell are manifold, and it is of interest to differentiate the
spectral signatures of the direct interaction from the subsequent cellular response.
Notably, this study demonstrates that, although PLSR predictive models based on
regression of the combined dataset, including all spectral responses, against the
target of concentration range produce a similarly accurate, linear predictive
model, the contributing regression co-efficient (RCs) are derived exclusively
from the introduced concentration dependent variations in ranges where all other
spectral variations are limited. For example, as shown in Figures 4.8 and 4.9,
regression over the limited range of C+4 produces a model which is based on RCs
which include contributions derived from the direct effect of the interaction of the
drug within the cell (Concentration construct), as well as the resultant cytological
response (Viability construct). Thus, care should be taken in interpreting the
spectral features which contribute to such regressions to elucidate the underlying
mechanisms.
Nevertheless, in the sub-lethal regions, the direct effects of the drug
interaction can confidently be investigated employing such a PLSR analysis of
Raman spectral data, independent of the cytological responses, and these are
easily discernible above the intrinsic variability of the control. Although this
seems a trivial conclusion, such rapid, label free analysis could prove invaluable
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in screening of, for example, the mechanisms and efficacy of drug interactions,
evaluating drug uptake and receptor binding or nanoparticle uptake and
trafficking in regions where cytoxicity assays are insensitive.
The use of a parallel cytotoxic assay, such as MTT, serves as a range
finding test to establish the IC50, but also provides vital information about the sublethal doses and maximum responses. It also provides a target for regression of
the data in the regions of toxicity. Thus, the subsequent cytological effects can be
differentiated from the direct chemical effects of the agent and extracted from the
overall spectral response in the dose range where the viability is impacted, and
the cellular response can be independently mapped spectroscopically, as a
function of dose and time. Notably, the model described in Chapter 4, which
includes a single spectral construct to represent the cellular response is very
simplistic, as the response is a cascade of many responses, depending on the
mechanism of interaction13. Nevertheless, the analysis presented here
demonstrates that the spectral fingerprints of the direct mechanisms of interaction
and the subsequent cellular responses can be independently extracted from the
dose dependent spectral data, and thus, ultimately with improved screening
sensitivities and speeds, Raman spectroscopy could be employed to monitor in
quasi real time, in a label free manner, the efficacy and mode of action of, for
example chemotherapeutic agents and other exogenous agents, laying the basis
for improved quantitative structure activity relationships to guide drug
development or chemical regulation strategies.
This study demonstrates the reliability and also limitations of PLSR as a
method for predictive modelling and analysis of spectroscopic signatures of
cellular responses to exogenous agents such as radiation, chemotherapeutic
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agents or toxins. The spectroscopic profiles at any dose/time point can derive
from a complex mixture of direct interactions within the cell and a cascade of
subsequent cellular response. The analysis demonstrates that care should be taken
in choosing the response range and also highlights the importance of parallel
cytological assays in guiding the modelling and analysis. Correct choice of range
can help differentiate between the signatures of direct interactions, which are
dominant at sub-lethal doses and those of the subsequent cellular response which
evolve with increasing dose.
PCA of the same simulated spectral dataset was also investigated for its
ability to extract the systematic and continuously variable spectral perturbations
introduced. Limitations of PCA of the data are shown in figure 5.3 A, whereby
the algorithm was unable to extract the desired spectral features from the dataset,
as the magnitude of the perturbation was less than the intrinsic variability of the
cellular data. A successful partition of the data is shown to be possible when the
algorithm is seeded with the known spectral variation, as demonstrated in figure
5.5 A and B. In Dataset 3, which is continuously perturbed by the addition of
weighted contributions of the two spectral constructs, seeding the dataset with the
minority perturbation enables the continuous differentiation of the data, and
extraction of both independent spectral perturbations. Further improvements in
separation are shown using 1st and 2nd derivative spectral data for the seeded
datasets such that, in the case of the SePCA of Dataset 3, the PCA scatter plot
shown in figure 5.20A reproduces to some degree the experimental dose
dependent toxicity study of Nawaz et al. This has implications for in-vitro spectral
screening platforms as it shows that the correct trend in simulation can be
extracted from the data once the correct features are described to the algorithm
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i.e. a seeded approach. This is a positive step towards a multivariate dose response
curve.
The improvements shown have possible ramifications for both diagnostics
and in-vitro screening. Notably, however, in comparison to the PLSR approach
of Chapter 5, the method is supervised, in the sense that it requires some prior
knowledge of the spectral changes in the data set. In terms of Construct 1, this
could be facilitated by a library of spectral signatures of, for example, DNA major
and minor groove binders and intercalators, allowing a rapid screening of
mechanisms of action of novel chemotherapeutic agents. In a similar fashion,
spectral signatures could be established to represent Adverse Outcome Pathways
(AOPs), an approach to representation of toxicology recently endorsed by the
OECD14. In this approach, while the chemical binding of the agent to the receptors
represents the Molecular Initiator Event (MIE), cascade of events leading to, for
example apoptosis or necrosis constitute the AOP, which could be represented by
distinct spectral signatures.
For diagnostic applications such as classification e.g. using support vector
machines (SVM) or linear discriminant analysis (LDA), in which PCA
coefficients are input to the algorithms, seeding in combination with 1 st and 2nd
derivative spectra may provide improvements in dividing the data for training and
thus, improvements in the diagnostic classification accuracy if the correct variable
features can be identified across the patient data.
The nature of the continuously varying spectral changes is also relevant
for the interpretation of experimental changes. In this instance (Dataset 3), the
changes are continuous and linearly increasing across the entire dataset. However,
in experimental data, the changes may not be present in a continuous or linear
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fashion, or across the entire sampled range. If, as in many instances, the loadings
contain an ensemble of spectral features, multiple trends may be responsible for
the pattern of separation in the data. By seeding with the correct peaks the pattern
of partitioning in the data can be more accurately identified and adjusted based
on the correct spectral changes in the data.
This study demonstrates an analytical methodology, seeded PCA, which
increases the potential of the PCA algorithm to separate spectrally distinct data,
particularly in the case where continuous but minor variations are present over a
dataset range. The use of 1st and 2nd derivatisation of the dataset is demonstrated
to further enhance the differentiation potential of the algorithm. This has
important ramifications for improving separation of spectra, with a particular
emphasis on biomedical spectroscopy, be that in spectral diagnostics i.e.
classification protocols, and/or in-vitro screening of drugs and nano-materials.
The study also demonstrates the benefits of analysis of simulated datasets in the
development and validation of novel multivariate analysis algorithms.
Moving from dose dependent responses in cell populations to analysis of
cells and cellular processes, Raman spectroscopy may also be deployed as an
imaging technique with subcellular resolution. Previous studies have shown the
capability of the technique to investigate sub cellular structures and processes. As
an optical technique, Raman images are comparable to those produced using
wide-field and confocal fluorescent microscopy11,15–18. This is demonstrated
further in chapter 6, in which two analytical approaches, unsupervised and
supervised where assessed based on their ability to identify polystyrene
nanoparticles and biochemical distributions in an experimental single cell Raman
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map. Simulation models were employed to quantitatively compare the relative
sensitivities of the data mining techniques.
Unsupervised CLS analysis is demonstrated to be capable of identifying
the presence of nanoparticles in regions of the cell. However, while this method
is valuable for identifying distributions in the cell, the spectra generated in this
manner must be further analysed to extract any real biochemical information.
Therefore, while the analysis of the simulated dataset in figure 6.2. indicates that
the unsupervised model has a higher accuracy, the model spectra yielded by the
unsupervised CLS analysis do not directly compare to the pure component spectra
shown in Figure 6.1 and therefore cannot be used to unambiguously identify the
contributing components.
In contrast, employing supervised approaches to the analysis of Raman
data sets allows for the spectral array to be screened directly with the nanoparticle
or pure biochemical component spectrum of interest. Analysis in this way enables
a direct screening of the cellular distribution of a particular component while
simultaneously probing the chemical or biochemical environment of the
particular location in the cell. CLSA and SCCA are both used in a supervised
approach for analysing Raman cellular data sets (Figure 6.6 and Figure 6.6).
However, un-thresholded, both show a degree of error for all three components
tested (nano-polystyrene, RNA and Lipids). To correct for this, a threshold can
be applied to both CLSA and SCCA. Importantly, this threshold should not be
applied in an arbitrary manner, as this facilitates a loss of information from the
dataset. While thresholding for supervised CLSA is arbitrary and subjective, the
simulated datasets generated for SCCA provided a good estimation of where this
thresholding should take place and, in combination with cellular data containing

198

no nanoparticles, it was possible to accurately reveal where the nanoparticles
were located in the cell. It should be noted that the thresholding level appears to
be dependent on the spectral profile of the individual component, as it is
dependent on the degree of similarity of the spectrum of the target component
with that of the environment. Inappropriate correction of spectral background
may also add to the threshold. On the other hand, the simulated data for supervised
CLSA did not provide a threshold value to apply to the dataset and thus was
arbitrarily thresholded, which is far from ideal to gain any reliable information
about the dataset. Therefore, SCCA provides a more reliable supervised approach
for identification of nanoparticles and other biological components when used in
combination with a threshold generated by simulated datasets. In addition,
quantitative information can be extracted from the simulated data sets, each of the
three approaches showing some level of quantification based on how well they
matched the predicted response, SCCA showing the highest level of sensitivity of
the three techniques. SCCA is specifically a supervised approach, as it is
necessary to provide the pure component spectrum. However, it is conceivable
the technique could be extended to a library of reference spectra which could in
turn be screened against the data set in an unsupervised manner.
CLSA and SCCA are shown to be two methods capable of identifying
intracellular polystyrene nanoparticles and also to probe the local biochemical
environment the nanoparticles are trafficked to within the cell. CLSA is a
relatively straight forward method for analysing spectroscopy data sets. However,
SCCA is demonstrated in the simulated data sets to be a more sensitive approach
for nanoparticle identification. It is envisaged that both these and other supervised
methods will provide analytical approaches which can be used not only as
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identification methods for other nanoparticles inside cells and detection of
resultant biochemical changes, but also to provide alternate analytical approaches
to the study of other processes such as chemotherapeutic response of cells to
drugs.
Previous work investigating biochemical information, which can been
gained from using multivariate statistical methods has been explored by Bonnier
et al19 where PCA and k-means were used to investigate cellular data, while this
study primarily uses real data to explore the capabilities of these methods, some
of the work in this thesis uses simulations to probe the usefulness of such methods
in biomedical spectroscopy.
While these methods provide approaches for the study of individual cells,
it is important to note that the exact changes present in the spectra are still
partially unknown and thus it is difficult to ensure that all spectra are classified
and group precisely, in an error free manner.

7.1 Future work
Future work may involve the design of an advanced cellular simulated model, as
indicated in figure 7.1. As a demonstration of principle, the generation of a model
dataset was initially undertaken using K-Means clustering of the nanoparticle
exposed cellular dataset of Dorney et al11. The purpose here was to generate 6
clusters in the dataset which corresponded roughly to the different spatial regions
of the cell i.e. the nucleus, nucleolus, perinuclear regions of the cell, the
surrounding cytoplasm and an external agent, in this case polystyrene
nanoparticles. This was achieved by splitting the resulting matrix obtained from
KMCA into separate regions which correspond to the clusters identified in the
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analysis. The six matrixes were then converted to binary format by replacing all
values to a series of ones and zeros. This process allows for the generation of
template datasets or images. Next, spectra were chosen which, in this initial
dataset, are pure component spectra of two lipid spectra, phosphatidyl inositol
and phosphatidyl ethanolamine, DNA, RNA, a spectrum of the background and
a spectrum of polystyrene nanoparticles.
These spectra are then used to populate the image templates generated
using K-means clustering. Thus, if the templates consist of a series of ones and
zeros, by a process of multiplication only, the regions which contain a one will
contain a spectrum. Thus it is possible to populate the dataset with any spectrum
of interest. As stated, in this case the dataset is based on nanoparticle cell
interaction, so in this initial simplified dataset the examples used consist of pure
spectral components which are matched to a corresponding regional distribution.
This is shown in table 7.1
This outlines a preliminary example of a biochemical spatial simulation
of the cell based on pure cellular components. While this example is simplistic in
nature, mixing of the base components in different weightings may lead to a better
understanding of statistical methods used for Raman cellular imaging. Extending
this concept of Raman imaging to high content cellular imaging, such a cellular
simulated model could serve as a template to validate and extend data mining,
towards a robust analysis protocol.
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Figure 7.1. Initial template regions showing the known spatial distribution of
pure component spectra representing the Nucleus (A), Perinuclear 1 (B),
Cytoplasm (C), Nucleolus (D), Perinuclear 2 (E) and Polystyrene nanoparticles
(F). This spectral regions correspond to the pure component spectra in table 7.1
and figure 7.2.

Table 7.1. Pure spectral components and corresponding regional distributions
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Figure 7.2: Clusters representing the Nucleus (A), Perinuclear 1 (B), Cytoplasm (C),
Nucleolus (D), Perinuclear 2 (E) and Polystyrene nanoparticles (F).

Future work may also look to develop the algorithms of sePCA and
SCCA, this could possibly look at areas such as disease diagnostics, coupling
these methods with classifier algorithms such as SVM could lead to the
development of novel approaches, with a high sensitivity and specificity for
certain disease states.
While there are some limitations to this study, only Raman spectroscopy
is used, possibly incorporation of other spectral techniques such as IR, CARS,
SRS, might added to the scope of this study, expansion to include real data in the
evaluations could progress the methods used and see them progress to routine
usage in data analytics.
A sound knowledge of the workings of these and other multivariate
statistical methodologies validated and verified in simulation, may lead to more
robust and accurate multivariate statistical protocols in the biomedical
spectroscopy field. Other modalities may also benefit, such as CARS and SRS,
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as these techniques begin to gain ground and move towards a full spectrum video
rate imaging technology 20,21.
Advanced simulations may also be used to identify possible artefacts from
instrumental error and sample preparations, by the known introduction of these
changes and their effect downstream at the analytical stage.
In conclusion advanced simulations have been demonstrated to shed light
on multivariate statistical methodologies used for in-vitro screening for Raman
spectroscopy. The knowledge demonstrated in this thesis may aid in the
understanding and development of real data protocols to ensure accurate, valid
and correct application of multivariate statistical methods in the future.
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